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FORMULATION AND PHYSICO-CHEMICAL CHARACTERISATION OF NOVEL FILMS 
AND WAFERS FOR MUCOSAL DRUG DELIVERY 
Development of novel drug delivery systems has become a major research endeavour in the 
pharmaceutical industry. Drug administration via the traditional oral route (GIT) presents 
certain challenges including enzymatic and acid break down of labile drugs and first pass 
metabolism in the liver. 
 The research reported in this thesis involved the development of solvent cast films 
and freeze-dried wafers for the potential delivery of drugs via the buccal mucosa. The 
IRUPXODWLRQV ZHUH SUHSDUHG IURP WZR SRO\PHUV ț-carrageenan (CAR) 911 and poloxamer 
407 (P407)), two types of plasticizers (glycerol (GLY)) and various grades of polyethylene 
glycol (PEG) using paracetamol (PM), ibuprofen (IBU) and indomethacin (IND) as model 
drugs. The investigations involved extensive evaluation/characterisation of the initial 
formulation components and their optimum combinations to obtain the desired formulation 
by employing various physico-chemical characterisation techniques. Texture analysis was 
used to investigate the tensile properties (percent elongation and elastic modulus) of the 
films, the resistance of the films upon stretching as well as the behaviour of the films during 
handling. In the case of the wafers, texture analysis was used to determine the compressibility 
as well as in vitro mucoadhesive characteristics. The stability of both the initial components 
and within the formulated films or wafers was studied using thermal analysis (HSM, TGA 
and DSC). Thermogravimetric analysis (TGA) was used to estimate the residual water 
content of both formulations. XRPD was used to assess the different forms (amorphous or 
crystalline) of the various components, including the model drugs. Scanning electron 
microscopy provided topographic information with regard to surface architecture of the films 
and wafers. The drug loaded films and wafers were further characterised for chemical 
stability of the drugs, after storage at room temperature for twelve months and drug 
dissolution profiles using simulated saliva as dissolution medium. 
 The results of the preliminary development and optimization experiments showed that 
gels prepared with 2.5% (w/w) CAR 911, in combination with 4% (w/w) P407 and 5.5% 
ZZ3(*SURGXFHGDIOH[LEOHILOPZLWKµLGHDO¶FKDUDFWHULVWLFVDQGwas selected for drug 
incorporation. However, the concentration of PEG was increased to 6% (w/w) in the presence  
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of 1.6% w/w PM, and 6.5% (w/w) PEG with 0.6% (w/w) IND and 0.8% w/w IBU 
(concentrations relative total drug weight of film matrix).  
 
The initial results from the wafers demonstrated that a flexible wafer, obtained by freeze-
drying (incorporating an annealing step), could be produced from a gel containing  2% (w/w) 
CAR 911 in combination with 4% (w/w) P407 and 4.4% (w/w) PEG 600. Addition of 0.8% 
(w/w) IBU also increased the flexibility of the wafer approximately two fold, whilst the 
flexibility of 1.8% (w/w) PM and 0.6% (w/w) IND loaded wafers was slightly reduced. TGA 
experiments indicated a water content of approximately 5% and 1% for films and wafers, 
respectively. SEM experiments revealed an even surface without any macroscopic pores for 
the film whilst the microstructure of the wafer was observed as being porous. The data from 
DSC experiments demonstrated interactions between P407 and PEG 600 during film 
formation. Furthermore, the conversion of the originally added model crystalline drugs into 
the amorphous form within the film and wafers was ascertained by DSC and confirmed by 
XRPD.  
 Farnoosh Kianfar {Pharm-D, MSc (Enterprise in Bioscience)
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6XPPDU\RISURMHFWDLPV	REMHFWLYHV 
The aim of this project was to design and formulate novel mucosal drug delivery systems in 
the form of polymer (CAR and P407) based solvent cast films and freeze-dried wafers as 
potential matrices to deliver drugs via the buccal mucosa. 
 
Objectives include: 
x design and formulation of hydrogel based films and wafers with optimum mucoadhesive 
characteristics. To achieve the foregoing, the choice of optimum ratios of drug and 
excipients were investigated in order to design the desired dosage form. This will 
potentially aid in effective delivery of active pharmaceutical agents via the buccal tissues.  
 
x employing a range of analytical techniques (texture analysis, DSC, TGA, XRPD, SEM, 
dissolution studies and HPLC) to investigate the properties of starting materials and their 
corresponding formulations. Furthermore, the stability and possible transitions during gel 
formulation, solvent casting or freeze-drying and storage under a variety of stress 
conditions (which may cause alterations in the properties of the dosage form), will be 
evaluated. These will be followed by evaluation of the swelling, drug release and 
mucoadhesion properties of the final selected formulations.     
 
x the development of dosage forms with improved dissolution and drug delivery properties 
based upon observations achieved from testing various formulations and investigating 
their physico-chemical properties.  
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Chapter 1 *HQHUDOLQWURGXFWLRQ 
Active pharmaceutical ingredients are largely administered by two common routes i.e. oral or 
injection. However, previous studies have frequently demonstrated that these administration 
routes are not effective in all cases, and are also considered to have numerous side effects and 
disadvantages (Saxena, et al., 2004; Morales and McConville, 2011; Table 1.1) 
 
Table 1.1 Advantages and disadvantages of various pharmaceutical dosage forms (adapted from Fred, 
1994). 
Dosage forms  Solids Liquids Semi-solids 
Advantages   More stable than  
liquids, with longer 
expiration dates 
 Ease of shipping and 
handling 
 Less shelf space needed 
 No preservation  
requirements 
 Accurate dosage (single 
dose) 
 Suitable for sustained 
release formulations 
 Faster action than solid 
dosage form as 
dissolution step is 
avoided 
 Has more dosing 
flexibility in 
comparison to other 
forms  
 May be more practical 
to administer than 
solids   
 Localizes the drug at the 
site of action  
 Undesired side effects  
are minimized  
 Easy to administer  
 Risk of over dosage is 
very low   
 Easy application  
 
Disadvantages   Concerns raised 
regarding the 
dissolution profile 
 May have shorter 
expiry time 
 May have unpleasant 
taste on tongue  
 Not convenient as it 
requires careful 
measurement 
 Not appropriate for  
systemic treatments 
 Need to administer 
frequently as it is wiped 
off  the skin quickly   
 
 
In recent years, significant efforts have been made by pharmaceutical scientists to improve 
upon traditional and existing dosage forms by extensive research into alternative (novel) drug 
delivery systems. These vary from modifications of the existing formulations such as film 
(enteric) coated tablets to more sophisticated versions such as liposomes and nanoparticles to 
target specific routes or sites of action. 
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1.1 Drug delivery systems   
Drug delivery involves the process of administering a pharmacological compound to attain a 
therapeutic effect in humans or animals. Most drug delivery systems consist of non-invasive 
peroral (via the mouth), topical (skin) or invasive parenteral (injections) dosage forms. 
However, as noted above, they have the disadvantage of lacking site specificity and eventual 
drug action at the target organ. The need for targeting drugs to particular tissues, thereby 
decreasing the level of undesired side effects, has led pharmaceutical formulators to explore 
alternative routes of drug administration or employ novel technologies to deliver active 
pharmacological agents to the site of action with minimal losses (Ansel, et al., 1993., Loth, et 
al., 2007). 
One of the main objectives in novel drug delivery technology is protecting the patents of 
formulation technologies which include amending drug release profile, uptake, target organ 
disposition and elimination to improve efficacy and safety of the drug and patient 
convenience (Vogelson, et al., 2001).  
 
1.2 Classification of dosage forms   
A dosage form is the physical form of a dose of a chemical compound which can be 
employed as a drug or medication. They are designed to transfer drug molecules to the site of 
action the drug induces the desired physiological/pharmacological action. There are several 
types of dosage forms commonly available including tablets, capsules, syrups, aerosol or 
inhaler, liquid injection, pure powder or solid crystal and natural or herbal forms obtained 
from plant or food sources (FDA, 2004). Each of these dosage forms can be further classified 
into three main groups based on their physical state i.e. solid, liquids and semi-solids (Table 
1.1). They are employed to deliver a particular active compound, as various medical 
conditions require different routes of administration. Besides, a specific dosage form may be 
required for certain types of drugs, as a consequence of different factors such as chemical 
stability or pharmacokinetics (Breuer, et al., 2009). Each type of dosage form has specific 
advantages and disadvantages (Table 1.1) that need to be addressed and considered in order 
to select the most appropriate dosage form and minimize side effects (Allen, 2004).  
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1.3 Routes of drug administration  
The route of administration is, from a pharmacological perspective, the specific path via 
which a drug, fluid, poison, or other substance is transported into the body. A chemical 
compound should be transferred from the point of entry to the part of the body called the site 
of action where the desired action occurs and the role of the body's transport mechanisms to 
achieve this purpose is very important. Any kind of pharmacokinetic characteristics of a drug 
from absorption to distribution and elimination are vitally related and influenced by the route 
of administration (Breuer, et al., 2009).  
 
Table 1.2 Routes of drug administration (adapted from Merck manual, 2007). 
Route of administrations 
 
 
 
Oral 
Enteral/ digestive tract Solids Capsule ·Pill ·Tablet ·Orally disintegrating 
tablet ·  Film ·  OROS (osmotic controlled 
release capsule) 
Liquids Elixir ·Emulsion· Suspension ·  Syrup-
Tincture 
Respiratory tract Inhaler (Metered-dose, Dry powder) ·  Nebulizer 
Circulatory system Sublingual administration 
Eye/ENT Eye drop ·  Ear drop ·  Intranasal 
Transdermal Emulsion (Ointment ·  Cream · Lotion ·Gel ·  Paste ·  Film)  ·  Medicated 
shampoo ·  Transdermal implant ·  Transdermal patch 
Injection/ 
parenteral 
Subcutaneous (sc) ·  Intravenous (iv) ·  Intramuscular (im) ·  Intraosseous ·  
Intraperitoneal (ip) ·  Intrathecal ·  Intracavernosal 
Vaginal Pessary (vaginal suppository) ·  Vaginal ring ·  Douche ·  Intrauterine device 
Rectal Suppository ·  Enema 
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According to the FDA (2010), routes of administration can broadly be divided into three 
categories: 
1) topical; local effect, substance is applied directly to the desired site of action.  
2) enteral; the desired effect is systemic (non-local), drug is given via the digestive tract.  
3) parenteral; desired effect is systemic, substance is given by routes (e.g. iv, im) other than 
the digestive tract  
Other classifications and site specific drug administration routes are listed in Table 1.2. In 
recent years, there have been significant advances in the field of pharmacology and 
biopharmaceutics related to the administration of drugs to treat various conditions. Despite 
such improvements a significant proportion of pharmacological agents are still administered 
by the two common routes, (orally or by injection). 
 
1.3.1 Oral route  
The most common route of administering pharmacological agents is oral and generally 
formulated as tablet, capsule or a liquid based dosage forms which need to be swallowed 
(Liekweg, et al., 2004). The oral route comprises the buccal cavity through the oesophagus 
and the gastrointestinal tract (GIT). The advantages and disadvantages of this route are 
summarised below. 
Advantages 
1) It is the most commonly used route. 
2) The prices are considerably low and very economical. 
3) Administration does not require special skills. 
4) Self-medication is possible. 
5) This route is convenient.  
6) This route is painless (Aronson, 2009). 
 
Disadvantages  
1) Paediatric and geriatric patients have difficulty in swallowing.  
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2) Swallowing the medication requires fluids and gastric volume enhancement and therefore 
the probability of nausea and vomiting is increased in the case of patients with GI 
problems. 
3) Absorption rate of the drug into the bloodstream after swallowing varies depending on 
how fast the drug moves from the stomach to small (i.e. gastric emptying rate) or large 
intestines, differs from patient to patient and not exactly predictable. Intestinal and 
stomach secretions and pH are other factors which can interfere with the absorption 
process (Figure 1.1). In certain cases such as anxiety and stress, GI movements and 
secretions, are significantly reduced which prevents or reduces the intended effects of the 
drug, and causes delay in onset of drug action (Metcalfe &, 2010). 
4) Therapeutic peptides and proteins administered orally will be deactivated by the presence 
of a strong acidic (stomach) environment and proteolytic enzymes in the GI tract (Werle, 
et al., 2009).  
5) First pass effect. As the veins from the stomach and the small and large intestines pass 
directly through the liver, most drugs which are administered orally are instantly 
metabolized and about sixty percent of most drugs (hundred percent of certain drugs) are 
removed before reaching the systemic circulation (Figure 1.2). This causes an extra 
metabolic load for the liver and kidneys as they eliminate high levels of drug in the 
bloodstream especially in chronic treatment with a resultant risk of hepatic or renal 
disorders (Paediatrics, 2007). 
 
 
Figure 1.1 Mucosal delivery as an alternative to oral drug delivery. 
 
                            
Alternative route of administration  
Long 
onset 
 
Buccal 
tissues 
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1.3.2 Injectable dosage forms  
To eliminate and overcome some of the challenges involved in oral administration, injections 
have been frequently used. Drugs are commonly injected either intravenously or 
intramuscularly.  
 
Advantages 
1) A rapid access of drug to the site of action without the risk of first pass metabolism in the 
liver.  
2) A smaller amount of drug is required in comparison to the oral route.   
3) Drug rapidly disperses to various part of the patient's body before experiencing first pass 
effect in the liver. 
 
Disadvantages 
1) Most patients, predominantly infants and geriatrics, do not readily accept injections 
because of pain. This resistance is sometimes very obvious and causes a serious 
psychological stress which can make the patient's condition worse. Occasionally, it is 
undesirable to use injections where the patient is seriously ill and going through an 
unstable condition or injury.  
2) The metabolic rate varies from patient to patient and to prevent any possibilities of 
overdosing (especially drugs with central nervous system effect), the injection route is 
utilised with a lower than average dose and then an additional dose administered as 
required. However, this repeated injection process can increase the stress level in patients 
(Aronson, 2009).  
 
There are new strategies to develop delivery devices such as pre-filled syringes, pens, auto-
injectors and needle-free devices to reduce the problem of self-administration and improve 
patient compliance. In addition, development of micro-needles (Ji, et al., 2006) or employing 
nanoparticles compensate for some of the disadvantages of parenteral dosage forms (Joshi & 
Müller, 2009). However, the possibility of skin irritation, allergy, toxicity and cost 
effectiveness are a cause of concern for dissolvable needles (Prausnitz, 2004) and necessitates 
the need for alternative administration routes such as mucosal surfaces.  
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1.3.3 Topical route 
The topical route is commonly used for dermal dosage forms which are a convenient means 
of delivering drugs locally to the skin surface. Patients do not need to be trained or use 
special applicators during use. The advantages and disadvantages of this route are 
summarised as follows.  
 
Advantages  
1) It is a practical approach for local application to treat skin conditions.  
 
Disadvantages 
1) Formulating a drug in a dermal base does not always enable medication to penetrate 
deeply in order to provide a systemic effect. The rate of drug uptake across the skin is 
slow and in an emergency situation when the level of drug in the blood stream is expected 
to be high, this route cannot be employed.  
2) The skin surface is in continuous contact with air and its constituents which is a huge 
concern because either oxidation (i.e. hydroquinone creams) or contamination can change 
the properties of the drug and consequently may not have the desired effects.  
 
 
Figure 1.2 The various stages of loss encountered by a drug delivered in the form of an oral tablet. 
Tablet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                RECEPTOR 
 
 
 
Loss due to lack of 
permeability, 
enzyme 
degradation 
Cross epithelial 
membrane 
Loss due to deposition 
elsewhere in the body, 
degradation, binding 
Carried by blood 
to required organ 
Leave blood vessels 
(extravascular) 
Cross interstitial 
fluids to required 
cell 
Cross cell membrane 
and locate required 
organelle 
Loss due to inability 
to cross membrane 
Loss due to drainage 
into interstitial fluid, 
metabolism 
Loss due to inability 
to cross cellular or 
nuclear membrane 
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Even though traditional dosage forms are useful and continue to be used extensively, their 
major disadvantages and obstacles as discussed above have necessitated the need for 
designing a new generation of drug delivery systems. The combined effects of the 
shortcomings of the above formulations have been the driving force for researchers to design 
novel dosage forms (Figure 1.3, Figure 1.4) which will deliver drugs to the site of action in an 
ideal time and with minimum losses while providing the desired effect (Merck manual, 
2007).  
 
1.4 Novel drug delivery systems  
Current efforts in the area of drug delivery also include modifications of existing drug 
delivery systems to overcome some of the barriers encountered by traditional dosage forms, 
as illustrated in Figure 1.2 for a typical oral tablet. For example, new generations of oral 
dosage forms have been developed including pH-controlled (release under specified pH 
conditions), time-controlled (release from coated dosage forms typically occurs after a pre-
determined lag time) and osmotic pressure-induced (water penetrates through the pores of a 
semi-permeable outer film, created by a pore-forming agent). Others include enzyme-
controlled (release in specific enzymatic condition) or biodegradable polymeric coating 
(release occurs following degradation in the body) (Sato, et al., 2010, Nunthanid, et al., 2007) 
release methods. However, even though the new developments have resulted in further 
improvements, they still have not resolved major disadvantages such as first pass effect and 
onset delay (Sun, et al., 2007). 
 
Figure 1.3  Examples of novel pharmaceutical carriers (Copyright AZoM.com Pty Ltd). 
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Figure 1.4  New nanomedicines in the pharmaceutical market (Prof. Duncan presentation, 
www.ruthduncan.co.uk/#/recent-lectures/4551764748). 
 
Following the improvements in designing novel drug delivery systems, other innovative 
techniques (Figure 1.3) have been employed to enhance drug efficacy. Many attempts have 
been made to develop several pharmaceutical carriers with the ability to protect and transfer 
the drug molecules while controlling the release of the drug (Kiparissides, et al., 2008). Other 
advanced novel drug delivery systems (nanomedicines) are shown in Figure 1.4. 
 
1.4.1 Site specific delivery systems 
The aim of this type of delivery system is to activate the drug in the target area of the body 
(for example, in cancerous tissues) by transferring active ingredient to the specific target cells 
without causing unwanted side-effects in other parts of the body and thereby eliminating the 
disadvantages of non-specific traditional dosage forms (Kiparissides, et al., 2008). Site-
specific targeting is a complicated subject and involves factors such as limiting 
administration route opportunities, decreasing the amount of active component in the 
formulation to reduce side effects, eliminating/minimizing toxicity and enhancing safety 
(Ahmad, et al., 2009). Usually, physiological conditions of the target area cause 
conformational changes in the carrier material, which results in the release of the drug. One 
of the most applicable materials with high molecular weight and ability to deliver drugs 
properly and selectively are polymers.  
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According to Kiparissides, et al (2008), two main mechanisms which control drug release at 
the desired site in the case of cancer are: (1) passive and (2) active targeting. Passive 
targeting is the specific accumulation of a chemotherapeutic compound in solid tumours as a 
consequence of increase in their vascular permeability in comparison to healthy tissue. Active 
targeting, on the other hand, is based on surface functionality of ligands present in drug 
carriers that are selectively distinguished by receptors located on the surface of the target 
cells. Ligand±receptor interactions can be extremely selective; which causes a more precise 
targeting of the particular site (Husseini, et al, 2008). 
 
1.4.2 Time directed delivery 
This refers to any sort of sustained release of the drug from the administered dosage form in 
which the amount of drug released can be adjusted to decline or remain constant over a long 
period of time or even released frequently at precise time intervals. This could be achieved by 
using for example swellable and degradable polymers. It is possible to prolong the release of 
a drug, up to weeks; by prolonging degradation of the polymer matrix (e.g. use of block 
copolymers and hydrogels). Various types of sustained release formulations including 
liposomes, biodegradable microspheres with incorporated drug, drug polymer conjugates and 
medical devices (Serra, et al, 2010); can be considered as time directed. 
Potential mechanisms that will provide sustained drug release are desorption of surface-
bound/adsorbed drugs, diffusion throughout the carrier matrix, diffusion (e.g. nanocapsules) 
through the carrier wall, carrier matrix erosion or a combination of erosion/diffusion 
processes.   
 
1.4.3 Alternative delivery routes  
Administering and transferring drugs to the site of action is desirable; however, as noted 
earlier, the choice of drug is often influenced by the drug administration route. This has led to 
exploration of systems for drug delivery via alternative routes. These types of formulations 
are more desirable and have the potential to eliminate the problems encountered with 
traditional dosage forms and achieve desired efficiency in treatment of chronic conditions 
such as asthma (where steroid therapy can be over a prolonged period) via steady level of 
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medication while reducing side-effects and thereby enhance patient convenience and 
compliance.  
 
Table 1.3 Potential advantages and disadvantages of controlled-release therapy (Adapted from Lin, et 
al., 2006, Yang & Alexandridis 2000). 
Advantages Disadvantages 
 Reduction in administration frequency 
increases the patient compliance  
 Minimum drug loading 
 Minimize or eliminate side effects 
 Reduce the chance of drug accumulation 
by frequent administration 
 Efficacy of treatment is improved 
 Minimizing the fluctuation in drug levels 
 Improvement in bioavailability 
 Special effects can be achieved e.g. 
sustained release helps the morning relief 
of arthritis by administering the drug 
before bedtime. 
 Potentially expensive  
 Unpredictable and usually poor in-
vitro in-vivo correlations and dose 
dumping  
 Not applicable for rapid systemic 
availability 
 
 
The new routes of administration include:   
 Oral transmucosal (buccal, sublingual) 
 Transdermal patches  
 Transmucosal (rectal, nasal, vaginal)  
 
1.5 Mucosal dosage forms  
Mucosal routes include areas of the body where mucosal tissues are present such as the 
mouth, pharynx, oesophagus and nasal regions. Both the buccal and nasal mucosa is well 
vascularised and able to absorb hydrophobic drugs with small molecular size with high 
efficiency.  However, the nasal mucosa has specific disadvantages such as potential irritation, 
ciliary action of nasal cavity might be irreversibly damaged and there are significant 
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variations in mucosal secretion. Therefore, one of the most routes that have gained a lot of 
interest in recent years for drug delivery is the buccal mucosa. 
 
                               
 
              (a)                                                                                                    (b) 
Figure 1.5 Cross-sectional representations of (a) the oral mucosa (www.pharmainfo.net/reviews/currentstatus-
buccal-drug-delivery-system) and (b) the nasal mucosa tissues (www.vetmed.vt.edu/education/curriculum).  
 
                     
 
Figure 1.6 Mucosal delivery as an alternative to parenteral delivery (Hearnden et al.,2011). 
 
1.5.1 Buccal drug delivery   
The first attempts at buccal drug delivery involved manufacturing conventional medicated 
candy products by adding therapeutic agents to a molten candy mass.  
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However, during the formulation process such as addition of the candy mass at high 
temperatures, decomposition of the therapeutic agent could occur. Furthermore, many 
available medicated candy lozenges will disintegrate when placed in the mouth and hence 
mucosal tissues do not obtain uniform release of the drug. In addition, patients mostly chew 
and swallow lozenges resulting in most of the drug reaching the bloodstream through the GI 
tract and subsequent first pass metabolism in the liver. Therefore, lozenges are not considered 
desirable for administering potent, fast-acting drugs including those that affect the central 
nervous system, respiratory, cardiovascular and renal systems. This is because therapeutic 
bioavailability is critical and significantly lower levels of drug in the blood circulation can be 
life threatening (Degim, et al., 2006).    
 
Advantages of buccal dosage forms include avoiding the first pass effect and exposure of the 
drug to gastric and intestinal fluids thereby increasing their bioavailability. It also improves 
patient compliance by avoiding pain and the formulation can be removed if medication needs 
to be discontinued. In addition, the chance of accidental choking in the respiratory tract is 
diminished (Paediatrics, 2007). Compared with other routes, such as transdermal, mucosal 
surfaces do not have a stratum corneum, hence the main barrier to drug transport is removed 
and therefore provides quicker onset of drug action.  
The buccal route is a promising route for administering drugs which have high first-pass 
metabolism, low dose, log P value in the range of 1.60±3.30 and small molecular size. A 
selection of dosage forms for buccal delivery of small molecules reported in the literature are 
summarised in Table 1.4. 
 
The critical factors that need to be considered in mucosal dosage forms include stability, 
solubility, bioadhesion and bioavailability. In some cases the main objective is the gradual 
release of drug over a long time period to maintain therapeutic levels of the drug in the 
systemic circulation to prevent frequent administration. To achieve this goal, various forms of 
buccal dosage forms have been designed such as patches, gels and ointments, films and 
tablets (Dixit, et el., 2009). Commercialized buccal delivery systems available in the market 
in the form of thin film include ZuplenzTM (approved by FDA), BenadrylTM 
(diphenhydramine) and Gas-X (simethicone). In addition, insulin buccal spray or 
hydrocortisone buccal tablets are available.   
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 Table 1.4 Selected buccal drug delivery systems reported in the scientific literature within the last 
decade. 
Type Drug             Authors Year 
Double-layered mucoadhesive tablets by 
HPMC and carbomer  Nystatin Labot et al. 2002 
Mucoadhesive microcapsules for glipizide  Glipizide Chowdary & Rao 2003 
Buccal liposomal delivery  Silymarin El-Samaligy et al. 2006 
Release of naltrexone on buccal mucosa  Naltrexone Giannola et al. 2007 
Complexes of omeprazole with native and 
chemically modified b-cyclodextrin  
Omeprazole Figueiras et al. 2007 
Fenugreek gum /polycarbophil 
transmucosal disc  
Sumatriptan Amarjit Singh et al. 2009 (US Patent) 
 
 
 Labot, et al (2002) developed double-layered mucoadhesive tablets containing nystatin as 
API and various polymers as excipients including lactose (direct compression), carbomer and 
hydroxypropylmethylcellulose (HPMC). The formulation demonstrated sustained release 
profile over 6 hours. In addition, Chowdary and Rao (2003) formulated glipizide 
microcapsules coated with alginate and a mucoadhesive polymer such as 
carboxymethylcellulose, methylcellulose, HPMC, carbopol and was prepared by an orifice-
ionic gelation process. These mucoadhesive microcapsules showed suitability for controlled 
release of glipizlde in the oral cavity. As mentioned before, in transmucosal drug delivery 
systems, absorption is a major limitation which has an impact on drug bioavailability. 
Giannola, et al., 2007 assessed the ability of naltrexone hydrochloride (NLX) to penetrate the 
human buccal mucosa by histological approaches. Other factors that should be considered 
include pH conditions within the mouth which may affect the administration of certain 
lipophilic and hydrophilic drugs.  
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Previous studies have shown that maximum drug uptake through the mucosal tissues 
normally occurs when the drug is in the unionized form and pH variation alters the 
percentage of unionized drug at a particular point in time ('H÷LP, et. al. 2006). This affects 
the absorption of the drug across the mucosal membrane and subsequently systemic 
bioavailability. The optimum pH of saliva is between 6.2 and 6.9; hence drugs readily 
absorbed by mucosal tissues are those with a high pKa (Sasaki, et al., 1997). 
 
Most of the drugs are either weak acids or weak bases hence; they are part ionized and part 
unionized. The extent to which a drug is in its ionized and non-ionized forms at a certain pH 
is very important. pH (hydrogen ion concentration), affects the physical and chemical 
properties linked to absorption, such as solubility of the drug, lipid/water partition coefficient, 
electrical membrane potential, permeability of the membrane, and chemical reactivity. The 
ionized ratio is charged and attracts water molecules to form large complexes. They cannot 
cross the membranes due to less lipid solubility. Therefore, the ionized part of the drugs 
cannot cross the membrane and drugs are better absorbed in unionized form. Henderson-
Hasselbalch equation determines the relative concentration of the ionic and the molecular 
moieties of a drug at a certain pH (Aronson, 2009). 
 
              ݌ܪ ൌ ܮ݋݃  ?஺ ? ? ?ு஺ ?൅ ݌ܭ௔                                                                                            Eqn 1                            
The rapid elimination of drugs due to the flushing action of saliva or the ingestion of food 
materials may cause the need for frequent dosing in case of local delivery. Furthermore, the 
distribution of drugs in saliva is non-uniform due to uneven release from solid or semi-solid 
formulations which may result in lower amounts being absorbed by the mucosal tissues and 
subsequently the systemic circulation (Mizrahi and Domb, 2008).  
 
1.5.2 The buccal mucosa 
The buccal area forms part of the oral cavity bounded by the lips and the cheeks, as well as 
medially by the teeth and/or gums.  
The oral mucosa consists of a non-keratinized area (sublingual and buccal mucosa) and the 
keratinized area (the gum or gingiva, the palatal mucosa, and the inner side of the lips), with 
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the non-keratinized regions generally more permeable compared to the keratinized areas 
(Veuillez et. al., 2001).  
The oral cavity offers a large surface area for absorption (100± 200 cm2), is richly 
vascularized with blood reaching the buccal mucosa via the maxillary artery at a faster and 
richer blood flow rate (2.4 ml/min/cm2) than that in the other regions of the mouth cavity 
which facilitates passive diffusion of drug molecules across the mucosa. The buccal mucosa 
is composed of several layers of different cells as shown in figure 1.5 (b). The epithelium is 
about 40±50 cell layers thick and is similar to stratified squamous epithelia found in the rest 
of the body. Lining the epithelium of the buccal mucosa is the non-keratinized stratified 
squamous epithelium that has a thickness of about 500±ȝPDQGVXUIDFHDUHDRI2 cm2. 
The rough textured buccal mucosa is thus suitable for retentive delivery systems (Rathbone 
et. al., 1996). Basement membrane and lamina propria followed by the submucosa are found 
below the epithelial layer (Gandhi & Robinson, 1988). The lamina propria is rich with blood 
vessels and capillaries (20ml/min/100 gr of tissue) which open to the internal jugular vein. 
Lipids present in the buccal tissues include phospholipid (76.3%), glucosphingolipid (23.0%) 
and ceramide NS (0.72%) (Hearnden, et al., 2011; Sudhakar, et al., 2006). The buccal 
epithelium is primarily designed to offer protection of the underlying tissue. In non-
keratinized regions, lipid-based permeability barriers in the outer epithelial layers protect the 
underlying tissues against fluid loss and entry of potentially harmful environmental agents 
such as antigens, carcinogens, microbial toxins and enzymes from foods and beverages 
(Squier & Finkelstein, 1989). Based on the structure, the oral mucosa is classified into three 
main types: 
1. masticatory mucosa, 
2. lining mucosa, 
3. specialized mucosa. 
 
Masticatory mucosa is keratinized and similar to epidermis of skin in its pattern of maturation 
and lined up on the gingival and the hard palate area and is necessary due to mechanical 
forces of mastication such as abrasion and stress. The lining mucosa is non-keratinized and 
the thickness differs substantially in different parts of the oral cavity.  
Generally, their thickness is more than the masticatory mucosa though more permeable due to 
their non-keratinized texture. Buccal and sublingual regions are covered with this form of 
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epithelium. Specialized mucosa is found on the surface of the tongue with the characteristics 
of both masticatory and lining mucosa and is not effective for drug absorption purposes. 
The proportion of different types of oral mucosa differs in the oral cavity. Masticatory 
mucosa is about 25%, lining mucosa 60%, and specialized mucosa approximately 15% of the 
total surface area of oral lining. Small molecules with molecular weight less than 75±100 Da 
can cross the oral mucosa readily. Scientifically, as the molecular size of the drug increases, 
the permeability decreases (Sudhakar, et al., 2006).  
 
1.5.3 Drug absorption via buccal route 
As stated previously, drug permeation is one of the most critical parameters which need to be 
addressed and evaluated. The absorption rate of drugs from the buccal mucosa is 4-4000 
times higher than skin. However, this depends on the different parts of the oral mucosae 
(described above) which exhibit differences in permeability rates (Patil & Sawant, 2008). The 
various mechanisms of drug absorption through the oral mucosal cells are summarised below 
in (Table 1.5). 
 
Table 1.5 Mechanism of drug absorption in buccal tissues. 
Absorption Mechanism of absorption Schematic view 
Passive 
diffusion 
via 
para-cellular 
& 
trans-cellular 
route 
The driving force in the process of passive 
diffusion is the concentration gradient of the 
molecule which controls the transfer of molecules 
across the membrane. Diffusion occurs following 
the accumulation of a high concentration in a 
region which induces molecules to pass through 
membranes until it reaches the lower 
concentration region.  
 
 
Facilitated 
passive 
diffusion 
If the drug molecule transfers through the 
membrane with the help of a carrier protein, the 
process is called facilitated passive diffusion. 
However it is limited to particular types of 
molecules as the carrier proteins only bind to 
specific molecules. This process is entirely 
dependent upon the accessibility of carriers as in 
particular stages during transport, the carrier 
might be saturated.   
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1.6 Hydrogel based systems  
In recent years, attention has turned to hydrogel polymers and their use in pharmaceutical 
products as a desirable drug delivery system. These substances have numerous advantages 
including their functional characteristics such as hydrophilicity, high water content and 
absorption capacity. Hydrogels are three-dimensional polymeric systems with the ability to 
absorb high amounts of water or biological fluids. This hydration is polymer related and 
occurs to various degrees (occasionally reaching more than 90% w/w of original weight) 
though it depends on the nature of the aqueous environment and polymer structure. 
Hydrogels consist of cross-linked polymeric chains with very high viscosity, in contrast to 
others such as microgels with lower viscosity. 
 
The similarity between the physical properties of hydrogels and body tissues in terms of 
structure makes them suitable as effective drug delivery systems in comparison to other 
synthetic polymers. These characteristics include high water content, soft and rubbery 
conformation, and low interfacial tension with water or biological fluids. Although they are 
able to absorb high amounts of water, they swell in an aqueous environment instead of being 
dissolved following critical cross-linking (Li,et al., 2010) and their slow solution response 
allows prolonged drug release (Casolaro, et al., 2006).  
 
Covalent, hydrogen bonds and van der Waals interactions or physical entanglements are the 
fundamental reasons for the cross-links in the polymer network. Currently, various hydrogel 
systems consisting of natural or synthetic polymers have been introduced and their 
characteristics studied. Since the release mechanism of any loaded drug from a hydrogel 
matrix is complicated, regardless of the type of polymer, the main factors controlling drug 
release i.e. swelling of the hydrogel matrix and chemical reactivity of the drug/matrix must be 
considered.  
 
In order to design novel hydrogel systems, pre-formulation studies and determination of the 
physicochemical properties as well as knowledge of polymer chemistry is required. In 
addition, the structure of polymers, interaction parameters, disintegration /release kinetics and 
WKH FKDLQ¶V movement phenomena are fundamentally critical and require quantitative 
determination (Hoare and Kohane, 2008).   
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Hydrogels are classified according to their characteristics including: 
1) the nature of side groups which can be neutral or ionic, 
2) mechanical and structural features, 
3) method of preparation: whether they will be formulated individually or with another 
polymers (co-polymer), 
4) physical structure: there are several forms of polymers such as amorphous, semi- 
crystalline, hydrogen bonded, super molecular and hydrocolloids and 
5) reaction to physiological stimulants such as changes in pH, ionic strength, temperature 
and electromagnetic radiation.  
 
Temperature and pH are two common factors amongst physical and chemical stimuli for 
biomedical purposes to deliver drugs via the hydrogel based systems to the particular site of 
the body (He, et al., 2008).  
The critical point in the pH-sensitive polymers system is the presence of ionizable weakly 
acidic or basic groups attached to a hydrophobic back bone. Following their ionization, the 
coiled chains extend dramatically, reacting to the electrostatic repulsions of the produced 
charges (anions or cations). In temperature stimuli systems there is a balance between 
hydrophobic-hydrophilic structures. Therefore small temperature changes around the critical 
temperature will collapse or expand the chains in response to the new adjustments of the 
hydrophobic and hydrophilic interactions between the polymeric chains and the aqueous 
media (Meng, et al., 2009). 
 
Several characteristic advantages make stimuli-sensitive block copolymers a desirable choice 
for novel drug delivery. These include:    
 simplicity of drug formulation and administration procedures, 
 no requirement for organic solvent, 
 site-specificity, 
 demonstrating prolonged drug release behaviour, 
 considerably lower systemic toxicity, and  
 the ability to distribute both hydrophilic and hydrophobic drugs in the body.  
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1.7 Drug release kinetics  
The mechanism of drug release is affected by various factors, including diffusion through a 
rate-controlling membrane or a matrix, osmosis, ion exchange or degradation of the 
whole/partial matrix. Employing biodegradable devices to control the drug delivery 
mechanism has considerable advantages as it avoids the need to remove the system from the 
site of action following the completion of drug release. The most common polymers used to 
formulate systemic drug delivery systems are bioresorbabale polymers. They are suitable due 
to degradation to lower molecular weight fragments which are readily removed from the 
body. The kinetics of drug release from hydrogel based dosage forms can be determined by 
finding the best fit of the percentage release vs time data to distinct models. Examples of such 
models include the following.  
(1) Korsmeyer- Peppas model: 
Ɛn (Qt / Q) = Ɛ n k + n Ɛ n t          (Korsmeyer- Peppas equation)                            Eqn 2 
 
In this equation Qt is the amount of drug released at a given time (t), Q is the amount of drug 
present initially, while k is a constant (which reflects the structural and geometric 
characteristics of the formulation) and n is the release exponent. 
 
(2) Higuchi model: 
Qt = kH t½                                                     (Higuchi equation)                       Eqn 3 
 
Qt is the amount of drug released at time (t) and kH is a constant (the Higuchian release rate).  
 
(3) Zero order model:     
Qt í40 = k0t                                               (Zero order equation)                         Eqn 4 
 
Qt is again, the amount of drug released in time (t) while Q0 is the amount of drug dissolved 
at time zero, and k0 is the zero-order release constant. 
 
(4)First order model:  
 Ɛn (Q / Q1) = k1 t                                  (First order equation)                       Eqn 5 
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Q1 is the amount of remaining drug at time (t), Q is the initial amount of drug which exists 
in the system and k1 is the first-order rate constant. 
  
(5) Hixson±Crowell model:                                                                                                Eqn 6 
Q0 1/3 ± Qt1/3 = KHC t  
 
Where, Qt is the amount of drug released in time t, Q0 is the initial amount of the drug in 
sample and KHC is the rate constant for Hixson-Crowell rate equation. 
 
1.8 Mechanism of drug release from hydrogels 
Drug molecules with varying sizes and characteristics are released from hydrogels by 
different mechanisms. Drug molecules may diffuse out of hydrogel matrix during handling 
and storage which need to be considered and addressed. In addition, hydrogels are highly 
hydrophilic and behave differently from hydrophobic polymers in terms of releasing drug. 
Hydrogels control drug release occurs by three main mechanisms: diffusion-controlled, 
swelling-controlled and chemically-controlled (Lin, et al., 2006). 
 Diffusion-controlled  
The most common mechanism is diffusion±FRQWUROOHG ZKLFK LV EDVHG RQ )LFN¶V ILUVW ODZ
Diffusion controlled systems can be classified into two as follows.  
1) Reservoir  
In this system, an inert membrane encapsulates the drug core and the rate of drug diffusion 
via the polymer membrane is the rate-limiting step (Figure 1.7). By choosing various types of 
polymers to achieve the desirable diffusion and partition coefficients of the drug in the 
polymer, the release rates are predictable (Park & Shaly, 1993). 
 
 
Figure 1.7  Schematic view of reservoir diffusion. 
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2) Monolithic  
In this system, the drug is dispersed homogeneously in the wetted matrix (Figure 1.8) and 
therefore this system is called mono-bloc.  
 
The Higuchi model is commonly used to describe drug release form this system and states 
that ³if sink conditions are maintained in the dissolution medium, the amount of drug 
released is related to the square root of time´ (Miyajima, et al. 1998).  
 
For poorly water soluble drugs, this system enhances the rate of drug release in the human 
body in comparison to the other conventional dosage forms since the drug is molecularly 
dispersed rather than crystalline or amorphous aggregates which need to be disrupted prior to 
drug dissolution. To achieve high solubility, a fast hydrating hydrogel is important because 
WKHPDFURPROHFXODUQHWZRUNRI WKHPDWUL[ IRUPHU VKRXOGQ¶WKDYH any significant hindrance 
on drug release. This should however, be balanced by a parallel consideration of long term 
stability during storage and formation of thermodynamically stable crystalline form 
(Rathbone, et al., 2007). The rate of diffusion from a hydrogel matrix is entirely dependent on 
the pore sizes within the matrix and this factor is also related to the degree of cross-linking 
and chemical structure of the monomers. In addition, the type of monomers and the strength 
of external stimulants are important factors.  
 
The porosity in the matrix directly affects various characteristics such as mechanical strength, 
degradability, diffusivity and other physical properties of a hydrogel network (Hamidi, et al., 
2008).  
 
 
Figure 1.8 Schematic view of monolithic diffusion. 
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 Swelling- controlled  
If the rate of drug diffusion is significantly higher than swelling, the mechanism of drug 
release is swelling-controlled; with the rate of swelling being the rate limiting step. In 
swelling controlled release systems, the dosage form is initially dry.  
 
Following the placement of polymeric matrix in the body, the swelling process begins by the 
ingress of water or body fluids. In the early stages, water penetrates the drug delivery system 
as a consequence of a concentration gradient which results in enhanced mobility of the 
polymer chains and drug molecules followed by an increase in macromolecular mobility at a 
specific polymer-water concentration point.  
 
This process is termed polymer chain relaxation. Consequently, the water content and 
polymer network mesh size within the formulation increases allowing the drug to diffuse via 
the swollen network and into the external environment (dissolution medium). Subsequently, 
the swollen polymer chain dissolves (erodes) in the surrounding fluid and eventually, the end-
to-end distance of the individual polymer molecules will increase (Boateng, et al., 2008). It 
has been shown that in an aqueous environment, a polymer chain relaxation procedure takes 
place which induces the hydrated polymer to undergo direct erosion or dissolution (Ritger, et 
al., 1987). A large number of materials used to formulate swelling controlled release systems 
are capable of swelling spontaneously without a requirement for dissolution while in contact 
with water or biological fluids.  
 
As noted earlier, such polymers are usually cross-linked which makes them resistant to 
complete disintegration. This polymeric network causes the progression of swelling until the 
equilibrium state is attained where elastic and osmotic swelling forces are balanced. It is 
possible to achieve different types of drug release profiles, based on the ratio of the drug 
diffusion rate to polymer swelling rate.  
If polymer structural rearrangement, due to solvent penetration, occurs faster than drug 
diffusion, the dominant diffusion release will be Fickian or first order release (i.e. uncross-
linked polymers) (Kydonieus, 2004). 'UXJUHOHDVHIURPVZROOHQK\GURJHOVIROORZV)LFN¶VODZ
DQG )LFN¶V HTXDWLRQ KHOSV WR FDOFXODWH WKH UDWH RI GUXJ UHOHDVH IURP DQ HTXLOLEUDWHG VODE
device.  
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              Figure 1.9 Schematic view of swelling, erosion and diffusion fronts of a hydrogel matrix. 
 
This system is referred to as monolithic (as described above) where the drug is dispersed in 
the polymer medium.  
 
Mt / M0 = 4 (Dt ʌK²)½                                            )LFN¶V/DZ                                   Eqn 7 
Mt = amount of drug released, in time t   
M0 = total mass of the drug incorporated into the device  
D = diffusion coefficient of the drug 
ʌ = 3.14  
h = thickness of the device  
Mt / M0 = 1- ʌðH[S>- ʌð't) h²]                                  Eqn 8 
 
In monolithic devices with high drug loadings, drug release behaviour is modified by the 
shape of the device and the loading dose. Hence when the concentration of drug is lower than 
5 volume percent, the Higuchi equation is the most suitable model to describe the rate of drug 
release from the polymer slab.  
 
Mt = A [DCs (2C0 ±Cs) ²]½ = A (2DCsC0t)½                         Higuchi Model                                  Eqn 9 
 
Mt = amount of drug released, in time t    
D = diffusion coefficient of a drug 
Cs= drug solubility in the polymer matrix   
C0 = initial total drug concentration (includes both dissolved and dispersed drug)  
A= area of polymer slab 
Swelling Front 
 Diffusion front 
Erosion Front 
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The Higuchi equation is also the most appropriate method to calculate drug release in some 
systems where drug release from a polymeric system occurs following the penetration of 
fluid into the network rather than relaxation of the polymeric chain. In these systems, fluid 
penetration rate called swelling rate is the dominant mechanism that controls the drug release 
stage (Perioli, et al., 2004).  
 
 Chemically- controlled  
In chemically controlled release systems, the controlling mechanism of drug release is the 
rate of dissolution of the polymeric matrix during the drug diffusion process. This system is 
comparable to swelling controlled-release systems but mass erosion is replaced by the phase 
erosion (moving front). However, additional factors such as enzymes or biochemicals may 
induce the hydrolysis process.  
In general, bioerosion is distinctive from biodegradation; bioerosion is the fragmentation of 
the polymer by a chemical reaction that is occurring in the dissolution media (Chiellini, 
2001). During chemical bioerosion, the polymer will be fragmented into smaller molecular 
weight components attached to drug molecules and dispersed throughout the dissolution 
environment while in a biodegradable system, the large particle sizes of micro-spherical drug 
may be dispersed but not necessarily molecularly dispersed. The main parameter which 
controls the release process is chemical reaction taking place at the surface. This reaction 
produces oligomers and molecules with smaller molecular weight due to break down of the 
polymer until no further change in geometry occurs. At this point smaller polymer molecules 
plus drug that was incorporated in the remaining segment will be free to dissolve and diffuse. 
In addition, the geometric shape of the device in most chemically controlled systems play the 
main role in drug release. Other mechanisms such as polymer dissolution or reaction and the 
ratio of polymer surface degradation are contributing factors controlling drug release 
(Ranade, 1990).  
 
1.9 Erodible systems  
This term is used to describe water soluble polymers or very small molecules from water-
insoluble polymers which can occur in different parts of the compound or just limited to the 
surface area and referred to as bulk (homogonous) erosion or surface (heterogonous) erosion, 
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respectively. Bioerodible polymers in contact with physiological fluids will dissolve instead 
of disintegrating (Gijpferich, 1996).  
The drug-release mechanism occurs principally following the surface erosion although 
various mechanisms such as water diffusion, polymer hydration, disentanglement and 
dissolution are involved.  
 
An erodible matrix in contact with any available water will erode although it will be desirable 
to prevent water ingress into the matrix until the system reaches the critical release point. 
This is possible by eliminating hydrolysis, diffusion and reducing the effects of enzymes. In 
sustained-release systems erosion has some advantages compared with more conventional 
delivery systems including:  
 
1) capability of  delivering poorly water-soluble drugs, 
2) release mechanism by zero-order equation demonstrating that the rate of release depends 
on gastrointestinal motility and availability of water,  
3) simplicity in modification of dosage to achieve the most desirable release profile by 
changing size, width, and matrix composition of API and excipients. 
Both films and freeze-dried wafers, which are the subject of this study, can be classified as 
erodible systems and discussed further in the ensuing chapters.  
 
1.9.1 Molecular basis of polymer dissolution  
Structural molecules within polymers are arranged in a network and pulling them apart 
requires a considerable amount of energy. When the chain attachments are very strong, 
separation is actually difficult especially when the arrangement is straight, stiff, and lined up 
next to each other. This causes slower flow rate during dissolution, due to slower movement 
of long chains, (Li, et al., 2010). The rate determining steps implicated in this process are 
polymer swelling followed by the dissolution step. After addition of polymer to the solvent, 
two main forces namely attraction and dispersion begin to act between polymer sections 
based on their polarity, chemical properties and solubility parameter. When a high polymer-
solvent interaction is achieved compared with polymer-polymer attraction forces, molecules 
start absorbing solvent molecules.  
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Consequently the volume of the matrix increases resulting in a loss of polymer coil shape and 
production of a solvated polymer instead of aggregated (in solid phase). The entire process of 
solvation-unfolding-swelling is time dependent and affected by interactions between polymer 
and solvent molecules and stirring does not alter the time (Balaji and Peppas, 1996).  
 
The loosened coils disperse out of the swollen polymer, dissolving into a solution followed 
by stirring which results in further disintegration of the swollen polymer and an increase in 
the rate of drug dissolution. During the dispersion section in the solvent phase, polymer 
chains still have their fully solvated coiled structure. However spherical or ellipsoid shapes 
form due to the solvent molecules ingress between the spaces of the loosened sections and 
polymer coils which fill the hydrodynamic volume of the polymer coil (Miller-Chou and 
Koenig, 2003). 
.  
Figure 1.10 Schematic view of polymer molecule dissolution (adapted from Mississippi university website 
http://pslc.ws/macrog/property/solpol/ps3.htm, date accessed 21.04.2010). 
 
1.10 Solvent cast films  
Films are thin sheets, usually prepared from polymers and depending upon the type of 
application might be transparent or opaque. They have been widely employed in the 
pharmaceutical industry for various purposes.  
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Initially films were used as packaging materials and coatings for tablets to prevent any sort of 
undesirable side effects such as gastrointestinal disturbance, and protect the drug from 
environmental factors such as light, moisture and air. The coating application has been 
employed to produce film coated mucosal tablets (Dirim, et al., 2004; Sarbach, et al., 1996).  
 
Films are formulated as an alternative to oral dosage forms that have been broadly employed 
in pharmaceutical industries as a consequence of demonstrating reliable drug delivery 
characteristics. Boateng et al., 2008 and 2009, designed and formulated solvent cast films as 
a potential for wound healing dressings or mucosal drug delivery systems. General ideal 
characteristics of films included ease of administration and removal without any trauma or 
damage to the sensitive mucosal tissues. Formulation of films are based on initial preparation 
of aqueous gels or organic suspensions, emulsions or dispersions with appropriate flexibility 
(elasticity) and resistance to stress during handling, storage or even following administration. 
Fundamentally, the properties of a film depend on the composition of the initial materials and 
the preparation technique. Therefore, the initial development of films is important and several 
steps and processes are involved in designing an optimum formulation.  
 
The method of preparation and investigation of physico-mechanical characteristics before and 
after formulation should be considered carefully (Boateng, et al., 2009). In addition, polymer 
selection is an important and functional characteristic factor that should be considered based 
on the application of the film. Other ideal properties which should be considered while 
formulating films include (Jones, 2004): 
 low toxicity and ease of removal from the body, 
 low chemical reactivity, compatibility with a broad range of drugs/excipients and be 
thermodynamically stable, 
 sufficient mechanical strength i.e. flexibility/stiffness, 
 a high drug loading capacity and readily dispersed in aqueous solvents, 
 suitable viscosity and optimum bioadhesivity (mucoadhesivity),   
 glass transition (Tg) temperature should be controllable. 
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By employing an appropriate combination of polymers, the physic-ochemical properties of 
films can be predictable. For example insoluble polymers can be combined with soluble 
polymers which help to control release of drug from the polymeric film.  
Uniform drug content is required for all dosage forms, mainly those with low doses of very 
high potency drugs (Morales and McConville, 2011).  
 
1.10.1 Film forming techniques 
Various methods can be employed to produce films including solvent casting, hot melt 
extrusion and spray coating. In solvent casting (Boateng, et al., 2002), solvent evaporates 
from a solution or dispersion (gel) of polymer and produces a continuous layer of polymeric 
film while in spray coating technique the polymer solution is sprayed on a Teflon plate. 
According to the type of solvent employed, two main types of films can be obtained: solvent  
and water-based films. There has been a recent shift from organic solvent to aqueous based 
films (Kamada, et al., 2009).  
 
The main disadvantages of organic solvent-based films, for pharmaceutical purposes, are the 
complexity in eliminating the solvents entirely; rigorous regulations on exposure to these 
organic solvents, and increased public concern regarding ecological issues such as discharge 
into water bodies. The critical factors that should be considered during film preparation 
include temperature and humidity which impact upon the physical and mechanical 
characteristics of polymeric films (Boateng, et al., 2009; Donhowe & Fennema 1993).  
 
For example, the mechanical properties of films such as flexibility can be affected by 
handling (Boateng, et al., 2003). The simplicity of application is an important factor, as it 
influences clinical acceptance. In fact some of the characteristics such as brittleness can cause 
irritation to newly formed tissue during wound healing, for example, which can prolong 
clinical treatment and therefore lead to patient non-compliance. It is, therefore, important to 
formulate films with optimum plasticity to avoid tissue damage or contact irritation when 
applied.  
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 Film casting from solution  
In this method, polymeric solution or gel is produced by mixing polymer and other additives 
with solvent, either aqueous or organic. Dissolution of polymer occurs by hydration and 
swelling of the polymers in the aqueous media.  
Homogenising (stirring) also affects polymer dissolution especially with high speed overhead 
stirring, though the rate of stirring should be controlled to prevent excessive generation of air 
bubbles in the system. To eliminate the air bubbles, pressure techniques can be employed 
prior to pouring into casting moulds. After obtaining a clear and transparent solution a 
weighed amount of viscous solution is transferred into a clean glass plate or Petri dish. 
Occasionally, to achieve a uniform thickness film, the thick and jelly-like solution is spread 
by a glass rod moving over the surface and left at a precise temperature to remove solvent. 
Evaporation rate and process conditions significantly affect the film characteristics. In the 
case of very rapid evaporation, air bubbles or semi-crystalline precipitates can be formed in 
the final film (Averineni, et al, 2009).  
Some important points to consider during film formation include the following. 
 
1) Replacement of the glass plate with poly tetrafluroethylene film can help overcome 
the challenge of the final film sticking to the casting surface. 
2) Film thickness can be controlled by changing the volume of polymer solution and 
using a Gardner knife (a device with a micrometer adjustment) on the casting surface. 
3) By covering the casting surface with a removable lid the rate of solvent evaporation 
can be controlled  
4) Removing organic solvent from the system by locating the sample in a hood assembly 
can be easier and faster than placing on the normal bench (Siemann, 2005).   
 
 Film casting by spraying the solution   
In this technique, a thin layer of polymeric solution is sprayed onto a Teflon sheet and 
incubated to allow solvent evaporation at a suitable temperature until the film is formed. As 
soon as the film is dried it can be peeled off and stored in a controlled environment such as a 
desiccator. Film forming solutions create an alternative film technique although they are 
directly sprayed onto the body and organic solvents evaporate rapidly and film adheres to the 
skin or body part, e.g. locoryle nail solution (Weuts, et al., 2010).  
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 Films by hot melt extrusion (HME) 
Another technique used to generate films is hot melt extrusion. By employing this technique 
poorly water soluble drugs can be formulated as films because the film is produced using a 
solid melt solution instead of a liquid solution.  
In this technique all components (polymer, drug and any additives used) are mixed, and to 
obtain a uniform mixture (they should be blended in a blender at 100 rpm) before transferring 
them to the single screw extruder (Morales and McConville, 2011). Screw extruder machines 
have various segments known as feeding, melting and the metering segments.  
 
When the mixture is injected into the machine, via the feeding section, it passes through a 
melting segment and steadily melts before entering the metering segment where the melted 
mixture is pumped through a die in the form of a film. The extruded film is cooled by passing 
through a chill roll. HME can be a useful technique because of speed, economy, safety and 
ability to produce a broad range of film based (and other controlled) drug delivery systems as 
well as ability to mask bitter taste of drugs (Andrews, et al., 2009, Maniruzzaman, et al., 
2012). 
 
1.11 Freeze dried wafers 
Freeze-dried wafers are porous polymeric matrices produced by freeze-drying of polymer 
gels in solution or dispersion form. They have been used in different novel drug delivery 
systems including fast dissolving tablets e.g. Zydis and wound healing dressings (Boateng, et 
al., 2010., Matthews, et al., 2006). This novel drug delivery system is a practical way to 
formulate proteins due to avoiding high temperature during desorption of solvent from the 
systems (Grant, et al., 2009).  
 
Alfadhel, et al. (2011) also developed a polymeric lyophilized matrix in order to act as a 
bacteriophage carrier for the treatment of Staphylococcus aureus infections.  
Maintaining all relevant quality characteristic of the freeze-dried product is a critical issue. 
The glass transition of frozen systems must be analysed and considered in detail due to its 
significant effect on collapse, formation of eutectic mixture and crystallization following the 
temperature rise during the primary drying stage of freeze drying (Kasper and Friess, 2011).  
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It is feasible to make slight changes in composition of the formulation, for instance adjust the 
pH of the formulation, use buffer salts, vary the drug concentration, or add a suitable 
excipient to achieve an optimum product (Nail, et al., 2002).  
According to the most recent formulation studies on various hydrogel polymers, lyophilised 
wafers are able to produce stable and efficient formulations of insoluble therapeutic agents to 
deliver the drug directly to the site of action (Matthews, et al., 2008). The wafer should be 
able to absorb specific amount of fluid and maintain an appropriate high viscosity matrix to 
prolong retention and drug release by reducing the flow of polymeric matrix (Matthews, et 
al., 2006). 
 
1.11.1 Freeze-drying 
Freeze drying or lyophilisation is a technique used to dry a solution to produce a solid 
product. This method provides the means to dry heat-sensitive drugs or specimens at low 
temperatures due to reduction of the decomposition or deactivation of such products. Because 
of large surface area, a freeze-dried product is able to absorb solvent (typically) upon its re-
constiution. This is useful for solubilizing freeze-dried vaccines and antibodies during 
reconstitution for injections (Tang and Pikal, 2004).  
 
Lyophilisation involves three separate, unique and interdependent stages with each step being 
critical to the final quality of the product. These comprise freezing the formulation and 
reduction of the solvent (usually water) content by sublimation (primary drying process). 
This is followed by desorption (secondary drying process) to a residual solvent level that will 
no longer support biological activity or chemical reactions (Jennings, 2000).  
 
At industrial scale, the freezing stage is usually performed by use of a freeze-drying machine 
though the material should be cooled below its eutectic point in advance using a freezer or 
liquid nitrogen. At temperatures lower than the eutectic point, the possibility of solid and 
liquid material coexisting will be reduced which is desirable. The length of the freezing cycle 
can be altered as a consequence of the following:  
 Freezing and annealing procedures encourage crystallization while maximizing the size of 
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 The length of the freezing procedure is affected by the thickness of the sample which 
leads to water vapour molecules experiencing resistance while escaping from the dried 
portion of the gel.  
Therefore reducing the thickness of the starting material (e.g. gels) reduces the resistance to 
vapour flow; hence the drying process is faster (Tsinontides, et al., 2004).  
 
Freeze drying cycle  
i) Freezing or freeze-annealing    
The freezing cycle can be performed either by freezing sample continuously at a certain 
temperature while the drying process is on-going, or freezing coupled with annealing. During 
freezing and annealing the liquid sample is cooled until pure crystalline ice forms from part 
of the liquid and the residue of the sample is freeze-concentrated into a glassy state which 
possesses high viscosity and prevents further crystallization. 
 
ii) Primary drying  
During the primary drying sWHS WKH PDMRULW\ RI WKH VDPSOH¶V ZDWHU FRQWHQW SUHVHQW LQ WKH
form of ice crystals is removed which require specific pressure (vacuum) conditions in the 
freeze dryer instrument. Sublimation is the basic mechanism of water removal from the 
substrate (e.g. gels) during freeze drying and occurs by escape of free ice crystals through the 
frozen gel during the primary drying step. Primary drying or sublimation is a time consuming 
process, taking place at cooler temperatures and completed safely below the substrDWH¶V
critical temperature (eutectic point of the formulation). It also requires heat energy to initiate 
the sublimation process. To obtain the maximum drying yield during the primary drying, 
several parameters should be considered.  
 Samples must be cooled down to at least 5ºC below the critical temperature.  
 The shelf temperature during whole the process should be monitored.   
 The chamber pressure must be selected between one third and one half of the vapour 
pressure of ice at the freezing temperature. 
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 The temperature must be monitored and correlated with the stability point of the sample 
to ensure that it will not exceed the critical temperature.  
 Temperature and/or pressure should be adjusted accordingly, to control the energy input 
to the samples. 
Primary drying begins when a vacuum is applied to the sealed chamber, and pure frozen ice 
starts to sublime. The frozen ice, in the ice channels surrounding the interstitial area, is 
detached during primary drying.  
During the removal of these ice channels, critical temperature consideration is extremely 
important. Within the frozen system, the dense ice in the ice channels provides physical 
support to the frozen system and act as a scaffold to which other components are attached 
(Schewgman, 2009).   
Following the ice removal through sublimation, residual components within the interstitial 
area should have sufficient strength to preserve their own weight as the ice scaffolding is 
removed; otherwise they will collapse and produce a non-porous structure which remains at 
the bottom of the container.  
The critical temperatures, such as eutectic (Teu) and glass transition (Tg), demonstrate 
different phases from a rigid solid which is capable of supporting their own structure, to a 
rubbery product that will collapse after ice removal during primary drying. As a consequence, 
the product temperature should stay below the Tg, Teu or Tc (critical temperature) to retain 
interstitial space in the solid phase with ability to support its own weight after the ice removal 
(Schneid and Gieseler, 2009). 
 
As the heat input to the product is increased, evaporative cooling retains the temperature of 
the product below the temperature of its surrounding atmosphere. After the completion of 
primary drying, the temperature of the product rises and reaches the shelf temperature an 
indication of a successful primary drying process with desirable yield (Barley, 2009).    
 
iii) Secondary drying 
 After the sublimation phase all the ice will have disappeared from the sample and the 
SURGXFW¶VWHPSHUDWXUHVWDUWVULVLQJDQGDSSURDFKHVWKHVKHOIWHPSHUDWXUHDOWKRXJKWKHSURGXFW
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is not completely dry to remain stable during long term storage. The water content in most 
products after the primary drying state varies from 5% to 7%.  
In secondary drying, the product enter desorption phase and the last traces of water vapour 
DUHUHPRYHGDVZHOODVWKHWUDFHVRIWKH³ERXQG´ZDWHUZLWKLQWKHIUHH]H-dried matrix. 
The goal is a reduction in the residual water content of the product to acceptable levels of 
about 1-3% for long term storage and imparts several benefits such as preventing the product 
from being denatured. In addition it avoids chemical or enzymatic changes by reducing water 
content to lower levels. Therefore:   
 WKHVWDUWLQJSRLQWIRUVHFRQGDU\GU\LQJVKRXOGEH³DPELHQW´WHPSHUDWXUHH[FHSWZKHQWKH
product is unstable, e.g. proteins which aggregate.  
 during secondary drying an appropriate balance between time against final moisture level 
is important (Schwegman, 2010).  
  
1.11.2 Advantages of freeze-drying 
The advantages of freeze-drying include the following.  
1. Increase the potential to protect the product from microorganisms and enzymes.  
2. Prevents degradation of the active compound as a consequence of water content 
reduction.  
3. The possibility of damaging the sample by heating at high temperature during drying of 
the product is considerably reduced. 
4. The appearance of the product does not change because of shrinkage or toughening 
effects as well as smell or flavouring properties of the product. 
5. This technique is not only a practical choice to remove water but also other solvents such 
as acetic acid and alcohols. 
6. Rehydration will be rapid because of the existence of microscopic pores in the freeze-
dried products. 
CHAPTER 1                                                                                                  INTRODUCTION    
 
 
36 
 
7. As a consequence of sublimation of ice crystals, and retaining gaps or pores in their place, 
freeze dried products have pharmaceutical applications because their shelf life can be 
prolonged for many years (www.biopharma.co.uk- date accessed 27/05/2011).  
 
1.12 Physical properties of polymeric dosage forms  
1.12.1 Mechanical (tensile) characteristics  
Mechanical properties indicate the physical integrity of the dosage form. To determine the 
mechanical properties of pharmaceutical film formulations, tensile tests are employed. The 
relevant tensile properties that are measured include tensile strength, elastic modulus, percent 
strain at break, and the work done to break.  
The tensile strength of a film is defined as the resistance of the material to a force tending to 
tear it apart, normally identified as the maximum stress in the stress±strain curve (Shah, et al., 
2010). The tensile strength reflects how strong the film is mechanically (including 
brittleness). To enhance the abrasion resistance (in film coatings), higher values of tensile 
strength of the films are desirable. The type of polymer and its molecular weight are the main 
determinants of tensile strength. The relationship between film thickness, width and the level 
of applied force (Alanazi, et al., 2007) can be expressed as:      
                         ൬ ଶ൰ ൌ 	 ? ? െ  ?ଶ ? ? ? 
  
Although the aforementioned factors are determined in tensile strength calculations, they are 
not always reliable in predicting the functional performance of the films. 
  
Elastic modulus on the other hand is a fundamental physical parameter that affects the 
mechanical characteristics of a film. Elastic modulus or flexibility evaluates the stiffness of 
the film or how the film deforms in the elastic region. Elastic modulus is also defined as the 
initial linear elastic phase of deformation and obtained from the ratio of applied stress and 
corresponding strain (Perumal, et al., 2008). 
  
CHAPTER 1                                                                                                  INTRODUCTION    
 
 
37 
 
 ൬ ଶ൰ ൌ 	 ? ? െ  ?ଶ ? ൈ  ? ? 
 
Rigid materials exhibit a high elastic modulus, therefore to produce an acceptable strain more 
stress will be required. Different polymers can possess similar or different elastic modulus 
and flexibility properties (Cilurzo, et al., 2008).  
Another parameter that is measured by the tensometer is tensile elongation which is the 
eventual elongation of a material (the percentage enhancement in length that takes place 
before it breaks under stress). The elongation at break is a measure of the ultimate 
deformation of the film before tearing apart. In general, elongation (or strain) will increase 
with the addition of suitable plasticizing agents in a formulation. 
  ? ൌ  ? ? ൈ  ? ? ? ? ? 
 
Shah, et al (2010) have explained that soft and weak polymers have a low tensile strength, 
low elastic modulus, and low elongation at break; while a soft and strong polymer 
demonstrates adequate tensile strength, elastic modulus and a high elongation at break. 
Desired mechanical properties will vary depending on the formulation goals and the method 
selected. Most of the polymers used for film coating of pharmaceutical dosage forms 
demonstrate brittle characteristics under humid conditions and at ambient temperature. In 
addition, the strain and type of deformation under stress can fluctuate due to effect of the 
surrounding atmosphere. The presence of a plasticizer in an aqueous polymeric dispersion 
minimizes such deformation behaviour.  
 
There is a universal standard method introduced by the American Society for Testing and 
Materials (ASTM) to define tensile properties of thin plastic sheets which involves 
measurement of the ductility and brittleness of a film and is associated with elongation of the 
film at the breaking point. Calculation of the elastic modulus is by measuring the slope of the 
initial linear portion of the stress-strain curve. A firm and rigid film that is hard to break has a 
high elastic modulus, however the presence of plasticizers such as water or glycerol alters the 
elastic modulus, as is the case for the tensile strength. Plasticizers such as glycerol, act by 
increasing the free volume between the polymer chains, reduce the interactions between the 
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chains and provide flexibility to the polymer(s). The brittleness will be decreased due to the 
polymer chains sliding easily as a result of the decrease in tensile strength (Perumal, et al., 
2008). To run the test and measure the force required for breaking sample apart, a tensometer 
is employed (Figure 1.11).  
 
Figure 1.11 Schematic view of tensometer (texture analyser). 
 
This instrument exerts a force on the sample from both ends whilst the elongation and 
resistance is measured simultaneously in the samples before they break (De Moura, et al., 
2009).   
The resistance of the solid formulation such as wafers to deformation following the 
application of pressure is called ³hardness´, which is measured in units of force per unit area. 
It shows the brittleness or wafer¶VPHFKDQLFDO strength (upon hydration) and elastic behaviour 
which is used to characterise the material (Boateng et al., 2010).   
 
1.12.2 Bioadhesivity    
Bioadhesivity involves the process whereby polymers (synthetic or bio materials adhere to 
biological tissues and if the attachment occurs with mucus or a mucosal membrane, this 
phenomenon is referred to as mucoadhesion (Smart, 2005). Adhesivity is defined as the 
essential free energy required for removing a bioadhesive polymer from the body surfaces 
where it is attached and can be measured using texture analysis. The adhesive force depends 
on several parameters such as hydrophilicity (reported to progress bioadhesion), stage of 
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hydration and rate of polymer erosion after being in contact with the hydrating surface (Patel, 
et al., 2009).  
Smart (2005) explained that the mucoadhesion bonds formation depends on the nature of the 
mucous membrane and mucoadhesive material, formulation type, the attachment procedure 
and the environment of the bond. The mucoadhesion occurs as a consequence of various 
adhesive bonds at the interface of mucosal membrane and mucoadhesive agent.  
These bonds include (1) ionic bonds: where two oppositely charged ions attract each other via 
electrostatic interactions and a strong bond will be formed (e.g. in a salt crystal); (2) covalent 
bonds which are very strong bonds in which electrons are shared in space, between the 
bonded atoms in order to fill the orbitals; (3) hydrogen bonds: here a hydrogen atom, when 
covalently bonded to an electronegative atom such as oxygen, fluorine or nitrogen, carries a 
slight positively charge and hence, is attracted to electronegative atoms. The mucosal 
membrane and mucoadhesive share the hydrogen atom though this bond is usually weaker 
than ionic or covalent bonds; (4) van-der-Waals forces: these are some of the weakest forms 
of interaction that arise from dipole±dipole and dipole-induced dipole attractions in polar 
molecules, and dispersion forces with non-polar substances; (5) hydrophobic forces: give rise 
to the hydrophobic effect and occur when non-polar groups are present in an aqueous solution 
(Laidler, et al., 2003). The process of adhesion to mucosal cells can be summarized in three 
steps. 
 
 Wetting and swelling of polymer  
The wetting and swelling steps happen following the spread of a polymer on the surface of 
the biological substrate or mucosal membrane (e.g. oral cavity or vagina) to facilitate the 
development of a close contact with the substrate. Bioadhesives stick to biological tissues as 
a consequence of the surface tension and forces existing at the site of adsorption or contact. 
Swelling of polymers takes place because their constituent molecular components have an 
affinity for water which results in hydration (Semalty, et al., 2008).  
 
 Interpenetration between the polymer chains and the mucosal membrane  
The surface of mucosal membranes is composed of glycoproteins which are high molecular 
weight polymers. The bioadhesive polymer chains and the mucosal glycoprotein chains 
interact and entangle together to produce an adhesive bond. The strength of these bonds will 
CHAPTER 1                                                                                                  INTRODUCTION    
 
 
40 
 
be affected by the level of inter-penetration between the two groups of polymer. To obtain 
strong adhesive bonds, one polymer group should be soluble in the other and both polymers 
should have similar chemical structure (Shaikh, et al., 2011; Figure 1.12). 
 
                            
Figure 1.12  Schematic view of the interaction between the bioadhesive and mucosal tissues (Nangia, 2008). 
 
 Formation of chemical bonds between the entangled chains 
The formation of weak chemical bonds between the entangled polymer chains occurs after 
the second step (Figure 1.13). Various types of bonds formed between the chains are primary 
bonds such as covalent bonds and weaker secondary interactions such as van-der-Waals 
forces and hydrogen bonds.  
 
Primary or secondary bonds are employed to achieve bioadhesive formulations where strong 
adhesions between polymers are produced (Semalty, et al., 2008, Shaikh, et al., 2011). 
 
 
Figure 1.13 Final adhesion between bioadhesive polymer and the mucosal tissues (Shaikh, et al., 2011). 
 
Bioadhesive polymers are expected to possess certain µLGHDO¶ characteristics to make them 
suitable for their role as mucosal formulations (Smart, 2005).   
1) Flexibility- the flexibility of bioadhesive polymers is important since it determines the 
extent of the interpenetration between the polymers and mucosal/epithelial surfaces. 
Bioadhesive 
polymer chain  
Mucos  
polymer chain  
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2) Hydrophilicity ± hydrophilic polymers are able to form stronger adhesive bonds with 
mucosal membranes as the mucus layer retains significant amounts of water. 
3) Hydrogen bonding ± hydrogen bonding between the entangled polymer chains creates 
strong adhesive bonds, hence the existence of hydrogen bond ± forming groups such as 
OH and COOH groups are essential. 
4) Molecular weight ± high molecular weight polymers are more desirable since more 
bonding sites are available.  
5) Surface tension ± this is necessary to widen the bioadhesive polymer into the mucosal 
layer epithelial surface (Smart, 2005).  
 
According to the theories; generation of mucoadhesion force is based on the ability of 
bioadhesive polymers to form non-covalent bonds with mucin glycoprotein. Scientifically, 
ionisable polymers existing in their unionized form are able to form non-covalent bonds with 
mucus glycoprotein. Also in acidic polymers, pH plays a critical role to predict binding 
behaviour. The pH should be around or lower than their corresponding pKa values and the 
reverse is true for basic polymers. Unionized amino and carboxyl groups on polymers are 
important for polymer structures and formation of weak chemical bonds with mucus 
glycoproteins (Sigurdssona, et al., 2001).  
 
 
 
 
1.13 Drugs in the solid state   
Based on their structure, there are two types of solids (crystalline, amorphous) and each form 
exhibits different physical and chemical properties such as colour, morphology, stability, 
dissolution, and bioavailability. Therefore monitoring the polymorph of the drug during the 
various stages of drug development is critically important (Graeser, 2009). Amorphous forms 
of a drug do not possess long-range order of molecular packing or well-defined molecular 
Figure 1.14   The generic structure of mucin monomer. 
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conformation therefore far less energy is needed to dissolve them and consequently solubilise 
more quickly in comparison to the crystalline and hydrated forms of a drug (Yu, 2000).  
7KHµDSSDUHQWVROXELOLW\¶DQGGLVVROXWLRQDGYDQWDJHSURYLGHGE\WKHVHV\VWHPVLVDPHDQs to 
improve bioavailability of poorly water soluble drugs (Murdande, et al., 2010). However, 
amorphous systems present certain limitations which include physical instability and higher 
chemical reactivity with a tendency to convert to the crystalline form. This often leads to 
limited use in pharmaceutical formulations. Therefore, it is vital to determine the molecular 
and thermodynamic characteristic that contributes to the solubility and stability of amorphous 
drugs.  
Drugs in crystalline state may exist in several molecular arrangements (morphs). Such 
phenomenon is called polymorphism and it is defined as the ability of a material to be present 
in two or more arrangements or conformations of molecules in the crystal lattice. The most 
important pharmaceutical issues which are related to polymorphism are bioavailability and 
toxicity. The chemical reactivity in the solid state is related to the nature of the crystalline 
state (Giron, 2001b). Therefore, during pre-formulation studies characterisation of the 
polymorphic nature of the initial materials is essential. 
 
 
Figure 1.15 Schematic view of melting point of crystalline ( left) and glass transition of amorphous ( right). 
 
 
$ JODVV\ PDWHULDO LV DQ DPRUSKRXV VROLG WKDW H[KLELWV D ³JODVV WUDQVLWLRQ´ LQWR WKH UXEEHU\
state (Figure 1.15) upon heating in contrast to crystalline which show melting point. 
Therefore, all glasses are amorphous, but not all amorphous materials are glasses. Glass is 
classified as an amorphous solid with the energy level of a solution and a liquid-like structure 
but their high viscosity is not as observed for liquids (Angell, 2008).  
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1.13.1 Thermal properties of amorphous compounds  
As mentioned above, potential changes in the properties of amorphous systems during 
storage need to be ascertained. These changes include e.g. physical ageing, chemical 
reactions, crystallization and protein unfolding (i.e., destabilization). Such changes usually 
decrease and alter the potency and/or quality of the drug formulation therefore, those changes 
should be systematically studied (Yu, 2000).  
Thermo-analytical techniques and microcalorimetry are the most common techniques used 
for determination of the thermodynamic relationships between different phases of a 
compound of interest and the use of different thermo-analytical techniques e.g. differential 
scanning calorimetry (DSC), hot stage microscopy (HSM) and thermogravimetry (TGA) with 
X-ray diffraction (XRD) is complimentary (Giron, 2001b).  
 
1.13.2 Glass transition 
Forming amorphous material is possible if the cooling rate of a liquid is fast enough to 
prevent crystallization which would otherwise take place if time had been sufficient for the 
compound to reach equilibrium at each temperature (Royall, 1998).  
By cooling a liquid slowly, the material (substance) of interest can crystallize which causes a 
reduction in the specific volume as a consequence of the first-order phase transition (Figure 
1.16). When the liquid is cooled first (crystallization prevented) and material reaches a 
temperature T below the melting point (Tm) then it is called a super-cooled liquid. The 
specific volume and thermodynamic characteristics of a super-cooled liquid at lower 
temperature can be extrapolated according to the characteristics of the liquid above Tm 
(Angell, 2008).  
When a super-cooled liquid goes beyond the glass transition point and the system falls out of 
energy equilibrium, a glassy state is obtained (Edinger, et al., 1996). However, the crystalline 
form is invariably the thermodynamically stable form. Hence, there is a high possibility for 
the transition from glassy state with high energy and non-equilibrium meta-stable phase to a 
low energy level phase to occur (Wu, 2009).  
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Figure 1.16 Plot showing the transition from liquid to super-cooled liquid and glassy state. 
 
Glasses are generally produced with a constant cooling of the liquid state and frequently 
followed by an annealing stage, in that existing stresses during the vitrification are eliminated 
(Angell, 1995). Apart from fast cooling of the liquid form, the glassy state can be obtained 
practically by vapour-phase deposition, desolvation and in situ chemical reactions (Figure 
1.17).  
 
Figure 1.17 Different methods used to obtain amorphous material. 
 
1.13.3 Determination of glass transition temperature   
Amorphous polymers go through the glassy state to the rubbery state as temperature increases 
and the glass transition temperature is the temperature at which this phase change occurs. 
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There are several properties of a compound which are affected by the glass transition 
temperature including stability, swelling and elastic modulus (Figure 1.15). The variations in 
glass transition temperature values reported depend on the broad range of techniques selected 
to measure it as well as the choice of industrial polymers used. The most common method to 
determine Tg is specific volume. In this method a curve is plotted by measuring the specific 
volume as a function of temperature (Figure 1.16). The glass transition will occur and the 
corresponding accurate temperature is estimated by analytical methods such as differential 
scanning calorimetry (Ediger et al., 1996). 
 
1.13.4 Factors affecting the glass transition temperature   
 Molecular weight and its distribution can affect Tg because the mobility of the molecules 
decrease with increasing molecular weight and therefore a higher energy will be required 
to achieve the desired mobility level.  
 The fraction of free volume in the polymer will be affected by pressure. Increasing 
pressure causes a reduction in the free volume fraction which directly decreases the glass 
transition (Craig, 1995).  
 Size of the polymer pendant side chain can affect density variation and depends on how 
regular the arrangement of the pendant group is. When the arrangement of the pendant 
group is random, the density is lower than when the pendant arrangement is in a regular 
array. Consequently, the glass transition temperature is lower for polymers with lower 
density. If the density is not changed significantly (> than 2%) by the regularity of the 
polymer chain pendant, the glass transition temperature for ordered or random pendant 
structures will be similar (Menczel & Prime, 2009).  
 Other factors include rigidity of the backbone, branching, cross-linking, symmetry and 
polarity (Angell, 2000).  
 
1.14 Thermal analysis techniques (TA)  
The pharmaceutical industry utilizes a wide range of techniques to analyse, design and 
produce compounds with therapeutic efficacy. Physical properties of solid dosage forms are 
evaluated and utilized in early stages of the drug development process. 
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The final results of the characterization are critical in determining whether the examined 
component is nominated for further development and formulated into a commercial product.  
The characterization of hydrates and solvates are very important in determining the behaviour 
of polymorphs and pseudopolymorphs within a system. Some specific thermal analytical 
methods such as hot stage microscopy, DSC, TGA are used for analysis. Although TA 
techniques are fast and a convenient means of characterisation, the heat applied is 
considerably higher in comparison to actual storage conditions. To obtain reliable 
information, the data produced should be extrapolated to the real condition to predict the 
FRPSRXQG¶VVWDELOLW\*ODVVet al., 2004). 
In some cases, heating may result in new phases, including eutectics and solid solutions as 
ZHOODVWKHSRVVLELOLW\RIFKHPLFDOLQWHUDFWLRQVVXFKDV³KRVW-JXHVW´FRPSOH[DWLRQ*ODVVet 
al., 2004). Determination of all potential interactions is sometimes very complicated and 
requires use of various techniques and correlating the information obtained in order to arrive 
at a valid conclusion.  
 
1.15 Polymers  
1.15.1 Poloxamer 407 (P407)   
P407 (Figure 1.18) is a block copolymer synthesized by sequential addition of ethylene oxide 
to propylene oxide in the presence of hydroxide ions in an inert and anhydrous atmosphere in 
a high pressure environment. The main sources of P407 are natural gas and oil.  
 
 
HO (C2H4O) 101(C3H6O) 56(C2H4O) 101H 
 
Figure 1.18  Chemical structure of P407. 
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Pharmaceutical applications 
This compound is classified as a non-ionic surfactant and its low toxicity properties allow it 
to be employed in oral dosage forms.  
 
P407 also function as emulsifiers and viscosity stabilizers in dermatological creams and 
pastes. In addition, they have been added to drug formulations to control the particle size and 
as solubilising agents for hydrophobic drugs (Klang, et al., 1994). P407 is present in most 
mouth washes, except natural cleansing products. In addition, hydrogel-based microparticles 
containing thermo-gelling P407 with cross-linked alginate demonstrated potential as a 
controlled protein delivery system (Gong, et al., 2009).   
An in situ ocular gelling sustained release system formulated with P407 and containing IND 
showed the ability to release drugs over eight hours (Balasubramaniam, et al., 2003). As a 
consequence of their properties, such as ordered micellar packing structure and inter-micellar 
entanglement, P407 gels exhibit high viscosity and partial rigidity and therefore incorporation 
of hydrophilic and hydrophobic drugs will be enhanced (He, et al., 2 008). Extensive 
investigations have confirmed the use of P407 to formulate gels that can provide a potential 
controlled release drug delivery system with the ability to target drugs to particular sites in 
the body; which has attracted a great deal of attention (Yang and Alexandridis, 2000). In 
addition other potential clinical applications include stimulatory effects on the immune 
response; protection of human vein grafts during storage and uses in cleaning wounds 
Dumortie, et al. (2006) and Barichello, et al. (1999). This will provide the opportunity to use 
films or wafers on the buccal wounds as well.   
 
1.15.2 Carrageenan   
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Figure 1.19 Chemical structure of kappa-carrageenan. 
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Kappa Carrageenan (Figure 1.19) is an anionic sulphated polysaccharide produced from red 
seaweed (Rhodophyceae).  
According to the number of sulphate groups per repeat unit of polysaccharide, carrageenan is 
classified into three main types: kappa (N LRWD Ț DQG ODPEGD O) with one, two or three 
sulphate groups, respectively. They can occur as sodium, potassium, magnesium, calcium or 
mixed cation forms.  
In aqueous solution, kappa and iota types exhibit a thermoreversible sol-gel transition and 
retain pseudoplastic properties with some degree of µyield value¶ structure. Water dispersion 
is as a consequence of random coil formation in the sol stage. All solutions demonstrate a 
reversible decrease in viscosity upon temperature increase, while addition of electrolytes 
results in a decrease in viscosity. Carrageenan solution is stable at pH between 6 and 10. In 
addition low temperature causes galactose sequences to twist in a double helix manner 
(Yughuchi, et al., 2002, Thommes, et al., 2006 & 2008). Anderson, et al. (1973) proposed the 
theory of gel formation of carrageenan which is related to the formation of double helix 
structure. This image (Figure 1.20) was obtained by X-ray powder diffraction (Gabriele, et 
al., 2009). 
 
Figure 1.20 Schematic view of mechanism of gelation of carrageenan. 
 
Various grades of carrageenan obtained from different sources were used in the experimental 
part of the project and exhibited specific characteristics (Table 1.6). Also the physico-
chemical properties for each of the grades depend on the chemical structure and the salt 
FRQWHQW ț-FDUUDJHHQDQ LV SURGXFHG E\ DONDOLQH HOLPLQDWLRQ IURP ȝ-carrageenan isolated 
mostly from the tropical seaweed Kappaphycus alvarezii.  
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Kappa carrageenan easily binds to water and forms strong and rigid gels. Formation of the 
firm gel essentially occurs due to the presence of potassium salts. Increasing the level of 
potassium therefore results in formation of a gel with a tight cumulative structure. 
 
Table 1.6 Characteristics of various grades of carrageenan.  
Product 
name 
Carrageenan 
type 
Viscosity Gel 
characteristics  
Water 
solubility 
Use 
level 
Examples of use 
Gelcarin 
GP- 
379 NF 
Iota High 
thixotropic 
Elastic medium 
strength 
Hot 0.3-
1.0% 
Creams, 
suspension, 
useful for freeze 
drying 
protein reactive  
Gelcarin 
GP- 
812 NF 
Kappa Low Brittle 
Strong 
Hot 0.3-
1.0% 
Stronger gels 
than 
GP-911 Note: 
syneresis higher 
than GP-911 
 Gelcarin 
GP- 
911 NF 
Kappa Low Brittle 
Firm 
"Hot 
partial 
cold" 
0.25-
2.0% 
Encapsulation/ 
delivery systems 
protein reactive 
(Adapted from FMC Biopolymer corporate website)  
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Figure 1.21 N-Carrageenan rearrangement. 
 
Ț-FDUUDJHHQDQ LV SURGXFHGE\ DONDOLQH HOLPLQDWLRQ IURPȞ-carrageenan isolated mostly from 
the Philippines seaweed Eucheuma denticulatum (also called Spinosum). 
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Iota carrageenan
 
binds to water as well; however, the gel is dry and elastic, mainly due to the 
presence of calcium salts (BASF, 2009). The effect of divalent calcium ions induces bond 
formation between the carrageenan chains to produce helices.  
The two sulphate group on the exterior of the iota carrageenan molecule prevents the helices 
from aggregating to the same extent as kappa carrageenan, although it forms additional bonds 
via interaction with calcium. Therefore resultant gels are more elastic, dry but have excellent 
stability in freeze/thaw dosage form (Schmidt, et al., 2003). 
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Figure 1.22  Ț-carrageenan rearrangement. 
 
Addition of kappa-carrageenan causes an increase in drug bioavailability (Thommas, et al., 
2009) and has been reported for use in microencapsulation Suzuki and Lim (1994). 
Carregeenan is known as a bioadhesive agent due to the anionic nature which helps to bind to 
mucosal tissues more effectively. Besides, anionic polymers with sulphate groups bind more 
effectively to mucosal tissues compared to those with carboxylic groups. In addition, 
polyanions are much safer than polycations in terms of binding potential and toxicity (Rajput, 
2010). Carrageenan has been widely employed in the food industry as a gel or viscose base. 
However, it is used less widely in the pharmaceutical industry although it has been shown to 
exhibit physiological effects such as anti-tumour activity (Yughuchi, et al., 2002).   
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Eudragit, polyethylene glycol and glycerol  
Eudragit L100 has been used in the pharmaceutical industry as a film coating agent and 
demonstrated acceptable properties as well as adequate safety. Eudragit L100 is an anionic 
copolymer based on methacrylic acid and methyl methacrylate (Figure 1.23). It has good 
solubility in a mixture of methanol, ethanol, 3% water in isopropyl alcohol and acetone.  
CH3
H2C CH2
CH3
O
CH3
O
OH
n
    
Figure 1.23 Chemical structure of Eudragit L100. 
 
Polyethylene glycol is a well-known precipitant for protein crystallization and also been used 
in toothpastes as a dispersing agent. In the current project, the main use in the formulations is 
as plasticizer. Polyethylene glycols (PEGS) are water soluble synthetic polymers with 
monomers of oxyethylene and general structure of H-[-O-CH2-CX-] n-OH. In this structural 
formula n is the number of repeat units. PEGs have a wide range of molecular weights, 
starting from (PEG 200-600) which are liquids at room temperature  to semi-solids with 1500 
Da molecular weight, (PEG 3000-20,000) which are semi-crystalline solids as well as 
resinous solids with higher than100,000 Da molecular weight.  
 
The various biopharmaceutical advantages of PEGs such as ability to attach to the surface of 
liposomes to prevent recognition by the immune system, binding to proteins and to allow 
fusion with cells has contributed to the significant interests shown in these compounds 
(Craig, 1995). In addition theses polymers have been used in several pharmaceutical 
products, so there is adequate evidence of its safety. Glycerol has been used in 
pharmaceutical products mainly to improve smoothness, providing lubrication in tooth pastes, 
skin care products and in solid dosage forms such as tablets as a binding agent. According to 
the FDA there is no concern regarding safety issues. 
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Chapter 2 ([SHULPHQWDO 
2.1. Materials and equipment 
2.1.1 Chemicals 
Excipients Supplier Batch number 
ț-Carrageenan (Gelcarin GP 911) Honeywill & Stein Ltd Surrey, UK 50102070 
ț-Carrageenan (Gelcarin GP 812) Honeywill & Stein Ltd Surrey, UK 80402170 
Ț- Carrageenan(Gelcarin GP 379) Honeywill & Stein Ltd Surrey, UK 40021170 
Polyethylene glycol 600 
 
Aldrich, Gillingham, UK 25398PJ-139 
Polyethylene glycol 2000 Aldrich, Gillingham, UK 1415570 
Polyethylene glycol 6000 Aldrich, Gillingham ,UK 0001409391 
Polyethylene glycol 20000 Aldrich, Gillingham, UK 1382603 
Poloxamer 407  Sigma, Gillingham, UK 038k0071 
Glycerol Fluka, Gillingham, UK RB12720 
Eudragit L100 Degussa, Gillingham, UK B071003084 
Model drugs Supplier Batch number 
Ibuprofen  Sigma, Gillingham, UK 026H1368 
Indomethacin Sigma, Gillingham, UK 088K0666 
Paracetamol Aldrich, Gillingham, UK RB16652 
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2.1.2 Equipment & instruments   
Equipment Supplier 
Homogenizer-IKA;   RW20 digital Camlab, London, UK  
Texture analyser-HTI Hounsfeild Deutschland, Germany 
Heating magnetic stirrer up to 370°C- T.ARE 
(VELP scientific) Rhys Scientific, Chorley, UK 
Vortex up to 40 Hertz- Top Mix FB15024 Fisher, Loughborough, UK 
Oven up to 250°C Genlab, Widnes, UK 
Balance d=0.001 Max=200g Denver Instrument SI 230, USA 
Hi resolution TGA 2950 TA Instruments, Crawley, UK 
DSC 823e Mettler Toledo, Leicester, UK 
Hot Stage Microscopy FP90 central processor Mettler Toledo, Leicester, UK 
Setaram TGA  Thron Scientific Services, Surrey, UK 
Balance XS 105 dual range Max=41gr/120gr, 
d=0.01mg/0.1mg Mettler Toledo, Leicester, UK 
D8 Advance XRD  Brucker, Coventry, UK 
JSM5310LV SEM Jeol, Tokyo, Japan 
HPLC, G1329A    Agilent-1200 series Agilent Technologies Ltd, Wokingham, UK 
Varian Cary 100 UV/Vis spectrophotometer,  Varian, Yarnton, UK  
DSC Q2000 TA Instruments, Crawley, UK  
AdVantage Freeze-Dryer  Biopharma Process Systems, Winchester,UK 
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2.1.3 Consumables  
 
2.2 DSC analysis of physical mixtures of starting materials  
Prior to the formulation development step extensive DSC studies were conducted in order to 
evaluate the thermal characteristics of pure components and their physical mixtures 
corresponding to the amounts present in the films and wafers. Specifically, melting transition 
(Tm) and glass transition point (Tg) were determined as well as any possible interactions 
between the starting materials during gel formation. Initial mixtures were prepared by 
addition of two starting components to deionized water with heating up to 40-50°C and 
continuous stirring. Samples were analysed using a Q2000 instrument (TA Instruments, 
Crawley, UK) calibrated with indium and sapphire under a nitrogen atmosphere. T zero 
aluminium pans (75 µL) were packed with 3-10 mg of sample and hermetically sealed. The 
samples were cooled before heating, dynamically using the heating cycles below:   
 
1st heating: -80 to 180ºC at a rate of 10ºC/min.  
2nd heating: -80 to 180ºC at a rate of 10ºC/min. 
Cooling after each heating cycle was immediately undertaken at a rate of -10ºC/min. 
 
The foregoing steps were conducted in order to ensure that any physico-chemical changes 
(interactions/degradation) occurring during gel formulation could be detected. To evaluate 
the interaction between PEG 600 and P407 additional DSC studies were performed. This 
Consumable  Supplier 
ȝO$OXPLQLXPFUXFLEOHV Setaram, Ashtead, UK 
Magnetic stirrer Fisher, Gillingham, UK 
ȝO$OXPLQLXPFUXFLEOHV Mettler Toledo, Coventry, UK 
Aluminium lids Mettler Toledo, Coventry, UK 
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study was based on the possible interaction between PEG 600 and P407 which had been 
observed for the films during DSC analysis.  
The investigation involved preparation of various mixtures of P407 and PEG 600. They were 
physically mixed, melted and solidified before DSC analysis. Samples were prepared by 
heating the physical mixtures of PEG 600 and P407 at ratios of (0/100) up to (100/0) % w/w 
of PEG/ P407, respectively at 10% increments followed by solidification. 3-10 mg of the 
mixtures were loaded into the T zero DSC pans and DSC analysis were performed as follows: 
 
1st heating -40ºC to 80ºC at 10ºC/min 
2nd heating -40ºC to 80ºC at 10ºC/min 
3rd heating -40ºC to 80ºC at 10ºC/min 
Cooling after each heating cycle was at - 10ºC/min 
 
2.3 Formulation development of solvent cast films 
Different polymers were initially used to formulate solvent cast films. The films were 
evaluated in terms of transparency, satisfactory elasticity and ability to incorporate drug and 
selected for further development. Stability, during handling and storage was ascertained for 
blank and drug loaded films. The polymers used were P407, CAR țRUȚEudragit L100 and 
4 grades of polyethylene glycol (PEG 600, 2000, 6000, 20000). Different grades of PEG were 
used to evaluate the plasticity of the films and the most appropriate one based on the physical 
criteria mentioned above, chosen for further formulation development. This procedure was 
performed just for solvent casting.   
 
2.3.1 Gel preparation  
Prior to film casting, aqueous gels of the polymers were prepared. Formulation development 
to obtain the optimum gel involved three strategies (A1, A2 and B).  
A.  The preliminary method employed to produce gels involved adding the polymers to 
warm deionised water and heating to 70ºC. The percentage of PEG or glycerol, as 
plasticiser, was dependent upon the amount of CAR using three different ratios of 
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carrageenan: plasticiser of 1:2, 2:3 and 1:3, respectively. Producing a transparent gel with 
acceptable viscosity characteristics was conducted by two methods. 
 
1. CAR țRUȚ or Eudragit L100 was added to magnetically stirred hot deionised water (60-
70°C) in a beaker until a clear, swollen and homogeneous gel was obtained. P407 and 
PEGs or glycerol were then added together to the resulting gel and heated with 
continuous stirring for 30 minutes.  
2. The required amount of deionized water was divided into two equal portions. One portion 
was heated to 60°C and CAR or Eudragit L100 added with continuous stirring for 10 
minutes. P407 and plasticizer (PEG 600 or glycerol) were dissolved in the second portion, 
stirred for 5 minutes to produce a clear solution and then gently added to the initially 
prepared CAR or Eudragit gel.   
B. P407 was added to cold water and OHIWIRUWZRKRXUVDWURRPWHPSHUDWXUHEHIRUHDGGLQJț-
CAR powder to the resulting gel. This mixture was incubated at room temperature 
overnight to allow complete hydration of the CAR after which the gel was heated up to 
40-50°C to ensure a homogeneous mixture was obtained. The remaining components i.e. 
plasticiser (PEGs or glycerol) and model drug were added and mixing continued for a 
further 5-10 min.  
Initially, the gels generated were examined visually to evaluate their physical characteristics 
such as trapped air bubble, transparency, acceptable flexibility and viscosity (ease of 
pouring).  
 
Drying procedure for cast films 
The gels were poured into Petri dishes (90 mm diameter) to a height of 10 mm and placed in 
a vacuum oven at 60°C to remove excess moisture and help the drying procedure. The length 
of drying was investigated for optimum duration in the oven by measuring the weight at 24 
hour intervals until it remained constant. 
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2.3.2 Drug loading into optimized films 
Investigation of drug loading into the films was performed after selection of the optimised 
films. The purpose was to determine the maximum amount of drug that could be incorporated 
into the films whilst maintaining the ideal physical characteristics in terms of flexibility and 
transparency. 
This was achieved by formulating films using increasing concentrations of drugs until beyond 
the optimum amount; drug re-crystallization occurs and is visible on the surface of the films. 
Two strategies were evaluated based on the maximum amount of drug that could be loaded 
without being visible (to the naked eye) on the film surface.  
 
1. IBU (0.3-1.0% w/w), IND (0.1-0.8% w/w) or PM (1-2% w/w) were added to the P407 
solution 4% (< 15°C), kept for 2 hours before addition of 2.5% w/w CAR 911 and 
plasticizer (PEG 600 5.0 - 6.5% w/w) or glycerol (4.5-5.5% w/w) and incubated for 24 
hours. This was done with the aim of increasing drug incorporation based on the 
surfactant properties of P407.  
2. The second strategy was employed to increase the loading of the less soluble drugs IND 
and IBU based on the work reported by Watkinson et al (2009) observations. The model 
drug (IND or IBU) was dissolved in 2 mL of ethanol and the resulting solution added to 
the gel comprising 2.5% w/w CAR 911, 4% w/w P407 and 5.0-6.5% w/w PEG 600 or 
glycerol (4.5-5.5% w/w) prepared as in (B) above. 
 
2.3.3 Film formation  
Various films with different UDWLRVRIțDQGȚ-CAR were prepared in the presence of P407 and 
glycerol or different grades of PEG as plasticizers (Table 2.1). Subsequently, the blank films 
were evaluated to determine the composition that gave the most flexible film before loading 
with IBU (Table 2.2).  
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Table 2.1 Composition of gels containing P407 with various grades of carrageenan (CAR 812, 911, or 
379), PEG 600 or glycerol (GLY)  
CAR (% w/w) P407 (% w/w) Plasticiser  (% w/w) 
2.5 (911) 4 3.5 PEG 600 
1.5 (812, 911, 379) 2 4.5 PEG 600 
1.5 (812, 911, 379) 3 4.5 PEG 600 
1.5 (812, 911) 5 4.5 PEG 600 
1.5 (812,911) 6 4.5 PEG 600 
1.5 (812, 911) 7 4.5 PEG 600 
2.5 (812, 911) 4 5.0 PEG 600 
1.5 (812, 911) 4 5.5 PEG 600 
2.5 (812, 911) 4 5.5 PEG 600 
2.5 (812, 911) 4 6.0 PEG 600 
2.5 (812) 4 6.5 PEG 600 
2.5 (911) 4 6.5 PEG 600 
1.5 (812, 911) 4 5.0 GLY 
1.5 (812, 911) 4 5.5 GLY 
2.5 (812, 911) 4 5.0 GLY 
2.5 (812, 911) 4 5.5 GLY 
4.0 (911,812) 8 5.0 PEG 600 
3.0 (812, 911, 379) 8 5.5 PEG 600 
1.5 (812, 911, 379) 2 5.0 PEG 600 
2.0 (812,911, 379) 2 2.0 PEG 20000 
1.5 (812, 911, 379) 2 3.0 PEG 20000 
1.5 (812, 911, 379) 3 4.5 PEG 2000 
1.5 (812, 911) 2 4.5 PEG 2000 
2.5 (812,911) 4 5.5 PEG 6000 
2.5 (812, 911) 4 5.5 PEG 2000 
2.5 (812, 911) 4 5.5 PEG 20000 
2.0 (812, 911) 4 4.5 PEG 600 
2.0 (812, 911) 4 5.5 PEG 600 
2.5 (911, 812) 4 3.5 GLY 
2.5 (911, 812) 4 4.0 GLY 
2.5 (911, 812) 8 4.5 GLY 
2.5 (911, 812) 8 3.5 GLY 
 
Following the initial investigations with IBU, the procedure was repeated using various 
concentrations of IND and PM. 
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Table 2.2 Composition of the IBU loaded gels prepared during film formulation development and 
optimization process.  
Total dry weight 
of CAR (% w/w) P407 (% w/w) 
Plasticiser 
(% w/w) 
Model drugs 
(% w/w) 
2.5 (911) 4 5.0 PEG 0.3 IBU 
2.5 (812) 4 5.0 PEG 0.3 IBU 
2.5 (911) 4 5.0 PEG 0.4 IBU 
2.5 (812) 4 5.0 PEG 0.4 IBU 
2.5 (812, 911) 4 5.5 PEG 0.3 IBU, IND  
2.5 (812, 911) 4 5.5 PEG 0.4 IBU, IND 
2.5 (911) 4 5.5 PEG 1.0 PM 
2.5 (911) 4 5.5 PEG 0.8 IBO  
2.5 (911) 4 5.5 PEG 1.4 PM 
2.5 (911) 4 5.5 PEG 1.6 PM  
2.5 (911) 4 5.5 PEG 1.0 IBU 
2.5 (911) 4 5.5 PEG 1.2 PM 
2.5 (911) 4 5.5 PEG 0.6 IND  
2.5 (911) 4 6.5 PEG 0.6 IND  
2.5 (911) 4 6.5 PEG 0.8 IBO 
2.5 (911) 4 6.5 PEG 1.0 IBU, IND 
2.5 (812, 911) 4 4.5 GLY 0.3 IBU 
2.5 (812) 4 5.0 GLY 0.3 IBU 
2.5 (911) 4 5.0 GLY 0.3 IBU 
2.5 (812) 4 5.0 GLY 0.3 IBU 
2.5 (911) 4 5.0 GLY 0.3 IBU 
2.5 (812, 911) 4 5.5 GLY 0.4 IBU 
2.5 (812, 911) 4 5.5 GLY 0.8 IBU 
2.5 (812, 911) 4 5.5 GLY 1.0 IBU 
 
2.4 Characterisation of solvent cast films  
2.4.1 Texture analysis   
Texture analysis was employed to measure the tensile properties of the films including tensile 
strength, elastLFPRGXOXVHORQJDWLRQDQG³ZRUNGRQHto break´ the films. This technique was 
used to determine the effect of polymer, plasticiser and drug concentration on the tensile 
properties of the films and the resulting data used to select the most appropriate formulations 
for further development and drug release studies. For this purpose a texture analyser HD-plus 
with Exponent software to plot and interpret the data from the tensometer was employed. 
Before tensile measurements, the thickness of the films was measured by micro screw-meter 
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in five different areas of each sample (four edges and one in the middle) and showed 
thickness ranging from 0.33-0.37 mm which was considered quite uniform.  
The thickness of each particular specimen was entered into the texture analyser software prior 
to stretching. The films were cut into dumb-bell shapes prior to stretching (Figure 2.1).  
 
 
 
 
 
 
 
        
 
 
 
 
Wc = the width of the narrow section.  
G = gauge length, the film specimen is expected to break within this distance, or else a 
particular test is rejected. It is defined as the original length of that portion of the specimen 
over which change in length is determined. 
L = the length of the narrow section. The tensile force per unit area (stress) is greatest along 
this length and the test is centred within this section.  
D = the distance between the grips holding the films. This represents the portion of the whole 
film subjected to tensile stress. 
Lo = the overall length of the film. 
The dumb-bell shape specimens were clamped between two tensile grips and stretched till 
breaking point using the settings summarised below. The maximum force which the film 
could tolerate before break was measured as well as the maximum strain.  
 
Wc
G
L
Lo
D
Wo
Figure 2.1 Schematic diagram of typical dumb-bell shaped sample for tensiile testing of thin films. 
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Test mode: Tension                                                  Target mode: Distance 
Trigger type: Auto (Force)                                        Preload: 0 N 
Load Range:  10 N                                                    Extensions:  25 mm  
Gauge length: 30 mm                                               Test speed: 10 mm/min 
Pre-test speed: 0.2 mm/min                                      Post-test speed: 0.1mm/min 
Trigger force: 0.1 N  
 
 
Figure 2.2 Texture analyser instrument showing the on-going elongation tests. 
 
2.4.2 Hot stage microscopy (HSM) 
One of the preliminary analytical methods used to explore phase transitions in crystalline 
materials is hot stage microscopy and its development is based on light microscopy. The hot 
stage produces a high amount of heat which leads to thermal convection and conductive heat 
transfer that can be detected (Figure 2.3). HSM can be used to provide controlled temperature 
conditions for in-situ specimen investigation, while still protecting the microscope from 
damage due to excessive heat (Hanke, 2010).  
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Figure 2.3 Schemaatic set up of hot stage microscope (adapted from Mettler Toledo, date accessed 5.02.2010). 
 
 
In the pharmaceutical industry, HSM is employed in a variety of ways to validate transitions 
detected by other techniques. These include solid-state characterization of bulk drugs as well 
as evaluation of crystal forms and their hydrates (Shah, et al, 2006). The capability of this 
method to detect solvates by observing the evolution of a gas or liquid from a crystal can 
identify new polymorphic forms. This is feasible either by transition of one form to another 
following a high temperature exposure or recrystallization from the melt. To improve the 
sensitivity of HSM technique, vibrational spectroscopy or DSC can be coupled to the 
instrument. HSM was determined the experimental parameters for the TGA and DSC 
techniques with regard to the thermodynamic behaviour of pure compounds and films, with 
or without different model drugs (Figure 2.4). A known amount of the sample was placed on 
a glass slide located on the microscope stage. The lens should be clear and bright before 
runing the HSM programme.  
  
Figure 2.4  Hot stage microscopy instrument used in the analysis. 
            
Furnace 
Microscope  
Detector  
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HSM experiments to determine the thermodynamic properties of films were conducted three 
times with one of the following dynamic heating settings:  
30 to 300°C at a scan rate of 10°C/min 
30 to 300°C at a scan rate of 5°C/min 
100 to 250°C at a scan rate of 2°C/min 
 
2.4.3 Thermogravimetry (TGA) 
Thermogravimetric analysis is one of the most common analytical techniques used to 
characterise pharmaceutical products. The main purpose of performing TGA test on samples 
is to detect and identify stability and degradation. The reliability of this type of analysis 
depends entirely on the level of accuracy of measuring the weight and temperature changes 
(Bugay, 2001). The similarity in most of the weight loss curves necessitates the need for 
transformation of the results prior to interpretation. To obtain the best interpretation, a 
derivative plot of the weight loss curve can act as a guide to identify the most likely point at 
which the weight loss is noticeable and significant. Furthermore, accurate interpretation 
requires additional modifications and deconvolutLRQRIRYHUODSSLQJSHDNV5RGUÕguez-Spong, 
et al., 2004).  
 
Mechanism of operation during TGA measurements  
The main part of a TGA instrument is the high-precision balance and a pan, usually made of 
platinum, in which the sample is loaded. The measurement of temperature, with maximum 
accuracy, is achieved by means of a small thermocouple placed close to the sample pan. To 
prevent oxidation or any other undesired reactions that may affect the experimental results, an 
inert gas such as nitrogen or argon can be pumped throughout the system. To enhance the 
reliability of results, the carrier gas can be a mixture of ambient gas and oxygen (1 to 5% O2 
in N2 or He) to reduce the oxidation rate (Reed, et al., 1994). All the above parameters are 
operated by computer to control functions of the instrument. Analysis is performed by 
increasing the temperature and plotting the data as a curve showing weight change against the 
temperature (Reed, et al., 1994).  
CHAPTER 2                                                                                                  EXPERIMENTAL  
 
64 
 
Some specific instruments not only detect weight changes but also record the temperature 
difference between the sample and reference pans which means that these instruments are 
coupled with (differential thermal analysis, DTA) or (differential scanning calorimetry, DSC) 
to compare the heat flow into the sample pan relative to the reference pan. Sometimes TGA 
tests may be run in controlled heating rate mode; however, the determination of the 
percentage weight loss following heating to a certain temperature is the main purpose. This 
loss is the non-combusted residual water at the highest temperature (Tatavarti, et al., 2002). 
 
Applications of TGA  
 Determine the exact degradation temperature, amount of absorbed water and the ratio of 
organic and inorganic content in a product 
 Solvation points of volatiles and residual solvents present in the product can be identified 
 Compositional analysis of multi-component materials or blends 
 Thermal stability 
 Oxidative stability 
 Estimation of product lifetime 
 Decomposition kinetics 
 Effects of reactive atmospheres on materials 
 Filler content of materials 
 Moisture and volatile content 
 
TGA enables researchers to test and determine characteristic properties such as  
decomposition that occur following the release of volatile products from compounds such as 
low molecular weight polymers. Overall, the main application of TGA is the determination of 
the percentage of volatile components by plotting the weight loss change as the sample is 
heated and directly related to stability of the whole system. Sometimes this technique is used 
to analyse the kinetics of deterioration following oxidation due to high temperature 
5RGUÕJXH]-Spong, et al., 2004).  
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In the current project, TGA was used to measure the residual water in the films and wafers, 
since water molecules act as plasticizers and have an effect on the glass transition of 
amorphous compounds, which directly affects the stability, drug release and other physico-
chemical properties of the films such as tensile strength. By coupling TGA with DSC the 
degradation temperature of the films or pure compounds was also ascertained in order to 
evaluate their stability.  
About 3-10 mg of sample was weighed, placed in the T-Zero aluminium pans and weight loss 
determined using a high resolution TGA 2950 instrument (TA Instruments, Crawley- UK) 
(Figure 2.5a). The settings employed to measure the water content were as follows: 
isothermal: 25°C for 5 min, and 
dynamic heating from 25- 150°C at a scan rate of 10ºC/min.    
To confirm the results a SETARAM TGA Instrument (Figure 2.5b) combined with DSC was 
employed; 3-10 mg of sample was placed into the aluminium pans (100 µL) on the tared 
balance and analysed. Subsequently, the instruments were programmed to heat the samples 
using two different heating cycles to determine degradation point as well as the residual water 
content.   
 
To detect the degradation point the following parameters were used:  
isothermal: 25°C for 5 min, and dynamic heating from 25-500°C at a scan rate of 10ºC/min. 
 
 
 (a)                                                                       (b) 
Figure 2.5  (a) 2950 TGA instrument and (b) Setaram TGA Instrument. 
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2.4.4 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) measures the amount of energy absorbed or released 
during heating, cooling or holding the sample at constant temperature. The fundamental 
principle behind the technique is measuring the difference in heat flow between a standard 
(reference) material and an unknown material (sample). The two main types of DSC systems 
are described below. 
 
 Power compensation  
In this system two separate but identical furnaces independently control the temperature 
of the sample and reference (Figure 2.6). During analysis, the sample and reference pans 
are heated to the same temperature and the difference in the amount of input energy to the 
two furnaces detected.  
This difference is a measure of the enthalpy or heat capacity difference in the sample in 
FRPSDULVRQWRWKHUHIHUHQFH7KHUHIRUHSRZHUFRPSHQVDWLRQ'6&LVEDVHGRQWKH³=HUR
%DODQFH 3ULQFLSOH´ E\ PDLQWDLQLQJ WKH VDPSOH DQG UHIHUHQFH DW WKH VDPH WHPSHUDWXUH
measuring the difference in power supplied to them and then directly recording it as 
VLJQDOǻ4ǻ4 KHDW  
 
Figure 2.6 Schematic view of power compensation DSC instrument (adapted from institute of inorganic 
       chemistry, http://www.chtf.stuba.sk/kach/lab_538.php, date accessed 12.10.2009 ). 
 
Hence, an individual signal (dH/dt which is the normalized heat generated per time unit or 
normalized heat flow) is proportional to the difference of heat input between sample and 
reference (Marsh & Boyd, 2008). 
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 Heat flux  
In this method, both pans are located on a tiny slab of material with an identified 
(calibrated) heat resistance K (Figure 2.7). The temperature of the calorimeter is increased 
linearly with time (scanned) while the heating rate (dT/dt  ȕLVPDLQWDLQHGFRQVWDQW7KH
same heating power is applied to the sample and reference pans and the temperature 
GLIIHUHQFHǻ7EHWZHHQWKHWZRLVPHDVXUHG7KHRXWSXWVLJQDOLVREWDLQHGE\FRQYHUWLQJ
ǻ7WRǻ4KHDWGLIIHUHQFH 
 
Figure 2.7  Schematic view of a heat flux DSC instrument (adapted from evitherm website, 
http://www.evitherm.org/default.asp?lan=1&ID=982&Menu1=982, date accessed 24.07.2009 ). 
 
The time linearity needs well designed and (computerized) temperature control; however this 
might function as a controlled cooling and isothermal experiment (Sabau & Porter, 2007). 
 
Mechanism of DSC  
The DSC mechanism is that heat flows into the two pans by conduction. The flow of heat into 
the sample is greater because of its heat capacity, Cp. The variation in flow dq/dt creates a 
VPDOOWHPSHUDWXUHGLIIHUHQFHǻ7DFURVVWKHVSHFLPHQZKLFKLVPHDVXUHGE\D thermocouple. 
The heat capacity is determined as: 
 ¨7 .GT»GW=KCp ȕ                                                                  Eqn 13          
where the symbols represent the following: 
dq/dt  KHDWIORZ¨7  temperature variation     
Cp= heat capacity                                                  T = temperature  
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K = heat resistance                                                 t = time   
ȕ= heating rate  
In addition, an enthalpy or heat capacity difference causes a change in the temperature 
between sample and reference. The difference in temperature between the sample and 
reference is detected and recorded according to the enthalpy change in the sample, based on 
calibration experiments. 
Using this data (Figure 2.8) the enthalpies of transitions can be calculated by integrating the 
peak using the following equation:                           
                                                         ǻ+ .$                         Eqn 14 
ǻ+LV WKHHQWKDOS\RIWUDQVLWLRQ.LV WKHFDORULPHWULFFRQVWDQWDQG$LV WKHDUHDXQGHUWKH
curve. The calorimetric constant will differ from instrument to instrument, and can be 
determined by analysing a well-characterised standard sample (sapphire or indium) with 
identified enthalpies of transition (Skoog, 1997).   
To clarify the stability relationship between polymorphs, DSC is one of the most useful 
techniques. However, in some cases when the sample degrades following the heating process, 
this method might be confusing since decomposed product can recrystallize and modify the 
melting point of the compound. That notwithstanding, it is still an appropriate technique to 
characterize polymer and excipient interactions and also to estimate the percentage 
composition of each phase following a precipitation process (Barreiro-Iglesias, et al; 2002).  
 
Figure 2.8 DSC curve representing different phase transitions in a solid material. 
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Applications of DSC 
DSC is used to measure melting temperature, enthalpy of melting, percentage crystallinity, 
glass transition temperature, softening, crystallization, presence of recyclates/regrinds, effect  
of plasticisers and polymer blends (presence, composition and compatibility). The 
information provided by the measurements helps formulators to design new drug delivery 
systems with adequate stability and appropriate solubility in-vivo to obtain the ultimate goal 
of drug administration which is improving the bioavailability at the site of action (Chieng, 
2011). 
Following the initial DSC studies, optimized films were analysed using a Q2000 DSC 
instrument. 3-10 mg of each film were placed in T zero aluminium pans (75 µL) and 
hermetically sealed.  
The sample was cooled to -80ºC before heating dynamically:  
1st heating from -80 to 180ºC at a rate of 10ºC/min, 
2nd heating from -80 to 180ºC at the rate of 10ºC/min, and cooling after each heating cycle at 
a rate of -10ºC/min. 
 
In addition, experiments were performed in order to investigate the effect of polymers on 
drug transformation from crystalline to amorphous form during formulation process.  
 
 (a)                                                                   (b) 
                                  
Figure 2.9 (a) TA  and (b) Mettler Toledo DSC instruments. 
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A new set of samples were prepared by addition of the same weight of PM and each polymer 
(CAR 911, P407 and PEG 600) individually to the same amount of deionized water. 
Subsequently, the samples were heated to the same temperature as used during gel formation 
to simulate the formulation conditions. The gels or solutions were poured into Petri dishes 
and incubated in an oven at 60°C for 24 hours to remove the solvent. The samples were then 
analysed individually by DSC using the same method as for the films described above.  
 
2.4.5 Scanning electron microscopy (SEM) 
SEM (Figure 2.10) is used widely due to its ability to provide morphological information of 
biological and physical materials. Applications of SEM in the pharmaceutical industry 
include the following.  
 Deposits and wear debris analysis 
 Particle sizing and characterization 
 Determine the shape and the distribution statistics of particles 
 Quality control check  
 Failure analysis 
 Contaminant analysis (Mueller, 2002). 
 
 
Figure 2.10 Scanning electron microscopy (Adapted from Encyclopaedia Britannica, date accessed 18.08.2010). 
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Mechanism of SEM imaging. The fundamental theory behind the scanning electron 
microscope (SEM) instrument is imaging the surface of the sample following scanning with 
high-energy beam of electrons in a raster scan pattern. After interaction between electron 
signals and atoms in a specimen, various signals are generated which provide information 
FRUUHVSRQGLQJWRWKHVSHFLPHQ¶VVXUIDFHWRSRJUDSK\DQGSURSHUWLHVVXFKDVFRQGXFWLYLW\DQG
composition.  
 
Secondary electrons. During SEM analysis, a beam of electrons is focused on a spot 
volume of the sample, causing energy transfer to the spot. These bombarding electrons, 
known as primary electrons, consequently emit secondary electrons from the sample. 
 A positively charged grid or detector attracts the emitted electrons which are then converted 
into a signal. To construct the SEM image, the electron beam moves across the target area to 
generate lots of signals. These signals are then amplified, analysed and transformed into 
topographic images (Hanke, 2010).  
 
Back scattered electrons. The primary electron beam also results in the emission of 
backscattered (or reflected) electrons from the sample and these have a higher energy level 
and specific direction in comparison to secondary electrons.  
The secondary electron detector is unable to collect the back scattered electron beam unless 
the detector is located directly in their path. All emissions above 50 eV are classified as 
backscattered electrons. This method is useful for chemical analysis of compounds as the 
backscattered electrons have a direct relation with the atomic number of the sample which 
helps to differentiate between samples with at least 3 atomic number differences (Cosslett, 
1986).  
 
SEM was used to evaluate the topographic characteristics and the surfaces properties of the 
films with or without the model drugs. An S360 Cambridge SEM instrument was employed 
to image the surface properties of the film by the secondary electron method. Each sample 
was gold plated before placing in the high vacuum chamber (50 Pa). The image was captured 
using x 50 magnification, acceleration voltage of 5 kV and at a working distance of 10 mm. 
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Figure 2.11  Scanning electron microscopy instrument. 
 
2.4.6 X-ray powder diffraction (XRPD)  
In this technique, the position of numerous peaks demonstrates periodic spacing of atoms in 
the solid state. Since various lattice constants in novel batch crystallizer, can be utilized 
coincidently with dispersive X-ray diffraction to study solution crystallization in situ, this 
method is one of the best approaches to investigate polymorph characteristics. Molecular and 
crystalline structure is the most important information for crystalline solids existing as 
polymorphs and solvates. This data can be obtained by single-crystal X-ray diffractometry.  
 
Applications of powder X- ray diffraction  
The most common application of powder X-ray diffractometry is providing solid 
SKDVHµµILQJHUSULQWV¶¶ ZKLFK RFFDVLRQDOO\ PLJKW EH XVHG WR GHWHUPLQH FU\VWDO VWUXFWXUH
(Vippagunta, et al., 2001). To evaluate and determine the presence of solvent molecules in 
the lattice or changes in density between polymorphs, a comparison between the cell volume 
and other crystalline forms will be beneficial. 
 
Unique X-ray powder diffraction (XRPD) patterns of polymorphs and screening different 
phases or polymorphs in a particular compound can differentiate one form from another. 
Determination of amorphous versus crystallinity by XRPD can be performed via calculation 
of percentage crystallinity. The measurement and determination depends on volume 
concentration of amorphous filler to crystalline active matrix in a drug's dosage form 
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(Mathkar, et al., 2009). Percentage crystallinity is a critical parameter since it can influence a 
drug's processing behaviour and its pharmacological performance. All these tests provide 
information regarding stability. It can present unambiguous information about the formation 
of polymorphs or hydrates under different environmental (storage or processing) conditions. 
Conditions such as increasing temperature and/or humidity during transport or storage could 
have a harmful effect on a drug's performance and toxicity. The non-destructive nature of 
XRPD makes it a useful technique for systematic drug-excipient analysis in pre-formulation 
studies (Maccaroni et al., 2009). 
 Careful excipient selection and evaluation of the drug-excipient interactions, is critical to 
obtain reliable release and bioavailability data. It assists in preventing any unexpected 
stability problems during early formulation or final stages of formulation development.  
In addition, qualitative phase analysis by XRPD and polymorph screening can provide 
extended and full quantitative data which is valuable in optimizing pharmaceutical 
formulations (www.panalytical.com) (date accessed 17/09/2011).  
 
 
 
Figure 2.12  D8 XRD instrument. 
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Experiments were performed to determine the structure of all the pure components and those 
present in the films, with or without model drug, with the aim of determining the various 
forms (crystalline or amorphous) of components that existed within the formulation. The 
films were cut into small pieces to allow loading onto the sample holder. Powdered samples 
were spread on the sample holder and compressed to ensure an even surface.  
 
2T values were entered manually between 5 and 42. A D8 Advance XRPD diffractometer 
(Bruker, Coventry, UK) equipped with a Lyn X± Iris detector and 6.5 mm slit size was 
employed to obtain results in reflection and transmission modes. The instrument parameters 
were set at 40 kV and 40 mA with primary solar slit of 4o and a secondary solar slit of  2.5 
mm while the scattered slit was 0.6 mm. Samples were scanned at a speed of 0.02o, 2T step 
size every 0.1 seconds. Similar experiments were conducted using pure PEG 600, P407 and 
their physical mixtures before and after heating on the DSC.  
 
2.4.7 Stability test by high performance liquid chromatography (HPLC)  
An Agilent 1200 HPLC instrument was employed to quantify the amount of drug present in 
the films to determine the stability of the drugs in the films after storage under two sets of 
conditions. Samples were placed in humidity controlled desiccators (45% relative humidity) 
and at room temperature and the stability was studied for 12 months.  
 
 
  Figure 2.13 High performance liquid chromatography. 
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Films were wrapped in paraffin film to prevent moisture absorption by CAR, which is a 
hygroscopic polymer. Prior to analysing the drug content in the films a 0.5 mg/mL standard 
solution of IBU, and  IND and 1 mg/mL PM was prepared, serially diluted and analysed by 
HPLC to obtain their  calibration curves.  
The weighed samples were dissolved in deionised water (mixed with 2 mL of ethanol  in the 
case of IND and IBU loaded films to ensure complete solubility of the two hydrophobic 
drugs) and injected onto an ODS C18 reverse phase column (Hichrom H50DS-3814) and 
eluted with the respective mobile phases which were methanol: water: ortho-phosphoric acid 
(74:24:2), methanol: water: glacial acetic acid (74:24:2) and methanol: water: ortho-
phosphoric acid (25:75:3 (V/V %)) for IBU, IND and PM, respectively. The flow rate of the 
mobile phase was 1.5 mL/min for IND and IBU and 1 mL/min for PM containing samples. A 
diode array UV detector at 230, 214 and 242 nm was used for IND, IBU and PM samples, 
respectively.   
 
2.5 Formulation development of freeze-dried wafers   
2.5.1 Gel preparation   
As one of the main aims of the project was the development of two related buccal dosage 
forms and comparison of their mucoadhesion, swelling and dissolution characteristics, wafer 
development was performed on the basis of preliminary films evaluations. In order to 
produce freeze-dried wafers, similar optimised gels were prepared as for films containing 
YDULRXVUDWLRVRIț-CAR (1.5, 2, 2.5% w/w), 4% (w/w) P407, with or without the presence of 
PEG 600.  
 
Initially P407 was added to cold water then incubated for two hours at room temperature 
before adding CAR 911 to the solution. This mixture was left overnight at room temperature 
to allow complete hydration of the CAR after which the gel was heated to 40-50°C to ensure 
a homogeneous mixture. The remaining components i.e. plasticiser (PEG 600) and model 
drugs were added and mixing continued for a further 5-10 min. 10 g of the clear gels were 
poured into a six well plate and placed in the freeze-drier.  
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Table 2.3 Composition of the gels prepared during formulation development and optimization process 
for wafers.  
CAR 911 (% w/w) P407 (% w/w) PEG 600 (% w/w) 
1.5 4 ------ 
1.5 4 3.3  
1.5 4 5.5  
2 4 ------ 
2 4 4.4 
2 4 5.5 
2.5 4 ------ 
2.5 4 5.5  
 
 
2.5.2 Drug loading into optimized gels    
This step was performed by formulating wafers initially containing varying amounts of drug 
{0.6-0.7% (w/w) IND, 0.8-0.9 % (w/w) IBU and 1.6-1.9% (w/w) PM} within the gel. The 
procedure was continued until the drug concentration exceeded the optimum amount with a 
consequent collapse in the porous texture of the wafer.  
 
 
Table 2.4 Composition of the gels prepared during formulation development and optimization process 
for wafers.  
CAR 911 (% w/w) P407 (% w/w) PEG 600 (%w/w) Drug (% w/w) 
2.5 4 4.4 0.6 IND 
2.5 4 5.0 0.6 IND 
2.5 4 5.5 0.6 IND 
2.5 4 4.4 0.8 IBU 
2.5 4 5.0 0.8 IBU 
2.5 4 5.5 0.8 IBU 
2.5 4 4.4 1.8 PM 
2.5 4 5.0 1.8 PM 
2.5 4 5.5 1.8 PM 
2.5 4 4.4 0.7 IND 
2.5 4 4.4 0.9 IBU 
2.5 4 4.4 1.9 PM 
2.5 4 4.4 0.6 PM 
2.5 4 4.4 0.6 IBU 
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Drug loading studies were performed by either directly adding the drug to the aqueous gel or  
first adding to ethanol. Ethanol was employed to dissolve hydrophobic model drugs (IND and 
IBU) to increase the amount incorporated into the aqueous gels. The amount of CAR 911 and 
PEG 600 was 2% w/w and 4.4-5.5% w/w, respectively in the presence of 4% (w/w) P407. 
The various formulations prepared are summarised in Table 2.4.  
 
2.5.3 DSC analysis to determine optimized freeze-drying cycle incorporating an 
annealing step   
Identification of critical gel temperatures, such as the eutectic point (Teu), were used to 
ascertain the maximum temperature to which the gel could be heated during the primary 
drying phase and the glass transition (Tg). The Tg of the gel indicates the ultimate temperature 
of the cooling step. To detect the critical temperatures 3-10 mg of the gels were placed in a 
DSC crucible and heated from -80 to 180°C at a scan rate of 10°C/min.  
 
2.5.4 Preparation of freeze-dried wafers      
The first few attempts were conducted by simply freezing the gel in liquid nitrogen initially 
and then continuing freezing (at -55°C under 100 mTorr) and eventually the primary drying 
stage on the older freeze-dryer version (Heto Power dry LL3000, Biopharma Process 
Systems Ltd. Winchester, UK). Although several cycles with various time scales (24 up to 96 
hours) were conducted, the physical characteristics of the wafers did not meet the required 
criteria.   
Subsequently, freeze-drying was pursued with the more modern AdVantage freeze dryer. 
Two modes, manual or automatic, can be used for the freeze drying process on the 
AdVantage instrument; the automatic mode was used because it is considerably easier and 
saves time. Using automatic mode, the freeze drying procedure was carried out by 
programming the freezing and primary/ secondary drying cycles for different time periods 
and temperatures.  
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Freeze-drying cycles comprising freezing, primary and secondary drying were developed 
with the help of the DSC results from section 2.5.3 and consideration of the critical points 
(Tc). Further attempts were made to produce wafers using an annealing procedure, to increase 
the porosity of the wafers, by increasing the size of ice crystals during the freezing cycle.  
 
Figure 2.14  AdVantage Freeze-dryer used in this project. 
 
(a) The first annealing process was performed according to the procedure shown in Figure 
2.15. The gel (previously kept in room temperature, 5°C and -5°C for 30 minutes each) 
was slowly cooled to -35°C and kept at this temperature for 30 minutes before increasing 
the temperature to -10°C for 2 hours and returned again to the initial temperature of -35°C 
(annealing). Sample was maintained at -35°C for 2 hours and subsequently primary 
drying started by turning on the vacuumed pump to remove the ice crystals from the 
surface of the sample by sublimation. During the primary drying, the temperature was 
increased to -10°C for 3 hours, -5°C for 2 hours and finally reached 0°C and maintained 
for 2 hours.  
 
The secondary drying stage involved heating from 0 to 5°C kept for 1 hour and consequently 
25°C to reach room temperature. 
Visual evaluation of the wafers produced with the cycle shown in Figure 2.15 confirmed that 
the process was not suitable due to product collapse from melt back and/or incomplete ice 
removal. Because, the product temperature must be maintained below the Teu (eutectic 
temperature) to retain interstitial space in the solid phase and make it capable of supporting 
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LWVRZQZHLJKWDIWHUWKHLFHUHPRYDODQGSUHVHUYHWKHZDIHU¶VVWUXFWXUHDQHZIUHH]H-drying 
cycle was required. The new freeze drying cycle was planned based on the requirement of 
lower freezing and annealing temperature with a consequent increase in cycle time. 
 
 
 
     
 
 Figure 2.15 Schematic of the freeze- drying process comprising freezing, primary and secondary drying. 
 
(b) DSC analysis determined the eutectic point (12.8°C) of the mixture hence; the initial 
freeze-drying cycle involved cooling gels gradually from room temperature to 5°C, 
maintained for, cooled to 0°C and maintained for 40 minutes, and cooled finally to -55°C 
and maintained for 1 hour. Subsequently, annealing was performed by increasing the 
temperature to -35°C. The annealing process lasted 3 hours to provide adequate time for 
large ice crystal formation. The temperature was returned to the initial temperature and 
maintained for 2 hours before primary drying was initiated.  
 
During primary drying, as the ice crystals were sublimed, the temperature was increased from 
-55oC to -10oC and eventually 0°C (5°C lower than the eutectic point) to prevent melt back 
and preserve the stability of all the components. The whole primary drying procedure was 8 
hours at -10oC followed by 6 hours at -0oC. To increase the stability of the freeze-dried 
wafers at room temperature, secondary drying was performed to further reduce residual wa ter 
content. During all stages of the freeze drying process, from freezing to drying cycles, the 
Room tem 25°C
30 min 60 min
Annealing 5°C
5°C 0°C 60 min
30 min -5°C -5°C 60 min
30 min -10°C -10°C 120 min
120 min 180 min 50 mTorr
-35°C -35°C 100  mtorr
30 min 120 min
200 Torr
Freezing process Primary drying  Secondary drying  
 mTorr 
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pressure was adjusted according to the temperature and with the aid of information provided 
from the manufacturer of the freeze-dryer to achieve the most desirable wafer with acceptable 
water content and flexibility. Based on the optimisation, gels comprising 2% w/w CAR, 4% 
w/w P407 and 4.4% w/w PEG 600 were prepared according to Figure 2.16. 
 
 
 
 
 
Figure 2.16 Schematic of the final freeze- drying process that produced wafers with appropriate characteristics.   
 
2.6 Characterisation of freeze-dried wafers   
2.6.1 Texture analysis   
Texture analysis was employed to measure the mechanical strength of the wafers by 
measuring textural parameters including resistance to compression. The instrument employed 
was a ³7H[WXUHDQDO\VHU+'-SOXV´ZLWK([SRQHQWVRIWZDUHto plot and display the data. The 
experiments were used to select optimized wafers with acceptable flexibility for drug loading 
as well as to determine the effect of increasing drug content. A P6 (6 mm) cylindrical 
stainless steel probe was used to compress the wafers.   
 
Before compression measurements, the thickness of the wafer was measured by micro screw- 
meter in five different areas of each sample (four edges and one in the middle) and showed 
5°C
40 min                         25°C
0°C                     1200 min
40 min              Annealing
               0°C
-10°C           360 min
-35°C 480 min 50 mTorr
180 min
           -55°C -55°C                                  50 mTorr
         60 min 120 min
200 mTorr
Primary drying  Secondary drying  Freezing process  
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thicknesses ranging from 3.5-3.7 mm which was considered uniform. The exact thickness of 
each specific specimen was entered into the texture analyser software prior to compression. A 
force was applied by the probe to compress the wafer to a depth of 2 mm. The software plots 
force vs distance data and the area under the curve which is a measure of the work of 
compression. Instrumental settings to measure the compressibility were as follows: 
 
Test mode: Compression                                         Pre-test speed: 0.1 mm/sec 
Test speed: 0.1 mm/sec                                            Post-test speed:  1 mm  
Hold time: 2 Sec                                                      Trigger type: 2 Sec 
Trigger force: 0 gr                                                   Target mode: Distance 
Distance: 2 mm                                                        Break mode: Off  
Stop plot: Target distance                                       Advance option: On  
 
2.6.2 Hot stage microscopy (HSM) 
HSM was used to provide complimentary data to the results obtained by TGA and DSC with 
regard to the thermodynamic behaviour of pure compounds and wafers with or without the 
presence of model drugs.  
A small amount of the wafer was placed on a glass slide located on the microscope stage. The 
same experimental settings were employed for wafers as previously stated for films in section 
2.4.2. 
 
2.6.3 Thermogravimetry (TGA) 
TGA was employed to measure the residual water in the wafers and the degradation 
temperature/stability of wafers or pure compounds by coupling the TGA instrument with the 
DSC. About 3-10 mg of each wafer was weighed, placed in aluminium pans (100 µL) and the 
weight loss determined by using a high resolution TGA 2950 or a SETARAM TGA 
instrument. The experimental parameters used to evaluate the water content, was the same as 
for option 1 (section 2.4.3) while for degradation studies option 2 (section 2.4.3) was used.     
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2.6.4 Differential scanning calorimetry (DSC) 
As previously stated DSC experiments were used to ascertain the thermodynamic profile of 
pure compounds and the Q2000 instrument used to detect the melting point and glass 
transition point of the wafers, as well as to investigate any possible interactions between 
wafer components. T zero aluminium pans (75 µL) were packed with 3-10 mg of sample and 
hermetically sealed and the same method employed as for the DSC film experiments (section 
2.4.4).  
 
2.6.5 Scanning electron microscopy (SEM) 
SEM experiments involved the topographic investigation of the blank wafers produced with 
GLIIHUHQWUDWLRVRIț- CAR 911 and 4% (w/w) P407, with or without PEG 600 as a plasticizer. 
In addition the optimized gel was loaded with 0.6% (w/w) IND, 0.8% (w/w) IBU or 0.6/1.8% 
(w/w) PM and SEM images of the wafers obtained.  
The samples, which were not gold coated, were placed in a low vacuum (20Pa) SEM 
chamber. SEM images were obtained using a Jeol instrument (Tokyo, Japan) with an 
accelerating voltage of 20Kv, magnification of x 50 and back scattered electron technique 
with artificial shadowing.  
 
2.6.6 X-ray powder diffraction (XRPD)  
XRPD was employed not only to evaluate the diffraction profiles of all the pure components 
in the wafers, but also to analyse wafers with or without model drugs.  
The aim was to investigate the various forms (crystalline or amorphous) of drug components 
that existed in the formulation.  
The wafers were broken up into smaller pieces and placed in the sample holder in order to 
obtain transmission mode XRPD data at the 5 and 42(2T) range. All the other parameters and 
instrumental settings were the same as those employed for XRPD analysis of the films 
(section 2.4.6). 
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2.6.7 Stability test by HPLC  
HPLC (Agilent 1200 Technology) was used to check the stability of the drugs remaining in 
the freeze-dried wafers during storage at room temperature (about 15°C) and 45% RH for 6 
months. Wafers were wrapped in paraffin to prevent moisture absorption by CAR. Prior to 
analysing the drug content in the wafers a 0.5 mg/mL standard solution of IBU or IND or       
1 mg/mL PM was prepared, serially diluted and analysed by HPLC to plot the calibration 
curves. The samples were dissolved in deionised water (PM) or ethanol/ deionised water 
4:100 by volume (for IND and IBU loaded wafers only) to ensure the two hydrophobic drugs 
were completely dissolved. The sample solutions were then injected onto an ODS C18 reverse 
phase column (Hichrom H50DS-3814) and eluted with mobile phases. The experimental 
conditions used were the same as for film stability tests (section 2.4.7). 
 
2.7 Hydration, dissolution and mucoadhesion of the films and wafers  
2.7.1 Hydration and swelling studies 
Before performing the dissolution studies, the behaviour of the films or wafers under aqueous 
conditions were investigated. Hence, hydration tests were conducted using two different 
media at 37°C temperature and the results obtained were correlated with the dissolution 
profiles. Medium 1 was 0.9% sodium chloride solution, to mimic biological fluids.  
Since the secretion of saliva is 0.3 ml/min (Eliasson, at al., 2009), the volume of medium 1 
used was 42 mL so that films or wafers were immersed for 140 minutes.  
 
The other medium used was phosphate buffer which was prepared by the addition of 100 mL 
of KH2SO4 (0.1 M) to 13 mL of NaOH (0.1 M) and final pH confirmed with a pH meter and 
maintained at 6.2 (mimicking the buccal mucosa and saliva pH).  
 
The swelling capacity of polymeric films and wafers were determined by immersing samples 
of films and wafers cut to 3 cm×3 cm in size in buffer solution (pH=6.2) or sodium chloride 
solution in a 100 mL beaker. Samples of film or freeze-dried wafer were weighed before 
placing in the saline or phosphate buffer solution. The sample was taken out of the solution 
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every 20 minutes and reweighed and the procedure was continued for 140 minutes; and 
results were plotted as weight changes versus time. Calculation of % swelling (% weight 
change) for the polymeric matrices was determined using equation (15) below, where W0 and 
Wt are the weights of the films or wafers initially and after swelling at time t respectively. 
Each data point represents the mean (± s.d) of three replicates.   ? ൌ ଴ െ୲଴ ൈ  ? ? ? ? ? 
 
2.7.2 Drug dissolution studies   
To determine the drug dissolution profiles of the films and freeze-dried wafers a Varian UV 
spectrometer was employed. Before performing dissolution studies, the actual content of 
IBU, IND and PM in the film or freeze-dried wafer specimens was calculated, based on 
amounts initially loaded. Dissolution studies were performed using two different dissolution 
media deionised water as a control and buffer solution mimicking saliva pH conditions:  
 
a. Saline solution (0.9% sodium chloride) with measured pH of = 5.6 and 37°C. 
b. Buffer solution with pH= 6.2 to simulate that of saliva and 37°C. 
 
As a control, equal amounts of model drugs in the wafer or film specimen were weighed and 
dispersed separately in two 100 mL beakers containing 40 mL buffer solution and 40 ml 
deionised water, at 37°C with continuous stirring and the same procedure repeated for the 
wafer specimens.  
 
The drug released from the polymeric films and wafers was measured using samples cut in 3 
cm×3 cm size and immersed in buffer solution (pH = 6.2). Each data point represents the 
mean ± s.d. of three replicates. Dissolution media were sampled at 5 minutes intervals 
starting from time zero and UV absorbance measured using a Varian Spectrophotometer 
(Yarnton, UK). The absorbance at 318 nm for IND (Malamataris, 1990), 221 nm for IBU 
(Kislalioglu, et al., 2006) and 245 nm for PM (Di Martino, et al., 1996) loaded films and 
freeze-dried wafers which was dissolved in the deionized water/ethanol was measured. 
Amount of drug released (mg) was calculated from the UV calibration curve and % release 
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versus time profile plotted. The kinetics of drug release from the films and wafers was 
evaluated by finding the best fit of the dissolution data to zero and first order, Higuchi and 
Korsmeyer±Peppas equations. 
 
2.7.3 Mucoadhesion studies for films and wafers 
Mucoadhesivity tests were conducted by employing a P/75 (75 mm diameter) probe with 
films or wafers specimen fixed on the surface of probe using double sided adhesive tape. A 
Petri dish containing agar gel was employed as the mucosal substrate equilibrated with       
200 PL of buffer solution (pH = 6.2) to simulate pH conditions in the buccal environment. 
The sample was then placed on the agar surface and contact maintained for one minute to 
allow water absorption and adhering to the surface (Figure 2.17). The texture analyser 
settings summarised below were applied to pull the sample and detach it from the agar 
surface and the peak force of detachment measured.  
Test mode: Tension                                                   Pre-test speed: 0.5 mm/sec 
Target mode: Distance                                              Trigger type: Auto (Force) 
Trigger force: 1 N                                                     Break mode: Off 
Stop plot at: Target distance                                     Tare mode: Off 
Advance: on 
 
 
Figure 2.17  Texture analyser instrument showing the on-going adhesion tests. 
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2.8. Statistical analysis  
To compare the dissolution and mucoadhesion results (WOA and stickiness) statistical 
analyses were employed. All measurements were performed in triplicate in each experiment 
and the results are presented as the mean ± standard deviation (s.d).  
To test for significant differences between means, statistical analysis was performed by one-
way ANOVA. The results were considered statistically significant if the p value of < 0.05 
was obtained. To compare the dissolution profiles for films and wafers variables, additional 
investigations were performed using the modified Moore and Flanner equation (Eqn 16) by 
calculating the similarity (f2) factors. The dissolution profiles of the pure crystalline drug 
were used as a reference in calculating the similarity factors (f2), where n is the number of 
time points, R is the dissolution value of the reference t (pre-change) batch at time t, and T is 
the dissolution value of the test batch at time t (post-change).  
 ᐦ2=50×log { ? ? ൅  ?ଵ௡  ȁ ௝ܴ െ ௝ܶȁି଴Ǥହ௡௝ୀଵ  ?} ×100                                                                                      Eqn 16 
 
The similarity factor is a logarithmic reciprocal square root transformation of the sum of 
squared error and is a measurement of the similarity in the percent (%) of dissolution between 
the film and wafer drug release curves. For curves to be considered similar, f2 values should 
be close to 100. Generally, f2 values greater than 50 (50-100) imply similarity of the two 
curves (i.e. the performance of the test (post-change) and reference (pre-change) products) 
(http://www.fda.gov/cder/guidance.htm).
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Chapter 3  '6& VWXGLHV RI LQWHUDFWLRQ EHWZHHQ VWDUWLQJ PDWHULDOV
SK\VLFDOPL[WXUHV 
 
Chemical interactions between various ingredients alter the stability of pharmaceutical 
products. Investigating the interaction between starting materials is a pre-requisite to develop 
a stable high quality pharmaceutical formulation. Changes in melting point directly influence 
the stability of a product. One of the fundamental changes that might modify the melting 
point of a compound and consequently alter the stability of the system is the interaction 
between excipient(s) and API(s). The formation of a mixture, following the interaction 
between component compounds, influences the characteristics of the system which therefore 
need to be determined. The aim of the study was to evaluate the interactions between PEG 
600 and P407 prior to their use in a pharmaceutical formulation. In addition, the effects of 
existing polymers on crystalline-amorphous habits of models drug were evaluated. 
 
3.1 Study of the interaction between PEG 600 and P407    
The DSC results of films and wafers made by mixing PEG 600 and P407 showed additional 
melting transition which appeared between the melting peaks belonging to PEG 600 and 
P407. These observations led to further examination to explore possible interactions between 
P407 and PEG 600 (Bely, et al., 2010).  
DSC analysis was conducted using method described in section 2.2. Results were evaluated 
by comparing the melting transition of pure P407 and PEG 600 with the detected melting 
transitions from the first and second heating cycle of the mixtures. All of the mixtures 
contained P407 and PEG 600 but comprising different ratio of two components. Initial 
analysis showed a wide melting transition over temperature range of 40.0 to 63.0°C meaning 
pure P407 is in crystalline form (Figure 3.1). Similar result for pure PEG 600 (Figure 3.2) 
was observed at temperature range of -10.0 to 22.0°C. However, the normalized melting 
peaks were detected at around 51.4ºC and 6.2ºC for P407 and PEG 600, respectively. 
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Figure 3.1 DSC results for P407. 
 
 
Figure 3.2 DSC results for PEG 600. 
 
The DSC studies involved two heating cycles. When examining physical mixture of PEG 
600/P407(ratio 58/42) the results after the first heating cycle showed the first melting 
transition onset point corresponding to PEG 600 at 0.4°C and the second one for P407 at 
42.8°C (Figure 3.3). The results showed a significant difference between the detected melting 
points of the pure compounds and mixtures. However the difference is more significant after 
the second heating cycle.  
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As Figure 3.4 shows, the thermal events from the second heating cycle appeared at 3.6°C for 
PEG 600 and 41.1°C for P407 plus an additional melting point transition appeared at 23.4°C. 
The current observation explains the reason for the DSC profile of the film exhibiting three 
separate melting transitions instead of two transitions corresponding to PEG 600 and P407 
(Figure 3.1). In addition, the results clearly demonstrate that by mixing PEG 600 and P407 
sharper peaks for the melting points of individual components were detected which may 
suggest that molecules of different chain length from the majority of molecules for both PEG 
and P407 may be involved in that interaction. 
 
Figure 3.3  DSC results of the first heating cycle for a physical mixture of P407/ PEG 600 (ratio 58/42). 
 
 
Figure 3.4  DSC results of the second heating cycle for a  physical mixture of P407/ PEG 600 (ratio 58/42). 
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It is plausible therefore that a mixture of P407 and PEG 600 is formed within the film which 
has a direct modifying effect on the melting point of each compound (Figure 3.5).  
 
Figure 3.5 DSC results of film comprising 2.5% CAR+ 4% P407+ 6.5% PEG and 0.8% IBU within the initial 
gel.  
 
Figure 3.6 shows the melting point values for a series of PEG/ P407 mixtures. It is evident 
that with an increase in percentage of P407, the melting point of PEG is decreased from 
14.2ºC to 0.7ºC for pure PEG 600 and 10/90 mixture (PEG 600/P407), respectively. 
However, the same effect has not been observed with the change in melting point of P407.  
 
After addition of 20% of PEG 600, P407 reached its minimum melting point of 41.2ºC and 
remained fairly constant with further increase of PEG 600/P407 ratio. The most interesting 
finding is the formation of what is believed to be a complex (mixture) of PEG/P407 at ratios 
of 30/70; 40/60 up to 80/20 with the melting point of the complex being relatively uniform 
(26.7ºC). This additional transition confirms that not only do the two compounds physically 
interact but also form a unique entity that has characteristic properties i.e. melting behaviour. 
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Figure 3.6 DSC transition onset values for a mixture of 0/100 (%w/w) to 100/0 (%w/w) of PEG 600/ P407 
{mean ± s.d, (n=3)}. 
 
According to the DSC results significant changes in melting points values between the 
individual samples of PEG 600 and P407 and the mixture were detected (Table 3.1).  
 
Thus, this finding confirms that an interaction occurs between the two polymers. However, 
the extent of interaction varies and depends on the ratios of the two compounds in the various 
mixtures. Subsequent to the evaluations of DSC thermograms in terms of the transition point 
onset additional investigations were conducted to scrutinize the enthalpy values and the 
changes for each transition and the results are summarised in Table 3.2. However, the result 
UHODWHGWRWKHPL[WXUHRIRI33(*GLGQ¶WIROORZWKHVDPHWUHQGIRU3(* 600 
melting point with a sudden decrease in the onset at this point.  
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Table 3.1 Melting transition values for PEG 600, P407 and the new entity phase.    
Runs               1st                                    Heating 
 
                 2nd                                                              Heating 
Tm Peaks PEG 
600           
P407            PEG  
600          
Mixture            P407             
Sample Onset 
°C 
Peak 
°C 
Onset 
°C 
 
Peak 
°C 
Onset 
°C 
Peak 
°C 
Onset 
°C 
Peak 
°C 
Onset 
°C 
Peak 
°C 
100% 
PEG 
6.8± 
0.1 
20.2± 
0.6   
14.2± 
0.5 
20.2± 
0.4     
(90/10)% 
PEG/P407 
14.7± 
0.2 
25.4± 
0.2 
49.4± 
0.6 
57.1± 
0.7 
9.5± 
1.0 
16.5± 
0.9   
43.1± 
0.1 
44.1± 
0.2 
(80/20)% 
PEG/P407 
5.0± 
0.3 
18.9± 
0.7 
46.7± 
0.4 
56.4± 
9.4± 
0.6 
 
15.9± 
0.5 25.2±0.4 32.8±0.3 
43.6± 
0.3 
45.9± 
0.2 
(70/30)% 
PEG/P407 
10.0± 
0.1 
20.4± 
0.1 
47.8± 
0.5 
57.3± 
0.6 
5.0± 
0.1 
17.9± 
0.2 26.1±0.1 37.6±0.2 
43.4± 
0.1 
45.4± 
0.2 
(60/40)% 
PEG/P407 
11.8± 
0.4 
24.6± 
0.6 
44.2± 
0.7 
59.2± 
0.8 
7.8± 
0.4 
18.6± 
0.3 28.8±0.2 37.9±0.3 
42.8± 
0.3 
46.2± 
0.3 
(50/50)% 
PEG/P407 
9.1± 
0.5 
17.2± 
0.4 
47.5± 
0.5 
54.3± 
1.1 
1.3± 
0.3 
 
12.4± 
0.3 26.7±0.2 38.0±0.5 
40.3± 
0.2 
45.3± 
0.3 
(40/60)% 
PEG/P07 
8.9± 
0.3 
16.5± 
0.9 
48.5± 
0.1 
59.5± 
0.7 
5.2± 
2.0 
21.6± 
0.3 27.1±0.2 37.9±0.4 
41.7± 
0.7 
47.2± 
0.6 
(30/70)% 
PEG/P407 
55.1± 
0.4 
58.2± 
1.0 
50.1± 
0.2 
59.7± 
0.1 
3.1± 
0.6 
17.2± 
0.5 27.9±0.6 37.3±0.3 
41.4± 
0.2 
46.8± 
0.3 
(20/80)% 
PEG/P407 
  
45.3± 
0.2 
54.3± 
0.2 
0.7± 
0.4 
12.2± 
0.3   
41.3± 
0.2 46.3±0.5 
(10/90)% 
PEG/P407 
  
51.8± 
0.0 
59.9± 
0.1 
0.7± 
0.5 
11.5± 
0.6   
43.6± 
0.0 
49.9± 
0.1 
100% 
P407   
55.1± 
0.4 
58.2± 
0.4     
49.4± 
0.4 
50.2± 
0.4 
 
During the second heating cycle and after the interaction a similar trend was observed for 
either P407 or PEG 600 enthalpy values as an increase in the ratio of one component caused a 
decrease in enthalpy value of the other compound (Table 3.2).  
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same trend as melting point. Instead the sudden increase in enthalpy value at (70/30) % PEG 
600/P407 ratio might be due to stimulation effect of mixture in recrystallizing the PEG 600, 
however this requires further investigations.         
 
Table 3.2 Enthalpy values for PEG 600, P407 and the new entity phase transition peaks.    
DSC Runs 1st                    Heating 2nd                                      Heating 
Sample 
PEG 600 
enthalpy 
(J/g) 
P407 
enthalpy  
(J/g) 
PEG 600 
enthalpy 
(J/g) 
Mixture 
(J/g) 
P407 
enthalpy 
(J/g) 
100% PEG600 92.1±1.8 
 
90.5±0.8 
  
(90/10)% PEG600/P407 84.0±2.3 108.0±2.8 84.3±1.2 
 
8.2±0.4 
(80/20)% PEG600/P407 83.3±1.8 103.8±1.3 59.7±0.9 
 
16.9±0.7 
(70/30)% PEG600/P407 92.7±2.9 91.2±1.0  75.5±0.5 7.3±0.6 36.1±1.3 
(60/40)% PEG600/P407 53.5±1.1 85.4±0.9 37.1±1.4 11.8±0.8 36.7±0.9 
(50/50)% PEG600/P407 49.9±1.2 63.6±1.6 40.6±0.9 13.0±1.1 35.7±1.7 
(40/60)% PEG600/P407 30.4±0.6 85.4±1.3  23.3±1.7 2.8±0.4 64.4±1.9 
(30/70)% PEG600/P407 23.2±1.6  91.2±1.1 14.3±0.9 15.6±0.9 71.9±0.9 
(20/80)% PEG600/P407  7.3±0.7  103.8± 0.8 3.1±0.5 8.3±0.7 89.3±0.4 
(10/90)% PEG600/P407 2.1± 1.5 108.0±1.8 1.0±0.2 
 
96.0±1.4 
100% P407 
 
113.9±0.5 
  
111.5±0.6 
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Figure 3.7 XRPD profiles showing  combined diffractograms for PEG 600, P407 and mixture of PEG 600/P40 
before and after interaction. 
 
Figure 3.7 presents the results of additional XRPD studies conducted to investigate and 
support the DSC observations (results enclosed in appendix chapter). The results confirmed 
the presence of crystalline P407 plus amorphous form of PEG 600 within the sample. By 
evaluating DSC and XRPD results feasibility of co-crystallisation or production of new 
crystalline form is unlikely. Therefore, there are two possible explanations with regards to the 
identity of the new entity within the film matrix and discussed in the section below. 
 
3.2 DSC analysis for interaction between the compounds in films  
As mentioned above there are two explanations including the solubilisation of P407 in the 
PEG 600 which could result in formation of micelles of P407 in the core surrounded by PEG 
600 in the shell. However, the comparison of XRPD diffractogram (Figure 3.7) for pure PEG 
600 and P407 and their mixtures before and after heating in DSC demonstrates that this 
explanation is unlikely to be true as PEG 600 is predominantly present in amorphous form in 
the system. Furthermore, the DSC results and the above hypothesis relate to the non-drug 
loaded films but not the physical mixtures or drug loaded films and therefore cannot account 
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 for the incorporation of model drug within the micelles. Although a shift in the melting 
transition of P407 and PEG 600 was observed, it did not have any effect on the thermal 
characteristics of IBU. Therefore it can be concluded that the model drug was not 
incorporated in micelles comprising PEG 600 and P407.     
Furthermore, the chemical structure of P407 shows that it comprises 79% PEG and 21% PPG 
(polypropylene oxide). PEG has the ability to form inter-chain hydrogen bonding as well as 
hydrogen bonding with water. It is therefore possible that the presence of water may promote 
greater interaction of the PEG chains of P407 and PEG 600 through greater hydrogen 
bonding. Consequently increase in the residual water promotes greater interaction of the PEG 
chains of P407 and PEG 600 through greater hydrogen bonding.  
In addition, the comparison between the enthalpies of PEG 600 and P407 demonstrated that 
the enthalpies variation was negligible which confirmed the probability of inter chain 
hydrogen bonding occurring (Sawatari and Kondo, 1999).  
 
3.3 Effect of polymers on model drug 
DSC analysis revealed new data which explained the reason for drug transformation from 
initial crystalline to amorphous form. Additional DSC analysis was conducted to evaluate the 
effect of various polymers on one of the model drugs (PM) during film formation. According 
to Figure 3.8 PM has two polymorphs including monoclinic polymorph (Tm= 168.6ºC). This 
form is the initial form and due to fast cooling it can produce amorphous form with glass 
transition point at around 21.8ºC. However amorphous form is unstable and recrystallization 
can be initiated upon heating and resulting in the orthorhombic form (Tm= 158.1°C).    
 
According to Figure 3.9 the sharp melting transition at 168.5°C was observed for pure PM 
film showing the presence of monoclinic polymorph. Similarity of the results with melting 
transition value of the initial form of PM demonstrates that applied temperature during film 
formation process did not have any effect on the physical properties of the PM.    
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Figure 3.8 Amorphous PM, recrystallization and converted orthorhombic polymorph. 
 
 
Figure 3.9  DSC results for solvent cast film prepared from PM and film. 
 
 
In addition, the melting thermal event was still detected after addition of the P407 and CAR 
911. However, due to addition of CAR 911 the monoclinic polymorph (Tm= 168.5ºC) of PM 
was converted to orthorhombic form with melting transition onset at 158.0°C. Though such 
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phenomena confirmed that, CAR GRHVQ¶WKDYHDQ\LPSDFWRQIRUPDWLRQRIDPRUSKRXVIRUP
of PM (Figure 3.10).  
 
         Figure 3.10  DSC results for film prepared from PM, CAR and water. 
 
 
According to Figure 3.11 addition of P407 could have an effect on the physical properties of 
PM and produced polymorphs, however did not impart on formation of the amorphous form.  
 
 
Figure 3.11  DSC results for film prepared from PM, P407 and water. 
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Furthermore, results from DSC analysis of combination of PEG 600 and PM (Figure 3.12) 
demonstrated the recrystallization of PEG 600 at -14.5°C. Subsequently, this crystalline form 
melted at two different temperatures -4.6°C and 66.7°C. 
  
Figure 3.12  DSC results for film prepared from PM, PEG 600 and water. 
 
The most important outcome from the DSC thermogram is the absence of PM melting 
transition which is evidence of conversion (Figure 3.12). The comparison between DSC 
results in Figure 3.9, Figure 3.10 and Figure 3.11 demonstrate that the conversion of PM was 
not due to addition of CAR 911 and P407 or applying heat (40-50°C) during the gel 
formation process. They also however, suggest amorphous formation due to the presence of 
PEG 600. In summary, DSC results of physical mixtures showed that PEG 600 and P407 
interacted during heating. These phenomena have a direct effect on melting point transitions 
of both PEG 600 and P407 as well as formation of the new entity. Additional results were 
thermal events following the addition of each individual polymer. The observations showed 
that crystalline PM was converted to amorphous form due to addition of PEG 600 and 
remained stable owing to prevention of recrystallization. Furthermore, the later results 
confirmed that heat which was applied during the gel formation (40-50°C) and film formation 
(oven 60°C) was not the cause of crystalline to amorphous conversion. This observation was 
compatible to previous studies by Bely and co-workers (2010) and Chakravarty and co-
workers (2011). 
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Chapter 4 'HYHORSPHQWDQGFKDUDFWHULVDWLRQRIILOPV 
4.1 Film development 
4.1.1 Gel formulation 
Eudragit L100 did not dissolve in the aqueous system and did not produce a gel except with 
high percentage of ethanol as a co-solvent. This was deemed undesirable therefore this 
polymer was not used for further film development. In addition, stirring the system on a hot 
plate with a magnetic stirrer was time consuming and resulted in excessive loss of water by 
the time gel was formed. As a result, a motorized overhead homogenizer was employed for 
subsequent gel preparation. In addition, because P407 is a surfactant, its natural physico-
chemical properties resulted in the generation of thick foam during the overhead stirring of 
the hydrated gels. This resulted in hydrated gels with lots of entrapped air bubbles (Figure 
4.1) which were not easily released and affected the final appearance of the film. Such 
entrapped air bubbles can consequently affect other properties of the film such as tensile 
testing and drug release profiles. To reduce the amount of generated air bubbles and ease of 
their removal, two different approaches were attempted: 
 
1) heating the polymer at very high temperatures (70-80°C). 
2) stirring very slowly.  
 
Figure 4.1  The physical appearance of gels containing high levels of P407 showing thick and foamy  
characteristic. 
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The time required for complete dispersion, hydration and subsequent dissolution of different 
polymers was different as most of the polymers are high molecular weight components with 
low ability to readily disperse in water. This was overcome in two ways; increasing the 
temperature of the water during dispersion caused an increase in hydration rate of the 
polymer and subsequent dissolution. By prolonging the swelling time of CAR in water from a 
few minutes to a 24 hour period, more complete hydration was achieved which allowed 
reduction in hydration temperature. This approach has both advantages and disadvantages: 
lowering the jellification temperature from 70-80°C to 40-50°C was deemed advantageous 
for possible future film formulation with thermolabile drugs such as proteins or peptides. 
However, this method is very time consuming as the hydration and swelling time is increased 
and requires formulation to be planned in advance to allow the 24 hour hydration time. 
Another observation from the slow homogenisation approach was that the upper layer of the 
gel solidified quickly and thus the gel becomes non-uniform which resulted in films with 
non-uniform thickness. Therefore, the most effective and optimum concentration of P407 to 
avoid excess bubble formation was 4% (w/w). 
 
Interestingly, the maximum percentages of the two insoluble drugs that could be loaded in the 
gels prepared by dissolution of drugs in deionized water were 0.4% for IND and 0.5% for 
IBU while the results from the films produced by dissolving drugs in ethanol showed a 
maximum drug loading of 0.6% (w/w) and 0.8% (w/w) for IND and IBU respectively. 
Therefore, it is confirmed that the drug loading capacity was increased by employing ethanol 
as a co-solvent and helped disperse the drug evenly within the gel. 
 
4.1.2 Drying time 
After several other experiments to investigate the appropriate time for various films to be 
dried in the oven, there were no significant differences in weight after 24 hours. It was 
decided to retain gels in the oven for 24 hours maximum for film formation. Noticeably, the 
drying process of unplasticized films took a shorter time (about 12 hours) whilst plasticized 
films required the maximum 24 hours for complete drying. This is because both glycerol and 
PEG used as plasticizer can retain water molecules which therefore slows down the rate of 
water removal.  
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4.1.3 Visual evaluation of initial gels and resulting films 
The gels before solvent casting and the resulting films were visually evaluated and the results 
are summarised in Table 4.1. Evaluation of films was based on criteria such as: 
 Transparency: films must be transparent without any entrapped air bubbles  
 Plasticity: the  film should not be brittle and fragile as it will affect physical and 
mechanical stability during handling  
 Thickness: ideal films must have optimum thickness (less than 0.4 mm) as this impact 
on patient convenience when applied to the buccal mucosa. In addition, it has an 
effect on the drug release rate as it determines the thickness of the gel formed after 
hydration and therefore the diffusion distance of drug during release studies (Miller-
Chou and Koenig, 2003). See Figure 4.2-Figure 4.5. 
 
Figure 4.2 Clear, transparent gel (2% CAR 
812 + 2% P407+2% PEG 2000). 
 
Figure 4.3 Clear, transparent, well plasticised  
Film (1.5% CAR 911+2% P407+ 4.5% PEG 600). 
 
Figure 4.4  Non transparent and brittle film  
(1.5% CAR 379+2% P407+3% PEG 6000). 
 
Figure 4.5 Transparent, brittle unplasticised 
film (1.5% CAR 911). 
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4.1.4 Evaluation of drug loaded films 
The preliminary evaluation of the physical appearance and characteristics of different films 
formulated, with different ratios of two grades of CAR (911 & 812), P407 and model drugs in 
the presence of two different plasticizers (glycerol & PEG) showed slightly different 
observations. The results demonstrated the need for modifications in the amounts and type of 
formulation components as well as the preparation method to achieve optimum 
characteristics. This implied further optimisation of the film formulation to account for the 
properties of the model drugs (PM which is a hydrophilic molecule and IBU and IND which 
are less hydrophilic). Dispersing the latter two model drugs within the gel required a co-
solvent for achieving a suitable film due to their hydrophobic nature and poor solubility in 
aqueous media compared with PM. Addition of the model drugs also had effects on the 
physical and mechanical characteristics of the resulting films which were subsequently 
investigated using suitable characterisation techniques.   
 
4.1.5  Poloxamer and carrageenan ratios 
When the amount of P407 was increased to 8% w/w combined with 3% w/w CAR, the 
resulting film demonstrated ideal physical properties. However, these films were undesirably 
thick (0.7- 0.8 mm) and also exhibited excess air bubble due to incorporation of P407 at a 
concentration > 4% w/w as previously mentioned. Therefore the concentrations of both 
polymers were reduced to produce thinner films within reasonable formulation processing 
time. Films containing of 2.5% w/w CAR (812 & 911) and 8% w/w P407 showed sufficient 
physical stability but the foam generated during high speed stirring, as a consequence of the 
high ratio of P407, was a serious limitation.  
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Table 4.1  Physical characteristics of gels and films formulated with carrageenan (CAR), poloxamer 
407 (P407) and different grades of PEG. 
P407 
(% w/w) 
CAR 
(% w/w) 
PEG 
( %w/w) Gel characteristic 
Film 
characteristic 
2 2 (812) --------- Transparent/ no bubbles/ easy to pour 
Transparent/ very 
brittle 
2 2 (812) 2 PEG 2000 Transparent/ no bubbles/ easy to pour 
Transparent/ very 
brittle 
3 
1.5 
(812,911,379 ) 
4.5  PEG 600 Transparent/ no bubbles/ easy to pour 
Transparent/ good 
film 
5 1.5 (812,911) 4.5  PEG 600  Transparent/ no bubbles/ easy to pour 
Transparent/ good 
film 
6 1.5 (812,911) 4.5 PEG 600  Transparent/ no bubbles/ easy to pour 
Transparent/ good 
film 
7 1.5 (812,911) 4.5 PEG 600  Transparent/ no bubbles/ easy to pour 
Transparent/ thick 
film 
2 2 (379) 4.5 PEG 20000  Transparent/ no air bubbles/ easy to pour 
Transparent/ very 
brittle 
4 ------- ------ No gel structure  NA 
2 2 (379) ------ Transparent/ no air bubbles/ easy to pour Not transparent 
2 2 (911, 812) 3 PEG 2000  Agar structure/ transparent Very brittle 
3 1.5 (812, 911) ------ Agar structure/ transparent Brittle 
3 1.5 (812, 911) ------ Easy to pour/transparent gel  Brittle 
2 1.5 (911) --------- Easy to pour/transparent gel  Brittle 
2 1.5 (379) 3 PEG20,000 Easy to pour/transparent gel  
Very brittle/not 
transparent 
8 4 5 PEG 600 Foamy  gel/ high viscosity Brittle/ thick   
 
However, such high percentage of P407 allowed the incorporation of higher amounts of drug 
in the final films due to the surface active properties of P407 which helps drug molecules to 
be readily dispersed within the formulation.  
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As a compromise, the most appropriate polymer concentrations for optimum film formulation 
were 2.5% w/w CAR 911 and 4% w/w P407. In the case of CAR 812 based films, reduction 
in the concentration of P407 from 8% to 4% (w/w) produced films with ³non-ideal´ physical 
properties including non-uniform texture, non-transparent, patchy appearance arising from 
individual components precipitating out and brittle to handle. Furthermore, addition of model 
drugs resulted in increased gel viscosity and produced brittle and opaque films (Figure 4.6).  
 
As a result, CAR 812 was not employed for further film development (Figure 4.6). CAR 379 
produced non transparent and very brittle films (Figure 4.4) which are not desirable, though 
the initial gel showed acceptable properties.  
 
 
(a) 
 
(b) 
Figure 4.6 Films formulated with CAR 812 and IBU with  (a) PEG and (b) GLY  
 
4.1.6 Films plasticised with GLY or PEG 
During the initial investigations, film formulation was carried out with and without 
plasticiser. Unplasticised films showed some plasticity but this was not flexible enough to 
satisfy the criteria outlined in section 4.1.3. Although use of GLY as plasticiser in blank films 
showed acceptable physical characteristics, employing GLY as a plasticizer had a detrimental 
effect on the physical properties of films containing a model active drug (Figure 4.7). The 
major limitation was that glycerol caused most of the incorporated drug to precipitate out and 
accumulate on the film surface resulting in an opaque and non-homogeneous film. 
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Optimization of various component ratios and plasticising effect of different grades of PEG 
was a critical step that required extensive investigation as summarised in Table 4.2 and Table 
4.3. This effect might be associated with the physical characteristic of the PEG 20,000. On 
the other hand, the flakes of PEG 20000 dispersed in the system easily and produced a very 
transparent gel but not able to reduce the glass transition and thereby improve plasticity, 
resulting in much more brittle films. The results confirmed that the optimum plasticiser was 
PEG 600, and was therefore the plasticiser of choice for all subsequent films formulated. 
Films containing PEG 600 exhibited better physical characteristics with and without drug 
incorporation. Films plasticized with PEG 600 were clear, transparent, and possessed 
appropriate flexibility (Figure 4.8). The plasticizer in the system functions by providing 
increased free volume between the polymeric chains which allows them to slide together and 
subsequently produces appropriate flexibility and tensile strength. The optimum level of PEG 
600 was evaluated by texture analysis and the results used to select the most flexible films 
that were easy to handle without breaking or sticking (Riggleman, et al., 2007).  
 
  
Figure 4.7 Films containing glycerol with loaded drug. 
  
Figure 4.8 Films containing PEG with loaded drug. 
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Table 4.2 Characteristic of films, gels and films with three CAR grades, P407 and various grades of 
PEG. 
P407 
(% w/w) 
CAR  
(% w/w) 
PEG 
(% w/w) Gel characteristic Film characteristic 
7.0 2.0 (812,911) 5.5 PEG 600 
Transparent/no bubbles/easy 
to pour 
Thick/transparent/flexible 
8.0 3.0 (911,812) 5.5 PEG 600 
Transparent/no bubbles/easy 
to pour 
Thick/transparent/flexible 
10.0 4.0 (812,911) 5.5 PEG 600 
Transparent/no bubbles/easy 
to pour 
Thick/transparent/brittle 
2.0 2.0 (911) 5.0 PEG 20000 
Transparent/no bubbles/easy 
to pour 
Thick/transparent/very 
brittle 
2.0 1.5 (812,911,379) 3.0 PEG 6000 
Transparent/no bubbles/easy 
to pour 
Transparent/very brittle 
2.0 1.5 (812,911,379) 4.5 PEG 600  
Transparent/no bubbles/easy 
to pour  
Transparent/good 
elasticity 
2.0 
 
1.5 (812, 911,379) 
 
4.5 PEG 2000 
Transparent/no bubbles/easy 
to pour  
Transparent/very brittle 
2.0 1.5 (812, 911) 4.5 PEG 20000  
Transparent/no bubbles/easy 
to pour  
Transparent/very brittle 
2.0 1.5 (812,911,379) 4.5 PEG 6000  
Transparent/no bubbles/easy 
to pour 
Transparent/ very brittle 
2.0 1.5 (812,911,379 ) ------------ 
Transparent/no bubbles/easy 
to pour 
Transparent/ brittle 
4.0 2.5 (911) 3.5 PEG 600 Transparent/easy to pour Very brittle 
4.0 2.5 (911) 4.5 PEG 600 Transparent easy to pour Very brittle 
4.0 2.5 (911) 5.5 PEG 600 Transparent/ easy to pour Flexible  
4.0 2.5 (911) 6.0 PEG 600 Transparent/easy to pour Rigid  
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4.1.7 Drug loading results 
Based on the observations, dissolving the IBU and IND in ethanol increased the amount of 
incorporated drug from 0.5 to 0.8% w/w for IBU and 0.4- 0.6% w/w for IND within the 
initial gel. Watkinson and co-workers (2009) have also shown that the pka of IBU increased 
from 4.44 to 5.68 due to addition of ethanol hence the IBU solubility was enhanced 5,500-
fold relative to its aqueous solubility. 1.6% (w/w) PM was easily dissolved in aqueous media 
hence, addition of ethanol as a co-solvent to dissolve drug was not necessary. The drug 
loading capacities of optimised films containing CAR 911: P407: PEG 600; as a function of 
total dry weight of film are summarised below: 
x Indomethacin (IND)  = 4.14 % 
x Ibuprofen (IBU)  = 5.79 % 
x Paracetamol (PM)  = 11.34 
 
4.2 Characterisation of physical and mechanical properties of films   
4.2.1 Texture analysis  
Texture analysis was used to measure tensile properties; tensile strength (brittleness of films), 
elastic modulus (rigidity) and elongation (flexibility and elasticity). 7KHVSHFLPHQV¶WKLFNQHVV
and width were measured and considered while calculating the stress and strain values. The 
elastic modulus was estimated from the initial linear portion of the stress-strain curve whilst 
tensile strength was calculated by dividing force at break by the initial cross-sectional area of 
the films specimen (Dixit & Puthli, 2009). Figure 4.9 shows that the elastic modulus 
decreased gradually with increasing PEG 600 concentration for films containing no drug. As 
Morales, et al.,(2011) stated, soft and weak polymers have low tensile strength, low elastic 
PRGXOXV <RXQJ¶V PRGXOXV DQG ORZ HORQJDWLRQ DW EUHDN ,Q FRQWUDVW D VRIW DQG VWURQJ
polymer displays a reasonable tensile strength, low elastic modulus and a high elongation at 
break.  
According to the results the concentration of 5.5% w/w PEG 600 in gel (corresponding to a 
CAR 911/PEG 600 ratio of 5:11) resulted in the elastic modulus reaching the minimum value 
while the percent elongation remained at the maximum.  
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Further increase in the PEG 600 concentration to 6.5% (w/w) resulted in a significant 
decrease in the percentage elongation and a corresponding increase in the elastic modulus. 
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Figure 4.9 Elastic modulus and % elongation profile for pure films formulated with different concentration of 
PEG 600 {mean±s.d, (n=3)}. 
 
However, different observations were made when drug was added to the optimized film. 
Figure 4.10 and Figure 4.11 show the tensile results for drug (IND, IBU and PM) loaded 
films. Following the addition of the model drugs, the elastic modulus was increased and 
required a change in PEG 600 content to obtain films with desirable tensile properties. The 
results showed that the optimum concentration of PEG 600 required increase to 6.5% w/w in 
the presence of the maximum 0.6% w/w IND or 0.8% w/w IBU to achieve desirable film 
flexibility matching that of the non-drug loaded films. In the case of PM, the maximum 1.6% 
loading required an increase in PEG 600 concentration to 6% w/w to match the flexibility of 
the non-drug loaded films. As noted above, such increase resulted in a sharp increase in 
percent elongation and corresponding decrease in elastic modulus for the non-drug loaded 
films which is an interesting observation. 
These observations might be the consequence of the differences in molecular weight and log 
P values for IND (mw=357.78), IBU (mw=206.28) and PM (mw=151.16). The impact of the 
drug could relate to reduction in free volume between the polymeric chains and therefore, 
decrease in elongation and increase in elastic modulus.  
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To provide appropriate flexibility more plasticizer was required for the drug loaded films to 
maintain the required free volume that allows optimum flexibility (Zelkó, et al., 2002).   
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 Figure 4.10 % Elongation profile for films formulated with model drugs {mean±s.d,(n=3)}. 
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      Figure 4.11 Elastic modulus profile for films formulated with different model drugs {mean±s.d,(n=3)}. 
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The tensile strength, elongation and elastic modulus values are relevant as they indicate the 
strength of the film under stress due to stretching and have a direct HIIHFW RQ SDWLHQW¶V 
acceptance and clinical performance of the final dosage form. Flexible films provide better 
patient compliance as they are less likely to cause contact irritation whilst an excessively 
elastic film can cause problems with handling such as folding and stickiness (Boateng, et al., 
2009a). 
 
4.2.2 HSM results 
As the system contained several compounds with different melting, degradation or glass 
transition temperatures, the observed phase transitions were not clearly distinguishable. 
Therefore HSM results mainly specified the degradation point which helped in developing 
suitable methods for TGA and DSC such as the maximum temperature at which they were 
heated to.  
 
4.2.3 TGA results (water content)     
Polymers contain some water molecules bonded to the monomer parts and impact directly on 
glass transition temperature and other physico-chemical characteristics such as elastic 
modulus. Therefore evaluation and calculation of the water content in the pure polymers as 
well as the films was essential. The results are summarised in Table 4.3. The results shown in 
Table 4.3 demonstrate that different films (either blank or containing model drugs) have 
similar water content. Also their degradation points decreased in comparison to the original 
compounds and this shows the effect of formulation process in changing the physico-
chemical properties of the starting materials due to interactions between the various 
components (Stephenson, et al., 2001). As shown in Table 4.4 use of GLY as plasticiser 
caused an increase in amount of residual water in the films and it may account for relatively 
less stable films produced using glycerol. This is because glycerol is a known moisturizing 
agent and has a high affinity for water. Furthermore, films containing IBU showed higher 
amount of water compared to the other drugs. In addition, the grade of CAR should be 
considered as an important factor since CAR 812 showed higher capacity to retain water 
within the film.   
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Table 4.3 Water content in starting materials and optimum films prepared from gels plasticised with 
PEG 600 containing optimum amounts of the model drugs (mean ± s.d, n=3). 
Materials used and their concentrations (% w/w) 
% H2O  content 
 
Degradation  
temperature (ºC) 
2.5% CAR 911  + 4% P407 + 5.5% PEG 600 5.6 ± 0.1 190 
2.5% CAR 911 + 4% P407 + 6.5% PEG 600  + 0.6% IND 4.8 ± 0.2 190 
2.5% CAR 911 + 4% P407  + 6.5% PEG 600 + 0.8% IBU 5.1 ± 0.03 190 
2.5% CAR  911 + 4 % P407  + 6% PEG 600 + 1.6% PM 5.0 ± 0.1 190 
CAR  911  powder 13.6 ± 0.1 220 
P407 powder 0.2 ± 0.01 370 
PEG 600 1.1 ± 0.3 360 
 
 
Table 4.4 Water content of films formulated with gels containing carrageenan {(CAR) 911 or 812}, 
poloxamer 407 (P407) and plasticized with glycerol (GLY) or PEG 600 mean ± s.d, n=3. 
CAR 
(% w/w) 
P407 
(% w/w) 
Plasticizer 
(% w/w) 
IBU 
(% w/w) % H2O content 
2.5 (812) 8.0 4.5 GLY --------- 16.5 ± 0.8 
2.5 (911) 8.0 4.5 GLY --------- 6.9 ± 0.4 
2.5 (812) 8.0 4.5GLY 0.9 19.9 ± 1. 0 
2.5 (911) 8.0 4.5 GLY 0.9 23.5 ± 1.2 
2.5 (812) 8.0 4.5 PEG 600 --------- 10.3 ± 0.6 
2.5 (911) 8.0 4.5 PEG 600 --------- 2.2 ± 0.3 
2.5 (812) 8.0 4.5 GLY 0.6 17.3 ± 0.7 
2.5 (911) 8.0 4.5 GLY 0.6 13.9 ± 0.8 
2.5 (812) 8.0 5.5 PEG 600 0.9 12.2 ± 0.8 
2.5 (911) 8.0 5.5 PEG 600 0.9 3.8 ± 0.2 
2.5 (812) 8.0 5.5 PEG 600 0.6 9.9 ± 0.5 
2.5 (911) 8.0 5.5 PEG 600 0.6 11.0 ± 0.4 
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TGA results for films stored over a six month period showed a decrease in water content 
(Table 4.5) which could be attributed to the conversion of free water to bound water within 
the polymeric matrix after six month of storage.   
 
 
Table 4.5 Water content in films prepared from gels with various  concentrations (% w/w) of CAR, 
P407, PEG 600 and optimum model drugs after six month storage (mean ± s.d,( n=3)}. 
Composition (w/w) of film specimen 
% H2O  content 
 
Degradation 
point (ºC) 
2.5%  CAR 911 + 4% P407 + 6.5% PEG 600 + 0.6% IND 1.5 ± 0.2 160 
2.5%  CAR 911+ 4% P407+ 6.5% PEG 600 + 0.8% IBU 1.0 ± 0.3 160 
2.5% CAR 911 + 4% P407 + 6% PEG 600 + 1.6% PM 1.0 ± 0.1 160 
 
4.2.4 DSC results (melting point, glass transition) 
DSC was used to characterize thermodynamic behaviour of CAR 911, P407, PEG 600 and 
three model drugs (IND, IBU, PM) within the films. However, to be able to interpret the 
results obtained from DSC analysis of the drug loaded films, the thermodynamic behaviour of 
pure drugs should be investigated (Barreiro-Iglesias, et al., 2002). The results showed the 
sharp melting point of crystalline form of IBU at 77.7ºC (Figure 4.12a). After sharp cooling 
all the crystals were changed to amorphous form which was stable during the second heating 
cycle (Figure 4.12b).  
 
Further DSC investigation proved that IBU in the film was in amorphous form. Comparison 
of the results to that of Figure 4.12 and Figure 4.13 a& b shows that during the the first 
heating cycle, glass transition of  IBU appeared at -59.5ºC and the absence of the sharp melt 
peak expected for crystalline IBU between 70-80ºC. Instead, three sharp peaks were detected 
at -11.0°C, 22.7°C and 34.1°C corresponding to PEG 600, mixture of PEG 600 and P407 and 
P407. This could be a eutectic mixture of PEG 600 and P407, however; additional 
experiments were conducted to identify the mixture (Newa, et al., 2008).    
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                                                                         (a) 
 
                                                                          (b) 
 Figure 4.12 DSC results showing (a) melting point and (b) glass transition of pure IBU.  
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Figure 4.13 DSC results of (a) fresh film prepared from gels comprising 2.5% CAR 911+ 4% P407+ 6.5% PEG 
600 and 0.8% IBU and (b) films containing IBU after 6 months storage.  
 
The results confirmed that the incorporated drugs were stable in the amorphous form within 
the film matrix. However, following storage, the films lost some of the residual water 
originally present which may account for observed changes in the DSC profile relating to 
PEG 600 and P407 phase transitions. This is illustrated by a comparison between the 
thermograms belonging to freshly prepared films and films stored for six months which 
indicate that water can have an effect on the physico-chemical characteristics of these two 
polymers.  
Analysis of the data in Figure 4.13b reveals that the transition peak corresponding to the 
mixture of PEG 600 and P407 disappeared following the reduction of residual water content 
in the films containing IBU. The foregoing conclusion is evidenced by detection of only two 
peaks in Figure 4.13b with onset of melting at -13.5°C and 34.8°C corresponding to PEG 600 
and P407, respectively. The proposed explanation is that the presence of water within the 
system increases the opportunity for interaction between PEG 600 and P407 which was 
decreased during storage as a result of water loss.  
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The consequence was the disappearance of the peak corresponding to the mixture formed 
from interaction between PEG 600 and P407. Similar results were observed for PM and IND 
loaded films after six months storage time and the fact that the amorphous forms were 
preserved during the storage period.  
 
Figure 4.14 DSC results of pure IND (a) melting point and (b) glass transition. 
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For pure IND the results from the first heating stage showed the sharp melting point of 
crystalline form at 161.0ºC. After fast cooling, all the crystals converted to a stable 
amorphous form and during the second heating cycle its glass transition was detected at 
40.2ºC (Figure 4.14 a & b). The DSC plot for films containing IND confirmed that the 
amorphous form of the drug was present in the film. Heat flow plots showed the glass 
transition at 23.4ºC and two melting transitions belonging to PEG 600 and  P407 alone 
(Figure 4.15). The reason for the disappearance of the melt transition corresponding to PEG 
600/P407 mixture could be due to the slightly lower water content in IND loaded films 
compared to films containing IBU (Table 4.3). This resulted in the melting peak of the 
mixture being masked by the P407 melting transition.  
 
Figure 4.15  DSC results of film comprising 2.5% CAR 911+ 4% P407+ 6.5% PEG 600and 0.6% IND within 
the initial gel. 
 
Similarly, PM showed a sharp melting peak at 168.6ºC in the first heating cycle. During the 
sharp cooling, the crystalline form was changed to the amorphous form (Qi, et al., 2008). 
However, this amorphous form was unstable and recrystallized at 80.5ºC. For PM, the Tg was 
detected at 21.8ºC and a sharp melting peak confirming the recrystallization process (Figure 
4.16). 
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This result is comparable with the thermogram for the film with glass transition at 23.1ºC 
while the expected melting peaks of PM around 157ºC (orthorhombic polymorph) or 170ºC 
(monoclinic polymorph) were absent and confirms that the drug within the film was in the 
amorphous form (Figure 4.17).  
 
 
(a) 
 
(b) 
Figure 4.16  DSC results showing a) melting point and b) glass transition of pure PM. 
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Figure 4.17  DSC results of film prepared from gels containing 2.5% CAR+ 4% P407+ 6% PEG 600 and 1.6%  
PM. 
 
Though amorphous forms are known to be more soluble, they do present stability challenges 
owing to their tendency to convert back to the crystalline form (Tusi, 2004; Hancock & 
Parks, 2000). To investigate the stability of model drugs within the films, further DSC 
experiments were conducted to determine whether it remained in an amorphous form or was 
converted back to the crystalline form during storage.  
 
4.2.5  SEM results  
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could affect dissolution profiles and stability. The microscopic appearance of the film surface 
showed continuous film formation which was also uniform with no obvious porous region.  
 
This continuous sheet of film was maintained after incorporation of drug although drug 
loaded films appeared slightly more brittle on the surface (Figure 4.18-  Figure 4.21). This is 
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dependent on the surface integrity of the film structure as it affects the initial rate of water 
ingress (Boateng, et al., 2010).  
 
Obviously drug release from the surface will be very fast during the initial stage of 
dissolution. However, drug which is completely dispersed within the polymer matrix will be 
affected by swelling, erosion and diffusion and this is expected to be the determining factor 
controlling drug release. 
 
Figure 4.18  Film prepared from gel comprisng 2.5% 
CAR 911+4% P407 +6% PEG 600. 
 
 
Figure 4.20  Film  prepared from gel comprising 
2.5% CAR 911+ 4% P407 + 6.5% PEG 600+ 0.6% IND. 
 
  Figure 4.21 Film  prepared from gel comprising 2. 5% 
  CAR 911+ 4% P407 + 5.5% PEG 600+ 1.6 % PM 
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Figure 4.19  Film prepared from gel comprising 
2.5%CAR 911+ 4% P407 +6.5% PEG 600+0.8% IBU. 
20µm    
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 Figure 4.22 to Figure 4.24 illustrate the surface morphology of the films with higher ratios of 
CAR 911 and P407, showing similar results as films with lower concentration of these 
polymers. The figures also showed that variation of the P SHUFHQWDJH GLGQ¶W KDYH DQ\
impact of the surface properties of the film. 
 
 
Figure 4.22  Morphology of the  film prepared from prepared from gel comprising 2.5% CAR 911+ 8% P407 
+ 5.5% PEG 600. 
 
Figure 4.23  Surface morphology of the film prepared from gel comprising 2.5% CAR 911 + 8% P407 + 6.5% 
PEG 600 + 0.7%  IBU. 
 
Figure 4.24  Surface morphology of film prepared from gel comprising 2.5% CAR 911 + 8% P407 +5% PEG 
+ 0.7% IBU. 
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4.2.6  XRPD results  
To investigate the crystalline/amorphous characteristics of all initial compounds and films 
XRPD experiments were conducted. Amorphous compounds showed very broad peaks which 
were distinguishable in comparison to the sharp peaks belonging to the crystalline form. 
XRPD also provided information about the crystalline-amorphous ratios for the various 
starting materials and for the formulated films.  
In the case of CAR 911 powder, the results showed some peaks which indicated a small level 
of crystallinity but significantly amorphous which was reproducible before and after grinding 
(crystalline/amorphous: 4/96%). Also XRPD analysis for P407 showed that the crystalline 
amorphous ratio was 50/50.  
 
 
 
Figure 4.25 XRPD diffractogram of PEG 600, P407, films containing CAR 911 + P407 and PEG 600 without 
drug. 
 
To check the crystalline-amorphous ratios and confirm the physical form of the various 
components within the films, further XRPD analyses were performed. Figure 4.25 shows the 
XRPD spectra of the non-drug loaded films. The results demonstrated that there are various 
crystalline forms present in the film belonging to PEG 600.  
Lin
 (C
ou
nt
s)
0
10000
20000
30000
40000
50000
60000
2-Theta - Scale
5 10 20 30 40
P407 
PEG 600 
Blank film 
PEG 
CHAPTER 4                                                                                        FILM  DEVELOPMENT 
 
 
122 
 
P407 is a block co-polymer comprising 56 units of a polypropylene oxide core (21%) and 
two polyethylene glycol tails (79%) with 101 units hence, the detected PEG crystalline peaks 
in crystallography results associated with P407. 
 
 
Figure 4.26 XRPD diffractograms of CAR 911, P407, PEG 600, blank and IBU loaded film.  
 
 
The XRPD results also confirmed the absence of crystalline IBU form in the film matrix 
(Figure 4.26). As CAR is available in amorphous form the background spectrum was 
subtracted from original curve (top spectrum) and the absence of the main peak for IBU 
expected DWDERXWș confirms the amorphous form of IBU in the film. Similar results 
showed the presence of amorphous PM (Figure 4.27) incorporated in the film matrix and the 
same result was achieved for IND loaded films (Figure 4.28). According to the calculations 
from area under the curve the ratio of crystalline to amorphous are as below:  
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0.8 % w/w IBU and 1.6 % w/w PM loaded films crystalline: amorphous = 4:96 which shows 
that addition of the drug induce the crystallization of PEG.  
  
     
 
Figure 4.27 XRPD spectrum of XRPS diffractogram of CAR 911, P407, PEG 600, blank and  PM loaded films.  
 
Among the many experimental techniques available for the identification of solid forms, 
(including polymorphs, solvates, salts, co-crystals and amorphous), XRPD is generally 
accepted as a gold standard. XRPD has applications throughout the formulation development 
process, usually in combination with other experimental techniques such thermal analysis 
techniques. The efficacy of XRPD is evident when one considers the direct relationship 
between the measured XRPD pattern and the molecular structure of the drug incorporated in 
films or wafer as it also provided information about the structure of the excipient material, 
whether it exhibits long-range order as in crystalline materials, or short-range order  as in 
glassy or amorphous materials. This information is unique to individual structure (crystalline 
or amorphous) (Ivanisevic, et al., 2010).  
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XRPD can also be employed to monitor re-crystallization of amorphous materials. A classic 
application of this technique would be to characterize the extent of crystallinity during 
storage over the intended shelf life of the drug product to ensure safety and efficacy 
(Ivanisevic, et al., 2010). This is relevant for the stability of the two formulations of interest 
in this project, where all the model drugs initially added in crystalline forms, were converted 
to the amorphous form during film formation and freeze-drying. 
 
 
 
 
Figure 4.28 XRPS diffractogram of CAR 911, P407, PEG 600, blank and IND loaded films. 
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Figure 4.29 XRPD diffractogram of films containing excess amounts of PM.  
 
 
Figure 4.30 XRPD diffractogram of films containing excess amount of IBU. 
 
XRPD analysis of films containing excess amounts of model drugs was performed and 
compared with previously discussed films containing only amorphous drug. The results 
showed that excess amount of drug recrystallized out of the film matrix. Consequently the 
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XRPD results showed significant differences with sharp peaks belonging to the                     
re-crystallized model drugs for PM (Figure 4.29), IBU (Figure 4.30) or IND (Figure 4.31). As 
the thermodynamic energy of amorphous is significantly higher than crystalline form, they 
are more soluble hence, are expected to be released more rapidly when applied in-vivo. 
However it is important to be maintained in amorphous form since higher energy level in 
amorphous form may cause it to revert back to the crystalline form. Therefore, further XRPD 
studies were conducted to confirm the DSC results of films stored for 6 months at room 
temperature. As it was shown in DSC thermograms, film matrix maintained all three model 
drugs in amorphous form after storage period (the reproducible XRPD spectra can be found 
LQ WKH DSSHQGL[ DQG FRQILUPHG WKH ILOP PDWUL[¶V DELOLW\ WR UHWDLQ PRGHO GUXJV LQ D stable 
amorphous form over six months (Figure 4.32, Figure 4.33 and Figure 4.34).    
 
 
 
Figure 4.31 XRPD diffractogram of films containing excess amount of IND. 
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Figure 4.32 XRPD diffractogram for IBU loaded films stored for 6 months.  
 
 
 
Figure 4.33 XRPD diffractogram for IND loaded films stored for 6 months. 
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Figure 4.34 XRPD diffractogram for PM loaded films stored for 6 months. 
 
4.2.7 Stability studies 
HPLC results showed that the actual assayed concentration of IND, IBU and PM in the film 
sample remained relatively unchanged (>96%) after twelve month storage at room 
temperature and 45% RH (Figure 4.35).  
 
The pure crystalline IBU, IND and PM used as control also remained stable over 12 months. 
Though this is highly desirable, longer term stability of model drugs within the films will 
need to be studied under accelerated conditions of higher temperature and relative humidity. 
Farmer and co-workers (2002) demonstrated that the degradation of IBU in bulk-drug 
samples ranged between 2.9 and 11.4% following storage at the higher temperature of 80°C. 
IBU degradation under high temperature conditions is likely given the alcohol functions 
present which could result in possible ester formation between PEG 600 and IBU. Cory, et 
al., (2010) have shown previously that PEG enhances the degradation of IBU in tablets under 
accelerated conditions of 70°C and 75% RH and such studies will be required to confirm this 
in the films.  
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These results show the ability of CAR 911, P407 and PEG 600 based films to maintain the 
chemical stability of IBU, IND and PM. However, the stability studies over a longer period of 
time will need to be conducted. 
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Figure 4.35 Plot showing the percentage  of drug remaining within the films during storage at room temperature 
up to twelve months{mean ± s.d. (n=3). 
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Chapter 5 /\RSKLOL]HGZDIHUGHYHORSPHQWDQGFKDUDFWHULVDWLRQ 
5.1 Formulation development  
5.1.1 Gel formation 
The initial studies during wafer formulation development involved the optimisation of gel 
formation, although the content of the starting materials and their characterisation were 
similar to the solvent cast films. This similarity allowed for a valid comparison of relevant 
characteristics such as dissolution, drug loading capacity, stability, hydration and tensile 
strength. However, due to the obvious differences between the freeze-dried wafers and 
solvent cast films, some of the physical evaluation and characterisation such as transparency 
and tensile elongation were not applicable to the wafers.    
 
This exception allowed the formulation development of wafers with or without plasticizer as 
well as varying the amounts of CAR 911 to enable the formulation of optimised wafer suited 
for potential buccal drug delivery application.  
 
5.1.2 DSC application to develop the freeze dying cycle  
Establishing a suitable thermal profile for any gel for freeze drying was fundamental and 
helped to develop an optimized lyophilization cycle. Each individual formulation component 
(either active or excipients) demonstrated unique thermal properties within the formulation 
and it was critical to characterize each component separately as well as within the 
formulation. There are three critical parameters which need to be determined; eutectic 
temperature (Teu), glass-transition temperature (Tg) and collapse temperature (Tc). Teu defines 
the crystalline systems detectable by DSC and exceeding that during primary drying
 
causes 
the compound to melt during processing. Generally, eutectic or glass-transition temperatures 
determine the maximum temperature that the formulated product can resist during primary 
drying without the loss of structure (Schwegman, 2009). Each formulation has a definitive 
collapse temperature, beyond the Tc point formulation might be unusable and experience 
processing defects.  
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Retaining the temperature below the critical limits before freezing or before the frozen water 
is removed is vital or the sample can be ruined during the process. Therefore, determination 
of the critical temperatures of a formulation before lyophilization is essential (McGinn, 
2009).  
In addition, following any of alteration either active ingredient or excipients or changing their 
constituent ratios, supportive DSC investigation was required to detect the critical points.  
The eutectic point (Teu) was observed at 12.8°C (Figure 5.1) for the initial gels with or 
without addition of model drugs.  
 
 
 
Figure 5.1  DSC results of the gel formulated with 2% w/w CAR 911 + 4% w/w P407 +4.4% w/w PEG 600. 
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Figure 5.2 DSC results of the gel formulated with 2% w/w CAR 911 + 4% w/w P407 + 4.4% w/w PEG 600 
+ 0.6% w/w IBU . 
 
Similar DSC results were obtained for IBU, IND and PM loaded wafers. Figure 5.2, Figure 
5.3 and Figure 5.4 confirmed that the Teu for all of formulations were close and increasing the 
temperature up to 0°C during the primary drying was feasible for producing ideal wafers. As 
a result, it was not deemed necessary to change the freeze drying cycle between blank and 
each drug loaded wafer.    
 
 
Figure 5.3 DSC results of the gel formulated with 2% w/w CAR 911 + 4% w/w P407 +4.4% w/w PEG 600  
+ 1.8% w/w PM. 
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Figure 5.4 DSC results of the gel formulated with 2% w/w CAR 911 + 4% w/w P407 +4.4% w/w PEG 600 
+ 0.6% w/w IND. 
 
5.1.3 Freeze-drying process 
Following the gel preparation they were dispensed into suitable containers. The ideal 
container must be stable during the freeze drying process and result in the gel setting with 
uniform thickness and surface area to allow rapid removal of water during sublimation. The 
resulting wafer should also be easily recovered from the container without sticking to it 
which could cause loss of material. Therefore, gels were poured into six-well polystyrene 
plates with diameter 0.354 mm and filled to a height of 1mm.  
 
Freeze drying cycles:   
(i) Freezing or freeze-annealing:    
The freezing cycle was performed initially as simple freezing which was conducted by 
freezing the gel up to -55°C and kept for 96 hours with primary drying step following 
immediately after freezing. The resultant wafers were not adequately dried with several traces 
of trapped ice visibly present on the surface (Figure 5.5). Therefore, an annealing step was 
added to the cycle to produce bigger ice crystals to allow the sublimation to proceed more 
efficiently.  
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Two different annealing steps were attempted. The step which was performed by cooling the 
gel initially to -35°C following a temperature rise to -10°C resulted in wafers with 
XQDFFHSWDEOHSK\VLFDOFKDUDFWHULVWLFVGXHWRPHOWEDFNZKLFKFDXVHGDFROODSVHLQWKHZDIHU¶V
structure (Figure 5.6).  
 
However, gels which were cooled down to -55°C and annealed by increasing the temperature 
to -35°C and cooling back to -55°C produced wafers with an acceptable texture and physical 
properties i.e. flexibility, porous texture, without any trace of ice crystals (Figure 5.7). 
Noticeably, the pressure condition was critical during the whole freeze-drying process and 
was maintained at 200 mTorr during the freezing and 50 mTorr during the drying stages as 
the pressure of environment should be higher than the pressure in the frozen gel. This results 
in sublimation of the ice crystals from the surface of the frozen gel.  
 
(ii) Primary drying  
The primary drying process was conducted by gradual temperature elevation from -10°C to 
0°C which is at least 5°C less than the Teu (determined from the preliminary DSC studies) 
while the appropriate pressure condition was applied which resulted in significant reduction 
in water content.  
 
(iii) Secondary drying 
During secondary drying desorption occurred and the last traces of water vapour were 
removed. This stage of freeze drying provided heat to maintain the wafers at ambient 
temperature and produce wafers with desirable texture and stability during storage. Overall, 
the optimised freeze-drying cycle incorporating the annealing step totalled 42 hours and 
produced wafers with a balance between flexibility and residual water content.    
The results from the optimised freeze-dried process ascertained the necessity to establish an 
ideal combination of shelf temperature and system vacuum level during each process stage 
(freezing, primary and secondary drying). This culminates in the appropriate vapour pressure 
for ice sublimation and ideal sample temperature.  
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During each step, the sample temperature was monitored by thermocouples while shelf 
temperature was increased to achieve the target sample temperature. If the gel has high 
resistance to vapour flow in the dried section of the cake, the shelf temperature should be 
elevated towards the end of primary drying to maintain the wafer temperature at target point  
and prevent it from collapsing (www.biopharma.co.uk- date accessed 20/06/2011).      
      
5.1.4 Results after freeze-drying 
Following freeze-drying the water content should be typically between 0.5% and 3%. 
Subsequently, the optimised wafers were selected with the aid of visual observations and 
analytical techniques such as SEM, compression profile and mucoadhesivity 
(www.biopharma.co.uk- date accessed 20/06/2011).    
 
 
 
Figure 5.5  Wafer prepared without annealing. 
 
2% w/w CAR 911 + 4% w/w P407 + 4.4% w/w PEG 600 
CHAPTER 5                                                                                   WAFER  DEVELOPMENT 
 
 
136 
 
 
Figure 5.6  Wafer prepared by non-appropriate annealing cycle. 
 
 
Figure 5.7  Wafer prepared by the appropriate annealing method. 
 
5.1.5 Visual evaluation of wafers 
The preliminary observations were performed and the results obtained are summarized in 
Table 5.1 however, this was the first stage and further investigations were required. 
Evaluation of wafers was based on criteria such as: 
 
 Softness: wafers must be soft and easy to apply on the mucosal tissues.   
 Plasticity: the wafer should not be brittle and fragile as it will affect physical and 
mechanical stability during handling as well as potential contact irritation during 
application.  
2% w/w CAR 911 + 4% w/w P407 + 4.4% PEG 600 
2% w/w CAR 911+ 4% w/w P407 + 4.4% w/w PEG 600 
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 Thickness: Ideal wafer must have optimum thickness (less than 2cm pre-hydration) 
otherwise it might not be convenient for patient to apply in buccal mucosal area. This 
will provide the stability to be placed at buccal surfaces and prolong the residence 
time. Thick wafers present the possibility of inconvenience from teeth movement and 
dislodging by tongue movement. In addition, thickness affects the drug release rate 
since wafer forms gel following hydration and drug diffusion distance has significant 
effect on drug release profile.  
 
Table 5.1  Characteristic of wafers prepared using different (% w/w) concentrations of PEG 600, CAR 
911 and 4% w/w P407.  
 
Formulating wafers with varying amounts of PEG 600 and CAR 911 with or without 
annealing and evaluating according to the above criteria was conducted. Afterward, 
additional texture analysis studies were performed to determine the physical properties and 
select the optimum wafers with appropriate flexibility. Results from the wafers produced with 
non-DQQHDOLQJF\FOHGLGQ¶WGHPRQVWUDWHDFFHSWDEOHSDUDPHWHUs during the initial observations 
due to excessive brittleness which was confirmed by the texture analysis results as well 
(Figure 5.5 and Figure 5.10).  
 
CAR 911% (w/w) P407% (w/w) PEG 600% (w/w) Wafer characteristics 
5.0 4 0 Rough & brittle 
2.0 4 0 Rough & brittle 
2.5 4 0 Rough & brittle 
1.5 4 3.3 Soft, flexible  
2.0 4 4.4 Soft,  flexible  
2.5 4 5.5 Soft,  flexible  
1.5 4 5.5 Soft,  flexible  
2.0 4 5.5 Soft,  flexible 
2.5 4 5.5 Soft,  flexible 
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Figure 5.8 Optimized wafer produced with appropriate contents of  CAR 911, P407, PEG 600 with annealing 
method. 
 
5.2 Wafer characterisation   
5.2.1 Texture analysis results  
Following the development of different wafers by annealing and non-annealing process, 
texture analysis studies were performed. All wafers were compressed to the depth of 2 mm 
and the work of compression and peak force at maximum depth of compression were 
measured. There were two sets of experiments performed to determine the optimum amounts 
of each starting material used to formulate the wafers.  
The preliminary evaluation involved texture analysis of wafers containing different amounts 
of CAR 911 with or without PEG 600 to determine effect on mechanical strength. The second 
evaluation involved the effect of the annealing process on textural (mechanical) 
characteristics of the wafers. Results in Figure 5.9 show that wafers formulated without PEG 
600 were very rigid with very high work of compression and peak compression force values. 
In addition, according to Figure 5.10 the non-DQQHDOHGZDIHUVGLGQ¶WFRPSUHVV appropriately 
upon application of force due to non-porous texture.   
 
2% w/w CAR 911 + 4% w/w P407 + 4.4% w/w PEG 600  
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Figure 5.9 Compression profiles for wafers formulated with various amounts of initial compounds {mean ± s.d.  
(n=3)} .  
 
 
Therefore, addition of PEG 600 and developing wafers by freeze-drying with an annealing 
step significantly impacted upon the mechanical strength of the wafers. The investigations 
showed that wafers containing 2% w/w CAR 911, 4% w/w P407 and 4.4% w/w PEG 600 
exhibited the most optimum mechanical strength (Figure 5.9) while the other wafers were 
very brittle and rigid. Although wafers prepared with 1.5% w/w CAR 911, 4% w/w P407 and 
3.3% w/w PEG 600 showed similar compression profiles, the comparison of other properties 
such as hydration, mucoadhesion and water content confirmed that the wafers containing 2% 
w/w CAR 911 and 4.4% PEG 600 as the most appropriate choice. 
 
Figure 5.10 show that addition of IBU increased the ZDIHUV¶ work of compression (De 
Brabander, 2002) while adding PM decreased this value to approximately half that of IBU 
loaded wafers, and also lower than the blank wafer. The similar decrease in work of 
compression was observed when IND was used. These results combined with SEM 
observations showing that addition of PM and IND decreased mechanical strength owing 
possibly to formation of polymeric matrix with lower porosity. To evaluate whether 
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increasing the concentration of PEG 600 (4.4%, 5% and 5.5% w/w) improved the 
compressibility a new set of experiments were conducted. According to the results shown in 
Table 5.2 addition of PEG 600 did not have a significant effect on compression profiles of the 
wafers loaded with IND or PM. Consequently, 4.4% (w/w) of PEG 600 was selected to 
formulate drug loaded wafers.  
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Figure 5.10  Work of compression of wafer produced using 2% CAR w/w 911, 4% w/w P407 + 4.4% w/w PEG 
600 {mean ± s.d. (n=3)}. 
 
Table 5.2 :RUNRI FRPSUHVVLRQ :2&DQGSHDNFRPSUHVVLRQ IRUFH &)RI WKHZDIHU¶V produced 
from (% w/w) concentration of CAR 911, P407 and various concentrations (w/w) of drugs{mean ± 
s.d. (n=3)}. 
Wafer composition         WOC (N.mm)   CF (N) 
2% CAR 911 + 4% P407+ 4.4% PEG 600 + 0.6% IND 3.6 ± 0.2 3.6 ± 0.3 
2% CAR 911+ 4% P407+ 5% PEG 600 + 0.6% IND 2.1 ± 0.4 2.3 ± 0.6 
2% CAR 911+ 4% P407+ 5.5% PEG 600 + 0.6% IND 2.5 ± 0.3 2.0 ± 0.3 
2% CAR 911+ 4% P407+ 4.4% PEG 600 + 1.8% PM 3.4 ± 0.3 4.5 ± 0.2 
2% CAR 911+ 4% P407 + 5% PEG 600 + 1.8% PM 3.5 ± 0.5 3.4 ± 0.3 
2% CAR 911+ 4% P407 + 5.5% PEG 600 + 1.8% PM 2.9 ± 0.2 3.1 ± 0.2 
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Further, the compression profiles of the wafers in the presence of 4.4% PEG 600 and 
containing IBU showed improvement in mechanical strength. Loading IND and PM into the  
wafers decreased the work of compression and higher levels of PEG 600 also did not present 
acceptable compression profile therefore PEG 600 at 4.4% w/w within the gel for all pure and 
drug loaded wafers was the concentration of choice. 
 
 
Table 5.3 Work of compression (WOC) and compression force (CF) of the wafers produced from (% 
w/w) concentration of CAR 911, P407 and various amount of drugs{mean ± s.d. (n=3)}. 
Wafer composition WOC (N.mm) CF (N) 
2% CAR 911 + 4% P407+ 4.4% PEG 600 + 0.6% IND 3.6 ± 0.4 3.6 ± 0.3 
2% CAR 911 + 4% P407+ 4.4% PEG 600 + 0.6% IBU 6.5 ± 0.2 6.6 ± 0.4 
2% CAR 911 + 4% P407+ 4.4% PEG 600 + 0.8% IBU 6.7 ± 0.4 6.8 ± 0.2 
2% CAR 911 + 4% P407+ 4.4% PEG 600 + 1.8% PM 3.4 ± 0.3 4.5 ± 0.2 
 
 
Therefore, it was concluded that the wafer with most appropriate mechanical strength was 
produced following the addition of 0.8% w/w IBU, 0.6% w/w IND or 1.8% w/w PM to the 
gel comprising 2% w/w CAR 911, 4% w/w P407 and 4.4% w/w PEG 600. The percent drug 
loading as a function of the total dry weight of the wafers are summarised below.  
 
x Indomethacin (IND)  = 5.45 % 
x Ibuprofen (IBU)  = 7.14 % 
x Paracetamol (PM)  = 14.40 
 
When compared with the corresponding films, it can be seen that the porous wafers exhibited 
higher drug loading capacities compared to the dense films. This was attributed to the 
differences in physical structure of the two formulations with the wafers maintaining the 
original volume of the initial gel due to the freezing stage with drug uniformly distributed 
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while the films were formed after collapse of the initial gel during drying, hence excess drug 
crystallise onto the surface which was undesirable (Boateng et al., 2010). 
 
5.2.2 TGA results (water content) 
The residual water within the wafers produced either by annealing or non-annealing process 
was determined by TGA. The water content of each individual wafer analysed by TGA is 
summarised in Table 5.4 and Table 5.5.  
 
The water content was considerably higher in non-annealed wafers which consequently could 
have an undesirable effect on the stability of incorporated drugs. There is a potential risk that 
residual water may act as seeds to initiate and accelerate the crystallization of amorphous 
drug during storage. Water is a very effective plasticizer which significantly depresses the Tg 
of the amorphous drug and excipients by increasing molecular mobility which results in 
instability (Passerini and Craig, 2001). Therefore, it has been confirmed again that annealing 
is a desirable process to develop and produce wafers with appropriate stability due to lower 
residual water content.  
 
Furthermore, the results show that increasing the CAR 911 content resulted in an increase in 
water content and similar trends were observed following the addition of PEG 600 to the 
formulation. However, the presence of PEG 600 was essential to achieve desirable flexibility 
in the wafers.  
 
Wafers prepared from 2% w/w CAR 911, 4% w/w P407 and 4.4% w/w PEG 600 retained the 
lowest amount of water and provides a greater likelihood of maintaining drug stability over a 
longer period and was therefore the formulation of choice for drug loading. The water content 
of drug (IND, IBU and PM) loaded wafers were measured in two different time periods: 
immediately after completion of the freeze-drying cycle and then after one month storage in a 
desiccator at room temperature and relative humidity of 10%.           
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Table 5.4 % Water content for wafers produced from concentrations (% w/w) of CAR 911, P407 and 
PEG 600 by annealing and non-annealing process {mean ± s.d, (n=3)}. 
Freeze±dried wafer Annealed  Non-annealed 
1.5% CAR 911 +4% P407+ 5.5% PEG600 2.1 ± 1.2 5.3 ± 1.3 
1.5% CAR 911 + 4% P407 0.7 ± 0.0 4.7 ± 0.6 
1.5% CAR 911 +4% P407+ 3.3% PEG 600 2.2 ± 1.0 4.3 ± 0.8 
2% CAR 911 + 4% P407 1.5 ± 1.4 4.7 ± 1.2 
2% CAR 911 + 4% P407+ 4.4% PEG 600 1.2 ± 0.5 5.3 ± 0.5 
2% CAR 911+ 4% P407 + 5.5% PEG 600 2.5 ± 1.0 5.4 ± 0.5 
2.5% CAR 911 + 4% P407 1.4 ± 0.0 4.5 ± 0.3 
2.5% CAR 911 + 4% P407 + 5.5% PEG 600 1.8 ± 0.1 5.8 ± 0.3 
 
 
TGA results for the wafers before and after loading IND, IBU or PM are presented in Table 
5.5. The results demonstrate that addition of model drugs has significant effect on residual 
water content in the wafer. All model drugs (IND, IBU and PM) are dispersed in the hydrogel 
(CAR 911) matrix through possible interaction by hydrogen bonding. Therefore, hydroxyl 
groups of the polymer are occupied by model drug molecules and less water would be 
retained within the polymeric matrix. This effect on the results of the water content is 
summarized in Table 5.5.  
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Table 5.5 Water content in the wafers formulated with different concentrations (% w/w) of the various 
drugs and initial compound either immediately (IM) after freeze-drying or after one month of storage 
{mean ± s.d (n=3)}. 
Freeze±dried wafer  %H2O  content      (IM) 
% H2O content  
(1 month storage)  
2% CAR 911+ 4% P407+ 4.4 %PEG 600 1.5 ± 0.1 1.5 ± 0.3 
2% CAR 911+ 4% P407 4.4 % PEG 600 + 1.8% PM 0.9 ± 0.0 1.9 ± 0.1 
2% CAR 911 + 4% P407 +4.4 % PEG 600 + 0.8% IBU 1.1 ± 0.2 1.4 ± 0.3 
2% CAR 911 + 4% P407+4.4 %PEG 600 + 0.6% IND 0.8 ± 0.2 1.2 ± 0.1 
 
According to the results the amount of residual water was reduced considerably due to 
addition of IND and PM while IBU loaded wafers showed higher water content. Wu and 
McGinity (2001) have shown that Tg of the polymers would be decreased due to the presence 
of IBU within the polymeric wafer though their study was based on solid dispersion of IBU 
in polymeric matrix. This effect might be a consequence of retaining more water in the wafer 
matrix which has been confirmed by the TGA results and previous texture analysis data.   
 
5.2.3 DSC results  
The thermodynamic characteristics of CAR 911, P407, PEG 600 and various model drugs 
(IND, IBU, PM) were conducted. The DSC results for the blank and drug loaded wafers 
demonstrated that all the model drugs were in amorphous form as was observed for the films.      
Figure 5.11 shows the DSC results for the blank wafer showing the sharp melting point of 
PEG 600,P407 and the mixture of PEG 600/P407 at about -4.4, 24.5 and 38.5°C respectively. 
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Figure 5.11 DSC results of wafer comprising 2% w/w CAR 911 + 4% w/w P407 + 4.4% w/w PEG 600. 
 
 
 
An extensive DSC investigation and comparison between Figure 4.12(a & b) with Figure 
5.12 proved that IBU in the wafer was in amorphous form. Reference to Figure 4.12 (a & b) 
DSC analysis of pure IBU showed that during the first heating cycle a sharp melting 
transition was detected at 77.7°C and following the sharp cooling glass transition of the 
amorphous was detected at -45.2ºC though this transition was shifted to -59.0°C within the 
wafer. Figure 5.12a also showed three sharp peaks (-2.4°C, 31.4°C and 39.6°C) 
corresponding to PEG 600, P407 and the mixture of these two polymers respectively and the 
lack of IBU melting transition.  
 
Figure 5.12b shows the DSC thermogram of IBU loaded wafer after six months storage. 
7KHVH UHSURGXFLEOH UHVXOWV FRPSDUHG ZLWK WKH IUHVKO\ SUHSDUH ZDIHU¶V Figure 5.12a) 
thermogram confirmed that the drug was maintained in amorphous form after six month 
storage in room temperature and 45% RH.  
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Figure 5.12 DSC results for (a) fresh wafer prepared from gels containing of 2% w/w CAR+ 4% w/w P407+ 
4.4% w/w PEG 600 and 0.8% w/w IBU in the initial gel and (b) wafer prepared from gel containing 0.8% w/w 
,%8DIWHUVL[PRQWK¶VVWRUDJe. 
 
 
 
Comparable results were observed with the thermograms of pure IND and within the wafers. 
From Figure 4.14a & b DSC thermogram of pure crystalline IND demonstrates melting 
transition at 161.0°C and glass transition after quench cooling at 40.2ºC. Additional studies 
were performed to investigate the stability of amorphous model drugs (whether 
recrystallization to the crystalline could occur). DSC results for IND loaded wafers showed 
three sharp peaks at 8.2°C, 44.2°C and 32.6°C corresponding to PEG 600, P407 and mixture 
of the two polymers (Figure 5.13).  
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Figure 5.13  DSC results for wafer comprising 2.5% w/w CAR 911+ 4% w/w P407 + 4.4% w/w PEG and 0.6% 
w/w IND in the initial gel. 
 
Similarly, pure PM showed a sharp melting peak at 169.0ºC in the first heating cycle. During 
the sharp cooling, the crystalline drug was changed to amorphous form (Qi, et al., 2008). 
However, amorphous form is unstable and recrystallized at 80ºC. The PM, Tg was detected at 
21.8ºC and a sharp melting peak confirmed the recrystallization process (Figure 4.16). This 
result was compared with thermogram of the PM loaded wafer and showed a stable 
amorphous form of PM in the wafer with glass transition at 21.7ºC with the absence of the 
expected melt peaks 157ºC (orthorhombic polymorph) and 169ºC (monoclinic) confirmed the 
existence of amorphous form of the drug in the wafer (Figure 5.14). The most interesting 
results is the absence of the melting transition of mixture of PEG 600/P407 in PM loaded 
wafers.  
As mentioned before, the presence of water in the system has a significant effect on 
interaction between PEG 600 and P407. As the PM molecules compete with water molecule 
to interact with CAR 911 through hydrogen bonds; this is possible given the higher amounts 
of PM within the polymeric matrix is compared with IBU and IND loaded wafers where the 
lower water content limited the interaction of PEG 600 and P407. Reproducible results 
similar to that observed for IBU loaded wafer (fresh and after six months storage) were also 
obtained for IND and PM loaded wafers. 
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Figure 5.14  DSC results for wafer containing 2.5% w/w CAR 911+ 4% w/w P407+ 4.4% w/w PEG 600 and 
1.8% w/w PM in initial gel. 
 
5.2.4 SEM results  
Scanning electron microscopy was performed to evaluate the morphology of freeze-dried 
wafer at the microscopic level. The topographic image of all of the wafers with various 
compositions of CAR 911, P407 with or without the presence of the PEG 600 showed a 
porous texture. Interestingly, the relative size of the pores relatively depends on the content of 
the CAR 911 while their uniformity of pore distribution correlated with the presence of PEG 
600. According to the SEM results for the non-drug-loaded wafer (Figure 5.15-  Figure 5.20) 
increasing the ratio of CAR 911 caused an increase in the size of the pores. Larger pore and 
free spaces can be occupied by higher amounts of drugs and water and consequently affect 
the release of drugs during dissolution studies.     
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Figure 5.15 Wafer comprising 1.5% w/w CAR 911+  
  4% w/w P407. 
 
 Figure 5.16  Wafer comprising 1.5% w/w CAR 911 
   +4% w/w P407 +3.3% w/w PEG 600. 
 
Figure 5.17   SEM of wafer comprising 2% w/w CAR 
 911+ 4% w/w P407. 
 
   Figure 5.18 SEM of wafer comprising  2% w/w CAR 
   911+ 4% w/w P407+4.4% w/w PEG 600. 
 
Figure 5.19  SEM of wafer comprising 2.5%  CAR 911 
 + 4% P407. 
 
  Figure 5.20  SEM of wafer comprising 2.5 % CAR 
   911+ 4% P407 +5.5% PEG 600. 
             1mm 
              1mm 
          1mm 
             1mm             1mm 
              1mm 
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This could be attributed to the increase in water ingress expected for wafers having larger 
pore. However, this is also dependent on the amounts of PEG 600 present as wafers with 
higher amounts of the hydrogel CAR 911 are expected to swell more slowly.  
 
Figure 5.25  2%   Wafers comprising 2% CAR w/w 911 + 4% w/w P 407+ 4.4% w/w PEG 600+  0.6% w/w  
 PM. 
 
Figure 5.21 Wafer comprising 2 % CAR w/w 
911 + 4% w/w P407 +4.4% w/w PEG 600. 
 
Figure 5.22 Wafer comprising 2% w/w CAR 911+ 
4% w/w  P407 + 4.4% w/w PEG 600+ 0.8% w/w IBU. 
  
Figure 5.23 Wafers comprising 2% w/w CAR 911 
+4% w/w  P407+4.4% w/w PEG600+ 0.6% w/w IND. 
 
Figure 5.24  Wafer comprising 2% w/w CAR 911+ 
4% w/w P407  407+4.4% PEG 600+ 1.8% w/w PM. 
           1mm 
                1mm             1mm 
           1mm             1mm 
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Figure 5.21-Figure 5.25 show the SEM images of drug loaded wafers showing differences 
between the surface topography of wafers formulated with various model drugs. The PM 
loaded wafer showed the least porosity as the surface texture appeared to be leafy while IND 
loaded wafer shows a more porous texture with uniform pore sizes. Comparison of the SEM 
images of wafers loaded with 0.6% w/w and 1.8% w/w PM showed that the leafy surface 
structure described above is due to KLJKHUDPRXQWVRI30LQFRUSRUDWHGLQWKHZDIHU¶VPDWUL[
The wafers containing lower amounts of PM (Figure 5.25) showed a more porous structure 
compared to the leafy texture of wafers containing 1.8% w/w PM.  
 
5.2.5 XRPD results 
XRPD studies provided supplementary data which confirmed the results obtained from DSC 
analysis and determined the physical form (polymorphic or amorphous) of incorporated drugs 
within the wafer matrices. Figure 5.26 VKRZVWKHGLIIUDFWRJUDPRIEODQNZDIHU¶VZKLFKVKRZV
the presence of PEG crystals belonging to P407 within the wafer matrix.  
 
 
Figure 5.26 XRPD diffractograms for pure wafer comprising 2% w/w CAR 911 + 4% w/w P407+ 4.4% w/w  
PEG 600.  
 
Similar XRPD results were obtained for drug loaded wafers as was observed for the solvent 
cast films. The absence of the peak which should be detected in a certain area for each model 
drug (IBU, IND, PM) confirmed the DSC thermogram results.   
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Figure 5.27 XRPD diffractograms for CAR911, P407,PEG600, blank and IBU loaded wafer.     
 
 
  
Figure 5.28 XRPD diffractogram of CAR911, P407,PEG600, blank and PM loaded wafer.     
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Figure 5.27 clearly shows the absence of IBU¶VFU\VWDOOLQHSHDNH[Sected to be detected at 
16.7 (2T). The results for PM (Figure 5.28) and IND (Figure 5.29) loaded wafers showed the 
same trend as in IBU diffractogram. It was evidenced by absence of the main crystalline peak 
expected at about 24.5 and 11.7 (2T) for PM and IND respectively. The implication of these 
results is the discovery of similar effect of wafer matrix on the drug molecules. These 
observations confirm the matrix capability to transform crystalline drugs to the amorphous 
form and maintaining the amorphous state by preventing recrystallization. 
 
 
Figure 5.29 XRPD diffractogram of CAR911, P407,PEG600, blank and PM loaded wafers.     
 
 
Additional studies were conducted to confirm the stability of amorphous drug within the 
system following the six months storage at room temperature. The reproducible results 
established that matrix had ability to maintain the drug molecules in the form of amorphous 
up to six months (Figure 5.30, Figure 5.31 and Figure 5.32).     
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Figure 5.30 XRPD diffractogram for IBU loaded films stored for 6 months. 
 
 
 
Figure 5.31 XRPD diffractogram for IND loaded films stored for 6 months.  
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Figure 5.32 XRPD diffractogram for PM loaded films stored for 6 months. 
 
As noted earlier, XRPD is an efficient technique to check the stability of amorphous drugs 
within the formulations. Such stability studies are especially essential because, apart from the 
possibility of re-crystallization, the amorphous materials are also more hygroscopic and often 
less chemically stable than the corresponding crystalline forms. This property is very critical 
especially for freeze-GULHGZDIHU¶V IRUPXODWLRQZKHUH WKH UHVLGXDOZDWHUFDQGHWHULRUDWH WKH
stability of the drug delivery system. Furthermore, the technique has also been employed to 
establish that the formulation tested in pre-clinical studies maintain its amorphous character 
and no detectable crystalline character (Sarsfield, et al., 2006).  
 
5.2.6 Stability studies  
HPLC results showed that the actual concentration of IND, IBU and PM ZLWKLQWKHZDIHUV¶
sample remained relatively unchanged (> 98%) after six month storage at room temperature  
and 45% RH (Figure 5.33). The actual drug content was measured quantitatively with HPLC.  
Unlike the films, these studies were only conducted over six months because of time 
wafer-paracetamol-4 months
Lin
 (C
ou
nt
s)
0
1000
2000
3000
4000
2-Theta - Scale
5 10 20 30 40
PEG 100%paracetamol peak
PEG
PEG
Intensity 
CHAPTER 5                                                                                   WAFER  DEVELOPMENT 
 
 
156 
 
constraints. The pure crystalline IBU, IND and PM used as control also remained stable over 
6 months.  
Although the stability studies were conducted up to six months period longer term stability 
test for model drugs within the wafer would be more desirable to ascertain how the drugs 
behave under accelerated conditions with higher temperature and relative humidity. The 
overall results from HPLC analysis, DSC thermograms and XRPD crystallographic pattern 
illustrate the ability of CAR 911, P407 and PEG 600 based wafers to preserve the stability of 
amorphous IBU, IND and PM though the stability inspection during longer period of time 
would be advantageous. 
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Figure 5.33 Percent drug content  within the wafers during storage of  up to six months {mean±s.d, n=3}.    
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Chapter 6  &RPSDULVRQ RI K\GUDWLRQ GLVVROXWLRQ DQG PXFRDGKHVLYH
SURSHUWLHVRIVROYHQWFDVWILOPVDQGIUHH]H-GULHGZDIHUV 
 
Subsequent to the development of two proposed buccal dosage forms (film and wafers) a 
comprehensive comparison was conducted to evaluate their functional properties which are 
drug dissolution and release profiles. However, since drug dissolution and release properties 
were directly affected by hydration and swelling, further experiments were required to  
determine the hydration and swelling behaviour. In addition, in-vitro mucoadhesion studies 
were necessary to evaluate the potential performance of dosage forms within the buccal 
mucosal membrane.     
  
6.1 Hydration\swelling profiles  
The preliminary studies were specifically focused on investigating the effect of pH on 
swelling as well as the maximum time requirement for films or wafers to be completely 
hydrated. Therefore, hydration and swelling experiments were conducted in two different 
media as: 
1) saline solution (0.9 mg/mL NaCl) at pH= 5.6  
2) phosphate buffer solution (prepared with 0.1 M of  KH2PO4 and NaOH) at pH=6.2 to 
mimic the saliva pH    
 
6.1.1 Films hydration and swelling  
In both media, maximum hydration for films occurred within 100 minutes although the 
percentage swelling was fairly constant after 80 minutes. According to Figure 6.1 (a & b) 
different pH conditions did not have a significant effect on hydration and swelling profiles. 
However, these figures also show that the percentage content of CAR 911 had significant 
effect on hydration properties of the films. They highlighted that the percentage swelling for 
films containing 2.5% w/w CAR 911 was increased to almost 200% in comparison to films 
formulated with 1.5% w/w CAR 911. This effect is associated with the increase in hydroxyl 
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groups which provide more hydrogen bonding sites for water molecules and therefore 
increases the swelling capacity.     
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                                                                                 (b) 
Figure 6.1 Hydration profile showing the % swelling for the films containing various concentration of CAR 911,  
4% w/w P407 and PEG 600 in  (a) saline solution and (b) phosphate buffer {mean±s.d, n=3}.  
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Comparison of the swelling profiles of the blank films (Figure 6.1) to those of drug loaded 
films showed that the maximum increase in percentage swelling for both sets of films 
occurred within 100 minutes. For example blank and IND loaded films showed increase in 
weight of about 600% and 500%, respectively of the initial weight in 60 minutes. The 
percentage swelling then increased more gradually to 650% and 520%, respectively for blank 
and IND loaded films at time 100 minutes. IBU loaded films also showed a similar swelling 
trend attaining 520% swelling in 80 minutes and a more gradual increase to 550% in 100 
minutes. In the case of PM loaded films, there was no sharp initial increase but a more 
gradual and continuous increase to 400% in 100 minutes. Although the films containing IBU 
and IND with higher Log P they absorbed more water in comparison to the films containing 
PM with lower Log P (more hydrophilic) which were expected to hydrate more. These results 
can be attributed to the availability of more hydrogen and OH group in CAR 911 to bind with 
water while in PM film higher amounts of drug within the polymeric matrix retained less 
hydrogen bonding sites. This explanation is applicable in blank film with higher hydrogen 
bonding sites.    
 
The overall results indicate that blank films showed a higher propensity to hydrate and swell 
more easily compared to the films containing the three model drugs. A similar swelling 
profile was observed for films formulated with or without model drugs in buffer solution 
(pH=6.2). However the overall swelling capacity in the buffer was lower than in the acidic 
medium (pH=5.6). This might be attributed to the presence of more hydrogen ions in the 
acidic medium which results in more hydrogen bonds with CAR and thereby enhanced the 
hydration capacity. The maximum % swelling for blank film in pH=6.2 was about 460% of 
initial weight within 40 minutes, ultimately reached 500% after 100 minutes. For IND loaded 
films the maximum swelling reached about 300% of initial weight and remained constant up 
to 100 minutes. The IBU film swelled to maximum capacity within 60 minutes and remained 
at about 340% afterward up to 100 minutes. PM film showed a gradual swelling within 60 
minutes and reached 230% of the initial weight.               
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6.1.2 Wafer hydration and swelling  
The overall observation of blank and drug loaded wafers (Figure 6.3 and Figure 6.4) in two 
different media at various pH values demonstrated the effect of pH on the swelling capacity, 
unlike the films.  
Figure 6.2  Hydration profile showing the % swelling for the  film formulated with 2.5% w/w CAR 911  with or 
without model drugs ( IBU, IND or PM)  in (a) saline solution and (b) phosphate buffer{mean±s.d, n=3}.  
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             (b) 
Figure 6.3 Degree of wafer swelling formulated with various ratios of carrageenan 911 (CAR), poloxamer 
(P407) and PEG 600 in (a) saline solution (pH= 5.6) and (b)  phosphate buffer solution (pH= 6.2) {mean ± s.d 
(n=3)}. 
CHAPTER 6                                                                      FILM & WAFER  COMPARISON 
 
 
162 
 
The results showed that the maximum swelling for wafers in slightly acidic pH (saline 
solution) occurred within a longer time period (120 minutes) and the overall swelling 
capacity is lower in comparison to wafers immersed in buffer media. Wafers placed in salt 
condition (buffer solution at pH=6.2) showed a maximum swelling capacity in 60 minutes 
that was 300% higher than in saline solution. The observations proved the stimulation effect 
of the higher pH on swelling ability.       
 
Figure 6.3 also showed that the wafers formulated with lower amounts CAR 911 and without 
PEG 600 showed the highest percentage swelling and this trend was steady during the whole 
experiment time. The effect is more related to the ratio of CAR 911 with its dominant effect 
on hydration profile. According to the SEM results (Figure 5.15 to   Figure 5.20) increasing 
the CAR 911 ratio resulted in wafers with smaller pores. Therefore, smaller pores have less 
capacity for water ingress as well as to be occupied by water molecules and therefore 
hydrated to a lesser extent. The highest swelling capacity of approximately 1000% and 
1300% in saline and buffer solution respectively was exhibited by wafers comprising 1.5% 
w/w CAR 911 and 4% w/w P407. As noted earlier, addition of PEG 600 however, decreased 
the swelling percentage significantly. This is shown in Figure 6.3 by wafers comprising CAR 
911 at 2.5% w/w and 5.5% PEG 600 had a lower swelling propensity.   
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Figure 6.4 Swelling profile for wafers formulated with various amounts of model drugs placed in (a) saline 
solution (pH=5.6) and (b) phosphate buffer solution (pH=6.2) {mean±s.d, n=3}. 
                                                                       
 
Figure 6.4 shows the swelling profiles of optimised wafers formulated with gels containing 
2% w/w CAR 911, 4% w/w P407 and 4.4% w/w PEG 600 containing the different model 
drugs (IBU, PM and IND) in two pH conditions.  
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The overall trend shows higher and faster swelling capacity in the buffer solution (pH=6.2) 
within 40 minutes compared to saline solution where complete and maximum swelling was 
attained in 120 minutes.  
 
The blank and PM loaded wafers in both saline and buffer solutions hydrated relatively 
rapidly. These formulations attained maximum swelling of 620 and 450% respectively after 
40 minutes after which the weight changes remained constant. The implication of this 
phenomenon can be related to the more extensive porosity in blank wafer and the alkaline 
nature of PM which will be more miscible with water. IND and IBU loaded wafers on the 
other hand showed slightly different swelling behaviour which continued for 120 minutes 
(580% and 620% respectively) in the saline solution, as the steepest weight changes occurred 
within the first 40 minutes due to slightly acidic nature of both model drugs. The hydration 
and swelling tendency for IBU loaded wafer in the buffer solution was higher than IND 
loaded wafer whilst the opposite was true in saline solution. This is correlated to the 
molecular structure of IND (Figure 6.6a) with three potential sites to form hydrogen bonds in 
acidic condition whilst IBU (Figure 6.6b) has two potential sites and the number of hydrogen 
bonds are less in acidic condition which directly affect the solubility.   
 
Figure 6.5 confirms that the swelling capacity of IND and IBU loaded matrices (films and 
wafers) in both media was considerably higher in comparison to PM, owing to the presence 
of more hydrogen bonding sites.  
 
The differences in swelling behaviour between films and wafer can be listed as:  
1. the general trend of swelling in either blank or drug loaded wafers is about three times 
higher compared with films due to significantly porous texture (Figure 6.5).     
2. the film swelling occurred within 100 minute in contrast to sharp swelling behaviour in 
wafers which was within 20 minutes.  
3. increasing the ratio of CAR 911 within the blank film formulation increased the swelling 
affinity in contrast to blank wafers.    
4. pH has a considerable effect on ZDIHU¶VVZHOOLQJSURILOHwhilst it did not have significant 
HIIHFWRQILOP¶VVZHOOLQJSURILOH  
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   Figure 6.5 Comparison of the swelling profile of optimized drug loaded films and wafers.  
 
6.2 Drug dissolution profile 
Before investigating the dissolution of films and wafers the physico-chemical characteristics 
of model drugs were considered. According to the literature IND (Figure 6.6a) has a pKa of 
4.5 which is stable in neutral or slightly acidic media while decomposing in strong alkali.  
 
 
Figure 6.6  IND, IBU and PM chemical structures. 
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PM (Figure 6.6c) is a weak basic drug with pKa 9.5 and is stable in alkali condition whilst 
IBU (Figure 6.6b) is a relatively weak acidic with the pKa about 4.4 also its solubility in 
water or at acid pH is very low. Scientifically a lower proportion of drug with higher Log P 
dissolve in aqueous media hence, it is expected for IND and IBU loaded films and wafers to 
have slower dissolution rate in comparison to PM loaded formulations.    
 
6.2.1 Film drug dissolution profiles 
Figure 6.7, Figure 6.8 and Figure 6.9 compare the dissolution profiles for IBU, IND and PM 
respectively in pure form (control) and within the films using the two different dissolution 
media (saline and buffer solution to determine the effect of pH). The most interesting finding 
was that the cumulative percentage release of pure model drug which was considerably lower 
in comparison to that present in the film matrices. This effect was observed for all three 
model drugs.  
Pure IBU initially dissolved relatively quickly possibly due to the immediate contact with the 
dissolution medium but reached a plateau in 10 minutes. In contrast, IBU was initially 
released from the film matrix more quickly but showed sustained release profiles overall, 
reaching release of 65% and 58% in 120 minutes for buffer and deionised water, respectively. 
The dissolution profiles and gradient derived from the initial linear portion of the drug release 
vs. time curves confirmed the effect of pH on drug release rate from the film matrix. These 
results showed that the rate of drug release was faster in the simulated saliva pH environment 
compared with the acidic pH condition (deionized water). In addition, the maximum drug 
release in buffer solution was about 8% higher than in acidic pH (corresponding to stomach 
dissolution media). This presents a potential advantage of buccal delivery over the traditional 
oral route. This is an interesting finding for films intended for buccal mucosa applications. 
However, this needs further investigations as the difference observed could relate to 
ionisation suppression of the acidic IBU at the lower pH of deionised water. These results 
indicate that IBU was present in the films in the amorphous form as compared to the pure 
crystalline form used as a control. Pure PM dissolved rapidly, within 5 min, before reaching a 
plateau in the percentage released. 
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The pure crystalline IND also dissolved relatively quickly initially and reached a plateau in 
the percentage released after 10 min in buffer solution. However, PM was released from the 
film matrix more slowly initially but showed higher cumulative release profiles (compared to 
pure crystalline drug) reaching about 40% in 25 minutes and ultimately 45% after 40 minutes 
in buffer. The ultimate drug release of PM from the film in buffer solution was about 25-30% 
less than IBU or IND loaded films which are related to the swelling index and low hydration 
capacity of PM loaded films.  
Similar trends were observed for IND loaded films though the release was slightly faster and 
the maximum release (57%) occurred within 40 minutes. Interestingly, drug loaded films 
demonstrated lower % release in deionized water than in buffer, which shows the effect of pH 
on drug release kinetics from the films. The faster release rate in buffer solution (mimicking 
pH of saliva) compared with acidic pH confirmed that the film was a viable matrix to deliver 
drugs via the buccal cavity rapidly. The maximum drug release from the IND loaded film in 
buffer solution was about 8-10% less than IBU loaded film; this can be correlated to the 
effect of pH on solubility of IBU.           
It is also interesting to note that the release profiles for PM and IND from the films were 
generally similar, even though the pure crystalline forms of the two drugs have significant 
differences in solubility. This seems to confirm the point that all three drugs were present in 
the films in the amorphous form as compared to the pure crystalline forms used as control.  
 
0 20 40 60 80 100 120
0
20
40
60
%
 D
ru
g 
re
le
a
se
Time (min)
 Film + ibuprofen in water
 Pure ibuprofen in water
 Film+ ibuprofen in Buffer 
 Pure ibuprofen in buffer
 
Figure 6.7 Dissolution profile showing the drug release from the film containing IBU {mean± s.d.(n=3)}. 
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Conventionally, the amorphous form of a drug displaying higher water solubility is expected 
to have higher rates of dissolution according to the Noyes-Whitney equation and therefore 
may account for the higher than expected rates of release by diffusion and eventual erosion of 
the polymer matrix when compared with the pure crystalline drug. The IBU release from the 
CAR 911 matrices is also medium-dependent due to the anionic nature of the polymer. As the 
pH increased, swelling index of the polymeric matrix increased and formed a gel layer which 
sustains the drug release. Due to the very rapid wicking, or water uptake, between the 
polymeric matrix and the resultant gelation, the surface pores are sealed preventing further 
rapid drug release (Boyapally, et al., 2010). 
 
The kinetics of IBU release from the films were evaluated by determining the best fit of the 
dissolution data (percentage release vs time) to the Higuchi, Korsmeyer±Peppas, zero order, 
first order and Hixson-Crowell equations by determining the R2 values. According to Table 
6.1 the drug release was proportional to time (or log of time in the case of IND). When 
percentage of cumulative drug released versus time was plotted in accordance with first-order 
and zero-order, Higuchi and Korsmeyer- Peppas equations, the determined R2 values for the 
ILOPV¶SRO\PHULFPDWUL[were.  
  
Verelas, et al., (1995) proposed that in many cases zero order kinetics can be applied to 
describe the drug release from several types of modified release pharmaceutical dosage forms 
such as polymeric matrices. When drug release rate is proportional to the remaining 
concentration of drug in the dosage form, dissolution can be described by first order release 
kinetics, predominantly for water soluble model drugs. The best fit for various models 
investigated for IBU and IND loaded films ranked in the order of Hixson± Crowell > first 
order. As shown in Table 6.1, the coefficients (R2) have similar values in more than one 
kinetic model of the same formulation. Thus, the selection of the adequate model was based 
on comparisons of higher determination coefficient, smaller standard error of model 
parameters and smaller residual mean square. On the basis of these comparisons the first 
order model was found to describe PM loaded film formulation (Yuksel, et al., 2000; 
Boateng et al., 2009b; Ritger and Peppas, 1987).  
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This shows that there is a change in surface area, diameter of the dissolved film specimens 
and the change in diffusion path length during the dissolution process following the cube root 
law. Further, the n values from the Peppas equation were considered. The Peppas equation 
(Q=ktn) is generally used to analyse the release of pharmaceutical polymeric dosage forms 
when the release mechanism is not well known (anomalous transport release). It is also useful 
when more than one type of release phenomenon could be involved, for example, swelling 
and erosion of polymer.  
 
The equation becomes more realistic in two main cases; pure diffusion controlled drug 
UHOHDVHQ DQGVZHOOLQJFRQWUROOHGGUXJUHOHDVHQ &DVHȱȱWUDQVSRUW2WKHUYDOXHVRIQ
indicate anomalous transport kinetics i.e. a combined mechanism of pure diffusion and 
swelling and the magnitude of n can be used as an indication of the type of transport 
PHFKDQLVPIRUWKHGUXJ$YDOXHRIQFRUUHVSRQGVWR)LFNLDQGLIIXVLRQUHOHDVHFDVHȱ
GLIIXVLRQDO Q WR DQ DQRPDORXV QRQ-Fickian diffusion) transport i.e. a gel 
erosion release mechanism, n=0.89 to a zero-RUGHUFDVHȱȱUHOHDVHNLQHWLFVDQGQ!Wo a 
VXSHUFDVHȱȱWUDQVSRUW. In the current study, the value of n was found to be greater than one 
for all the three drugs indicating super case II transport (Siepmann & Peppas, 2001) for drug 
release from the CAR based films. In this type of drug release kinetics the dominant 
mechanism for drug transport is due to polymer relaxation as the gel swells and are known as 
swelling-controlled release systems (Siepmann & Peppas, 2001). According to the above 
classification IBU and IND loaded films demonstrate an anomalous transport model whereas 
the drug release model for the film polymeric matrix, loaded with PM REVHUYHG DV FDVH ȱ
diffusional.    
The law of mass action proposed that, the velocity of a chemical reaction is proportional to 
the concentrations of drug. The change in concentration (dC) over a time interval (dT) is the 
velocity of the swelling (dC/dT) which is proportional to concentration. However, the 
velocity declines with time and decreases the drug content within the polymeric matrix and 
the concentration plot against time would yield a curve of gradually declining slope. 
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Table 6.1 Fitting of dissolution data of the three model drugs to various kinetic models for drug 
release from films. 
Dissolution  models IND film IBU film PM film 
Zero order k0 (%hr-1) 
R2 
RSM 
1.145 
0.988 
85.93701 
0.374 
0.991 
112.2964 
0.375 
0.998 
85.9370 
First order k1 (h-1) 
R2 
RSM 
7.2×10-3 × 6.3773E-005 
0.9988 
0.8877 
8.0×10-3 ± 6.9377E-005 
0.9989 
0.9337 
0.0084 ± 0,0012 
0.00 
247.1522 
 
Higuchi kH (% hr-1/2) 
R2 
4.5683 ± 0.1910 
0.9493 
35.5760 
           4.9269 ± 0.2018 
 0.9510 
                39.7184 
5.1909 ± 0.3267 
05305 
104.0539 
Hixson± Crowell  kHC (%h-1/3) 
R2 
RSM 
2.2×10-3 ±1.8684E-005 
0.9986 
0.9881 
 
2.4×10-3 ± 1.4722E-005 
0.9993 
0.5620 
2.4 ×10-3 ± 0,0003 
0.9777 
276.9067 
Peppas kP (hr-n) 
R2 
n 
RSM 
1.1269 ± 0.0925 
0.9979 
0.8323 ± 0.0188 
1.6081 
1.2372 ± 0.0811 
0.9986 
0.8281± 0.0150 
1.2015 
17.7272 ±  2.2737 
0.9134 
0.2004 ± 0,0328 
25.1892 
RSM: residual mean square; n: dissolution exponent. 
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Figure 6.8 Drug dissolution profiles from the IND loaded films {mean± s.d (n=3)}. 
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Figure 6.9 Drug dissolution profiles for the PM loaded films {mean ± s.d )(n=3)}. 
 
6.2.2 Wafer drug dissolution profiles  
Figure 6.10 to Figure 6.12 compare the dissolution profiles for IBU, IND and PM, 
respectively in pure form (control) and within the wafer using the two different dissolution 
media (deionised water and buffer to determine the effect of pH). Interestingly the effect of 
pH= 6.2 for IBU and IND loaded wafers on release profile were quite obvious which could 
be attributed to their acidic nature. For PM loaded wafer the change of the pH from 5.6 to 6.2 
did not have any obvious effect on the dissolution behaviour probably because PM is basic in 
nature and in both of these conditions it was existed in ionised form and therefore showed 
similar dissolution profiles.   
PM was released from the wafers relatively quickly initially before reaching a plateau in 15 
minutes, whilst IND and IBU showed sustained release behaviour with a gradual release from 
the matrix up to 110 and 100 and minutes respectively. The maximum cumulative percentage 
release of IBU from the wafer was about 75% and 69% for IND. The release of PM from the 
wafer matrix reached to just about 40% which is significantly lower than the other two model 
drug with are hydrophobic in nature.  
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Figure 6.10 Drug dissolution profile for wafers formulated with IBU {mean ± s.d. (n=3)}. 
 
Table 6.2 Fitting of dissolution data of the three model drugs to various kinetic models for drug 
release from wafers.  
Dissolution  models IND wafer IBU wafer PM wafer 
Zero order k0 (%hr-1) 
R2 
RSM 
0.453 
0.924 
206.3896 
0.951 
0.955 
159.2146 
1.255 
0.883 
101.5934 
First order k1 (h-1) 
R2 
RSM 
1.2 ×10-3± 0,0002 
0.9957 
5.5408 
         1.29×10-2  ± 0,0002 
0.9969 
4.0450 
8.4 10-3 ± 0,0015 
0.00 
409.7825 
 
Higuchi kH (% hr-1/2) 
R2 
RSM 
6.4306 ± 0,2226 
0.9618 
48.3261 
            6.7194 ±  0,2027 
 0.9693 
                   40.0501     
5.4055 ± 0.4663 
0.00 
212.0020 
Hixson± 
Crowell  
kHC (%h-1/3) 
R2 
RSM 
3.5×10-3 ± 8.684E-005 
0.9915 
10.8981 
     3.7 ×10-3± 8.0534E-005 
0.9925 
9.8788 
2.5×10-3 ± 4 ×10-4 
0.00 
444.4980 
 
Peppas kP (hr-n) 
R2 
n 
RSM 
2.7095 ± 0,4699 
0.9867 
0.7063 ±0,0401 
17.8553 
3.1281± 0.4519 
0.9898 
0.6826 ±0.0335 
14.1677 
31.5917 ± 1,6707 
0.9569 
6.48 × 10-2 ± 0.0143 
7.6352 
RSM: residual mean square; n: dissolution exponent. 
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The faster release rate in buffer solution (mimicking saliva) compared with acidic pH as well 
as higher maximum release for IND (approximately 10% higher) and PM (about 5% higher) 
in buffer solution showed that wafers are a desirable matrix for drug delivery via the buccal 
mucosa.   
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Figure 6.12 Drug dissolution profiles for wafers formulated with PM {mean ± s.d (n=3)}. 
 
Figure 6.11  Drug dissolution profiles for wafers formulated with IND {mean± s.d (n=3). 
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As was the case for the films, the presence of the model drugs in amorphous form within the 
wafers was confirmed, evidenced by the faster dissolution rates from the wafers compared to 
the pure crystalline drugs used as controls. According to the data in Table 6.2 the R2 values 
show that the kinetic model that best fit the release data was Korsmeyer-Peppas which 
involved a combination of diffusion in the first step followed by erosion of the polymeric 
matrix. The n value of drug release kinetics were calculated and compared with the literature 
(Balji & Peppas, 1996) $FFRUGLQJ WR OLWHUDWXUH Q  FRUUHVSRQGV WR )LFNLDQ GLIIXVLRQ
UHOHDVHFDVHȱGLIIXVLRQDODQGQ!IROORZVWKHVXSHUFDVHȱȱ WUDQVSRUWSince, IBU and 
IND loaded wafers showed 0.45 >n> 0.89, the drug release from the polymeric matrix was 
based on anomalous transport which means that diffusion and erosion played the key role in 
drug release behaviour.  
This value for PM loaded wafer however, showed the value of n< 0.45 corresponding to 
Fickian diffusion release FDVH ȱ GLIIXVLRQDO In this category of drug release kinetic, the 
dominant mechanism for drug transport is due to diffusion through the pores of polymer and 
the polymer chains relax and disperse in the media erosion occur which is known as erosion-
controlled release systems (Siepmann & Peppas, 2001). This type of drug release system also 
can be used for sustained release purposes.    
To compare the dissolution release profile from film and wafer matrices f2 similarity values 
were calculated. As Table 6.3 demonstrates, the f2 values are far less than 50 which indicate 
that the rate of drug dissolution from the polymeric matrices of film and wafer dosage forms 
are significantly different.   
 
    Table 6.3 Comparison of the f2 values (at 60 min) of drug release from films and wafers. 
           
 
 
   
 
 
 
Model drug loaded within the matrices Film f2 value  Wafer f2 value  
IND (t=60) 14.45 13.22 
IBU (t=60) 14.38 13.06 
PM (t=60) 14.39 15.04 
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This observed difference correlated very well with results obtained from swelling studies 
which showed significantly higher rates of swelling for wafers. This can be attributed to the 
differences in the microstructures between the porous wafers and dense continuous films 
(Boateng, et al., 2010).  
 
6.3 In-vitro mucoadhesivity 
In vitro mucoadhesion tests were performed to predict the stickiness and affinity of the films 
and wafers to adhere to buccal mucosal surfaces. According to the chemical structure of 
mucin the feasibility of hydrogen bonds formation between mucin and CAR 911 results in 
mucoadhesion. In addition, the possibility of the formation of dative covalent bond between 
the sulphate group in CAR 911 and NH2 group in mucin might result in stronger 
mucoadhesion force. Ruiz and Ghaly (2006) have also confirmed the ability of CAR film to 
adhere to agar gel surface. In addition to hydrogen bonds mucoadhesion can be generated due 
to van der Waals bonds or entanglement between polymeric matrix and agar (Smart, 2005).  
Also pH at the mucoadhesive interface affects the adhesion of mucoadhesives owing to 
generation of ionizable groups.  
 
As CAR 911 is a polyanion and the local pH=6.2 is above the pK=6.1, it will be mostly 
ionized and result in enhanced mucoadhesion. Shaikh and co-workers (2011) stated that ³the 
maximum mucoadhesive strength of polyanion is observed around pH 4±5 however, it 
decreases gradually above the pH of 6´. The application of CAR 911 based buccal dosage 
form in media with pH=6.2 is not expected to have a negative impact on mucoadhesion force 
since the pH is not considerably higher than 6. During the mucoadhesivity studies work of 
adhesion which is the work required to overcome the attractive forces between the surface of 
the film or wafer and the surface of the agar was measured.  
The stickiness factor identified as maximum force (N) required for detaching the film or 
wafer from the surface of the agar. Also cohesiveness is defined the distance (mm) film or 
wafer travels to detach from the agar surface. All of these factors are correlated with the 
mucoahdesion characteristics and the strength of the bonds formed between the polymeric 
matrix and agar during the contact time (Bansal et al., 2009).   
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6.3.1 Film mucoadhesion  
Boyapally, et al., (2010) reported that the highest work of adhesion and detachment force 
would be dependent on the formation of hydrogen bonds between the functional (hydroxyl) 
groups of the CAR 911 and the agar substrate. Physical entanglement is also associated with 
the highest detachment forces due to chain inter-locking induced following the inter-diffusion 
of the polymer chains into the agar glycoproteins. In addition, to obtain the highest work of 
adhesion and mucoadhesion force, the polymeric matrix should be in the non-ionized form. 
CAR 911 with pKa=6.2 at the pH corresponding saliva (6.2-6.8) is not ionized which induces 
the mucoadhesion force.     
 
Results for the film have been summarized in Table 6.4. Interestingly the results 
demonstrated that addition of drugs decreased the mucoadhesive strength of the film which 
could be due to a decrease in the hydrogen bonds between film matrix and agar. 
,QFRUSRUDWLQJ WKH K\GURSKRELF GUXJV VXSSUHVVHG WKH ILOPV¶ ZRUN RI DGKHVLRQ VOLJKWO\ IURm 
0.47 N.mm in blank film to 0.34 and 0.32 N.mm in IND and IBU loaded films respectively. 
However the statistical results derived from one-way Anova tests showed that the effect of 
hydrophobic drugs on the strength of mucoadhesion (stickiness) compared with the blank 
film was not significant (P=0.638 for IND loaded film and P=0.124 for IBU loaded film). 
High swelling index in IND and IBU films promotes rapid interaction with the agar, due to 
the large adhesive surface, leading to effective adhesion. Hydrogen bonding (secondary 
bonds) is the main mechanism for enhanced adhesion of CAR 911 matrices due to the large 
number of hydroxyl groups, which enhance hydrogen bond formation. This can be attributed 
to the more acidic nature of IBU and IND which provide more hydrogen bond sites for CAR 
911 following the decrease in the pH of the medium. Consequently the observed strength in 
IBU and IND films behaviour is probably due to chain interpenetration followed by the 
formation of secondary mucoadhesion bonds with the agar. As the polymer chains undergo 
rapid swelling, the interpenetration into the interfacial region occurs, whereas the extent of 
the adhesion in PM films is only superficial (Duchen, et al., 1988; Nair, et al., 1996). PM 
(hydrophilic model drug) loaded film showed a significantly lower work of adhesion and 
stickiness compared with the blank film (P=0.006).  
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The significant suppression in stickiness for PM loaded films is probably due to the higher 
swelling index which results in a slippery mucilage that looses mucoadhesion contact. 
However it might be due to the basic nature of the PM which increases the pH of the agar 
surface and consequently increase the CAR 911 ionized proportion thereby suppressing the 
mucoadhesion ability.  
 
In addition the higher percentage of model drug (PM) could have played a critical role in the 
reduction of mucoadhesion since the hydrogen bond between CAR 911 and mucoadhesive 
surface are displaced by new hydrogen bonds between the CAR 911 and PM. Sheikh and co-
workers (2011) also observed that the ratio of drug/polymers influence the mucoadhesion 
properties.  
 
Table 6.4 Mucoadhesivity results for films formulated with different model drugs in gels containing 
2.5% w/w of CAR 911, 4% w/w P407 with the appropriate content of PEG 600 for each sample 
(mean ± s.d. n= 3).       
Film sample Work of Adhesion 
(N.mm) 
Stickiness (N) Cohesiveness 
(mm) 
Blank film 0.47 ± 0.06 1.18 ± 0.21 0.65 ± 0.18 
Film +  0.6% w/w IND 0.34 ± 0.04 0.98 ± 0.24 0.57 ± 0.14 
Film +  0.8% w/w IBU 0.32 ± 0.01 0.84 ± 0.23 0.62 ± 0.25 
Film +  1.6% w/w PM 0.14 ± 0.03 0.36 ± 0.12 0.58 ±  0.11 
    
 
6.3.2 Wafer mucoadhesion 
Following the attachment of wafers on the agar surface mucoadhesivity bonds between CAR 
911 and agar are formed. This could be as a consequence of water absorption from the agar 
and formation of hydrogen and dative covalent bonds as previously noted. 
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Table 6.5 Mucoadhesivity profile for wafers formulated with gels comprising  CAR 911,  P407  and 
various ratios of PEG 600 (mean ± s.d, n= 3).    
Sample wafer on agar WOA (N.mm) Stickiness (N) Cohesiveness (mm) 
1.5% CAR 911 + 4% P407 0.36 ± 0.11 0.99 ± 0.35 0.36 ± 0.15 
1.5% CAR 911 + 4% P407 + 3.3%  PEG 0.33 ± 0.17 0.78 ± 0.29 0.67 ± 0.23 
1.5% CAR + 4% P407 + 5.5%  PEG 0.31 ± 0.14 0.95 ± 0.19 1.10 ± 0.31 
2% CAR  911+ 4% P407 0.39 ± 0.08 1.08 ± 0.21 0.34 ± 0.11 
2% CAR 911 + 4% P407 + 4.4% PEG 0.47 ± 0. 29 1.77 ± 0.23 0.41 ± 0.27 
2% CAR  911+ 4% P407 + 5.5% PEG 0.31 ± 0.18 0.79 ± 0.11 0.42 ± 0.09 
2.5% CAR 911 + 4% P407 0.43 ± 0.40 0.81 ± 0.35 0.69 ± 0.13 
2.5% CAR 911 + 4% P407+ 5.5% PEG 0.31 ± 0.14 1.29 ± 0.09 0.42 ± 0.21 
 
 
According to Table 6.5 which is the work of mucoadhesivity and maximum force that was 
applied to detach the wafers from the surface (stickiness) of the agar was positively affected 
by PEG 600. Results showed that maximum mucoadhesivity is observed for the wafer 
comprising 2% w/w of CAR 911 and 4% w/w P407 in the presence of 4.4% PEG 600 which 
previously showed appropriate flexibility to administer in mucosal area or remain stable 
during handling. The mucoadhesion and swelling index should be correlated since too much 
moisture and high degree of swelling produce slippery mucilage which can be easily removed 
from the mucosal surfaces. The content of the PEG 600 as a plasticizer is correlated to the 
amount of water within the polymeric matrix. 
 
In the presence of higher amounts of PEG 600, the quantity of water increased that result in 
the drug precipitation and a slight decrease in the adhesive performance (Shaikh, et al., 
2011). Therefore, the amount of the PEG 600 in the system should be kept at the lowest 
optimum level. The overall observations indicated that the most effective mucoadhesion 
profile would be obtained at certain polymer combinations and optimum ratio of CAR 911 to 
PEG 600.    
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Table 6.6 Mucoadhesivity profile for wafers formulated with gels containing CAR 911, P407 and 
various ratios of PEG 600 (n= 3).    
Wafer sample Work of Adhesion 
(N.mm) 
Stickiness (N) Cohesiveness 
(mm) 
Blank wafer 0.63 ± 0.06 1.77 ± 0.24 0.41 ± 0.08 
Wafer +  0.6% w/w IND 0.38 ± 0.04 1.29 ± 0.19 0.34 ± 0.03 
Wafer +  0.8% w/w IBU 0.43 ± 0.01 1.36 ± 0.31 0.39 ± 0.11 
Wafer +  1.8% w/w PM 0.78 ± 0.14 1.85 ± 0.27 0.60 ±  0.15 
 
The mucoadhesion results for the drug loaded wafers indicated that incorporating the 
hydrophobic drugs (IBU and IND LQ WKH ZDIHUV¶ PDWUL[ UHVXOWed in a slight decrease in 
mucoadhesion affinity compared with blank wafer though it was not significant according to 
statistical results obtained from one-way Anova (P=0.0532). 
Interestingly, addition of PM which is a hydrophilic drug had a positive effect on the work of 
adhesion, stickiness and cohesiveness values. The swelling index of the PM loaded wafer 
confirmed the lower swelling affinity in comparison to blank wafer or IBU and IND loaded 
wafers which helped the wafer to stabilize on the agar surface. This could be attributed to the 
swelling extent and prevention of slippery mucilage on the agar surface which decreases the 
mucoadhesion force. However, it could also be due to additional secondary forces such as 
vDQGHU:DDOVEHWZHHQZDIHUV¶PDWUL[DQGDJDUVXUIDFH in addition to hydrogen and dative 
covalent bonds and mechanical entanglement.  
The overall mucoadhesion results from the blank and drug loaded wafers confirm that 
porosity plays the most critical role due to affinity to absorb water and produce hydrogen 
bonds required for mucoadhesivity attraction.   
The P value (0.0328) confirmed the significant difference between blank film and wafer  
mucoahdesion force (stickiness) while hydrophobic drug loaded films and wafers did not 
follow the same trend and were not significantly different in mucoadhesivity index 
(P=0.1543). A significant difference between PM loaded wafers and films was observed in 
their mucoadhesion behaviour (P=0.0009).  
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In contrast to PM loaded films which might produce slippery mucilage between the film and 
agar interface, corresponding wafer is able to absorb more water and retain it resulting in less 
water present on the agar surface and therefore higher force of detachment. This phenomenon 
could be due to the non- porous nature of the film surface which does not allow water to 
penetrate the matrix to the the same extent as the more porous wafers (Madsen, et al., 1998., 
Roy, et al., 2009).      
The comparison between films and wafers mucoadhesivity results demonstrated the overall 
effect of porosity on mucoadhesion affinity. This is directly attributed to their ability to 
absorb water and generate hydrogen bonds. To summarize, wafers are better mucoadhesive 
dosage forms with acceptable mucoadhesion force which expected to remain in the buccal 
area for longer period of time compared to films (Sudhakar et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7                                                                     CONCLUSION & FUTURE WORK 
 
 
181 
 
Chapter 7 &RQFOXVLRQV	IXWXUHZRUN 
7.1 Conclusions 
The main advantage of solvent cast films and freeze-dried wafers as potential novel buccal 
mucosal drug delivery systems is that they contain lower drug loadings to achieve the 
desirable therapeutic effect compared with traditional systemic therapies such as tablets and 
capsules. Furthermore, these formulations would be potentially highly acceptable and 
comfortable subject to non-irritant nature and might be preferred over adhesive tablet in 
terms of flexibility. They also present the possibility to better protect the mucosa in the case 
of mouth ulcers or inflamed surfaces in comparison to mucoadhesive buccal tablets which 
have less flexibility. Both films and wafers possess relatively high mucoadhesive force and 
therefore less chance of involuntary dislodging by the tongue and therefore expected to allow 
better retention in the buccal region compared with sublingual dosage form.  
 
The overall outcome from this study was the formulation design, development and 
optimization of stable solvent cast films and freeze-dried wafers as potential platforms for 
buccal drug delivery. Optimised films with ideal flexibility and toughness were obtained 
from the polymeric gel comprising 2.5% w/w CAR 911 in combination with 4% w/w P407. 
Maximum drug loading of 0.8% w/w IBU and 0.6% w/w IND was achieved with 6.5% w/w 
PEG 600. However, the content of PEG 600 required for loading a maximum 1.6% w/w of 
the more water soluble PM was 6% w/w. Similarly, optimized wafers were developed from 
gels comprising 2% w/w CAR 911, 4% w/w P 407 and 4.4% w/w PEG 600 with maximum 
drug loadings of 0.8% w/w IBU, 0.6% w/w IND and 1.8% w/w PM. These percentages 
correspond to 4.41%, 5.79% and 11.34% of the total dry weight of films for IND, IBU and 
PM, respectively as well as 5.45%, 7.14% and 14.40%, respectively of total wafer dry 
weight. The optimum formulation was the one with an ideal balance between flexibility, 
swelling capacity and mucoadhesivity which is expected to enable longer contact time and 
patient convenience during handling and application.   
 
Thermal analysis showed that an interaction occurred between PEG 600 and P407 within the 
films. However, the extent of such interactions was dependent on the ratio of the two 
components within the film.  
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The interaction occurred due to the formation of inter-chain hydrogen bonding between PEG 
600 and P407. The key finding of this study lies in the fact that model drugs (IND, IBU and 
PM), originally added as crystalline polymorphs, were converted into a stable amorphous 
form during film formation and freeze-drying and this has an impact on the drug release 
profiles from the film and wafer matrix in dissolution medium simulating the pH of saliva at 
37°C.   
 
Interestingly the most significant observation during hydration and swelling studies was the 
higher ability of wafers to swell in the buffer solution compared with films with significant 
differences in the drug release characteristics between the two formulation types.  
By fitting of dissolution data to Korsmeyer-Peppas equation, the results showed that the 
drugs were released from the film matrix following diffusion and swelling with the kinetics 
of release following VXSHU FDVH ȱȱ transport. This indicated that drug solubility and mass 
transfer (diffusion) phenomena were involved in drug release as a consequence of zero order 
kinetics where the plasma concentration of a drug within the polymeric matrix decreases at a 
constant rate. For IBU and IND loaded wafers n> 0.89 corresSRQGLQJ WR WKH VXSHU FDVH ȱȱ
transport drug released from the polymeric matrix showed that drug release occurred due to 
diffusion and erosion. However, this value for PM loaded wafer showed n  
corresponding WR)LFNLDQGLIIXVLRQUHOHDVHFDVHȱGLIIXVLRQDO 
The p value for drug release rate comparison between films and wafers confirmed that the 
drug release rate form WKHZDIHU¶Vmatrix was significantly higher WKDQILOP¶Vmatrix owing to 
the differences in porosity. In addition, the results showed that drug release rates were faster 
at pH corresponding to that of saliva than at slightly acidic pH for deionised water which 
could be related to ionisation suppression of the slightly acidic IBU or IND at the lower pH 
of deionised water. This effect was not observed for PM loaded films and wafers and could 
be attributed to the weakly basic nature of the drug. The positive effect of pH on the drug 
release rate for dosage forms intended for buccal applications is considered favourable. 
However the dissolution profiles were more significantly affected by SRO\PHUV¶ &$5
and P407) content with increasing CAR content resulting in sustained drug release.  
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In addition, the drug loading capacity of hydrophilic drugs in wafer was about 20% higher 
than film and attributed to the differences in the physical nature of the two formulations; 
wafers being more porous with higher volume compared to the denser and thinner films. 
In summary the differences between the physico-mechanical properties of the films and 
wafers will enable formulators to design appropriate buccal formulations to achieve the 
expected therapeutic effect.  
 
7.2 Future work 
Studies which would provide additional information with regards to the developed films and 
wafers could involve the following.  
x Investigation of the effect of polymeric matrix on alternative drugs with different log 
P such as lipophilic drugs ({e.g. steroids, thyroid hormones or anti-fungal drugs)} 
which are required at lower doses than the model drugs used.  
 
x Also additional in-vivo studies to determine bioadhesivity on ex-vivo tissues model 
surfaces.  
 
x Investigation of the mechanism of drug incorporation into the PEG 600/P407 mixture. 
For example the possibility of formation of micelles or nanoparticle could be 
explored.  
 
x Further supplementary studies should be performed to obtain in-vivo data for drug 
release and transport across buccal tissues and systemic drug bioavailability. 
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9.4 Supplementary results  
XRPD results for physical mixture of 50% P407 and 50% PEG 600 after DSC run 
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XRPD results for physical mixture of 50 % P407 and 50% PEG 600 before DSC run 
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XRPD results for physical mixture of 90% P407 and 10%PEG 600 after DSC run 
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XRPD results for physical mixture of 90% P407 and 10%PEG 600 after DSC run 
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XRPD results for physical mixture of 60% P407 and 40%PEG 600 after DSC run 
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XRPD results for physical mixture of 90% P407 and 10%PEG 600 after DSC run 
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XRPD results for physical mixture of 30% P407 and 70%PEG 600 after DSC run 
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TGA result for PM loaded films and wafers stored for 1 month 
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TGA results for IND loaded films stored for 1 month 
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TGA results for IBU loaded films and wafers stored for 1 month  
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 TGA results for PM loaded films and wafers stored for 6 months  
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TGA results for IND loaded films and wafers stored for 6 months 
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 TGA results for IBU loaded films and wafers stored for 6 months  
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